



UNIVERSIDADE FEDERAL DE PERNAMBUCO
CENTRO DE BIOCIÊNCIAS
DEPARTAMENTO DE BIOQUÍMICA
PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS BIOLÓGICAS

DEYZI CAROLINE DA SILVA BARBOSA

**AVALIAÇÃO DO POTENCIAL BIOLÓGICO DO ÓLEO ESSENCIAL DA CASCA
DO FRUTO DE *Myrciaria floribunda* (H. WEST EX WILLD.) O. BERG**

Recife

2020

DEYZI CAROLINE DA SILVA BARBOSA

**AVALIAÇÃO DO POTENCIAL BIOLÓGICO DO ÓLEO ESSENCIAL DA CASCA
DO FRUTO DE *Myrciaria floribunda* (H. WEST EX WILLD.) O. BERG**

Dissertação apresentada ao Programa de Pós-Graduação em Ciências Biológicas da Universidade Federal de Pernambuco, como requisito parcial para a obtenção do título de Mestre em Ciências Biológicas.

Área de concentração: Biotecnologia

Orientadora: Prof.^a Dr.^a Maria Tereza dos Santos Correia.

Recife

2020

Catálogo na fonte:
Bibliotecária Claudina Queiroz, CRB4/1752

Barbosa, Deyzi Caroline da Silva

Avaliação do potencial biológico do óleo essencial da casca do fruto de *Myrciaria floribunda* (H. West ex Willd.) O. Berg / Deyzi Caroline da Silva Barbosa - 2020.

93 folhas: il., fig., tab.

Orientadora: Maria Tereza dos Santos Correia

Dissertação (mestrado) – Universidade Federal de Pernambuco. Centro de Biociências. Programa de Pós-Graduação em Ciências Biológicas. Recife, 2020.

Inclui referências e apêndice.

1. Cambuí 2. *Myrciaria floribunda* 3. Fitoterapia
I. Correia, Maria Tereza dos Santos (Orientadora) II. Título

572.2 CDD (22.ed.)

UFPE/CB-2020-241

DEYZI CAROLINE DA SILVA BARBOSA

**AVALIAÇÃO DO POTENCIAL BIOLÓGICO DO ÓLEO ESSENCIAL DA CASCA
DO FRUTO DE *Myrciaria floribunda* (H. WEST EX WILLD.) O. BERG**

Dissertação apresentada ao Programa de Pós-Graduação em Ciências Biológicas da Universidade Federal de Pernambuco, como requisito parcial para a obtenção do título de Mestre em Ciências Biológicas.

Aprovada em: 19/02/2020.

BANCA EXAMINADORA

Prof.^a Dr.^a Maria Tereza dos Santos Correia (Orientadora)
Universidade Federal de Pernambuco

Prof.^a Dr.^a Ana Paula Sant'Anna da Silva (Examinador Externo)
Universidade Federal de Pernambuco

Prof.^o Dr.^o Andre de Lima Aires (Examinador Externo)
Universidade Federal de Pernambuco

Dedico esse trabalho aos meus pais que não tiveram a oportunidade de estudar. Mas, sempre me incentivaram a buscar o conhecimento através do estudo como ferramenta fundamental para o crescimento pessoal e profissional.

AGRADECIMENTOS

Agradeço a Deus por guia-me durante cada ciclo da vida e por demonstrar que os sonhos são possíveis quando não deixamos de acreditar.

Agradeço à professora Dr.^a Maria Tereza dos Santos Correia, pelos anos de orientação e pela acolhida no Departamento de Bioquímica durante minha jornada acadêmica.

Ao Ms. Vanderlan Nogueira Holanda por todas as contribuições enriquecedoras e essenciais para a conclusão deste trabalho, pela paciência e disposição em compartilhar seu conhecimento. E principalmente pela acolhida e incentivo diário.

À profa. Dr.^a Regina Celia Bressan Queiroz de Figueiredo pela colaboração neste trabalho e pela acolhida no Laboratório de Biologia Celular de Patógenos.

À Dr.^a Ana Paula Sant'Anna da Silva um exemplo de profissional que não mede esforços para ajudar todos a sua volta.

Agradeço à Prof.^a Dr.^a Márcia Vanusa, Júlio Aguiar, Caio Assis, Welson Vicente, Helton Marlon e Pedro Nascimento pela colaboração para realização deste trabalho.

Aos meus familiares e amigos que me acompanham em todas as etapas de minha vida, sempre me fornecendo incentivo, apoio e dividindo os momentos de alegria e tristeza.

À todos aqueles que são incentivadores diários no mundo acadêmico e na vida, com gestos simples mas que fazem toda diferença no cotidiano seja de forma direta ou indireta.

À Capes e CNPq pelo apoio ao desenvolvimento desta pesquisa. À Universidade Federal de Pernambuco, Departamento de Bioquímica, Coordenação da Pós-Graduação em Ciências Biológicas, Laboratório de Química de Produtos Naturais, Laboratório de Biologia Celular de Patógenos e Instituto Aggeu Magalhães-Fiocruz/PE pelo suporte prestado.

Gratidão

Enfrente-se.
Desafie-se. Vença-se.
Busque, e o que não
Encontrar, torne-se

Wandy Luz, 2019.

RESUMO

Óleos essenciais (OE's) são compostos voláteis obtidos de plantas aromáticas que podem ser promissores em atividades biológicas. *Myrciaria floribunda* (H. West ex Willd.) O. Berg é uma espécie nativa do Brasil pertencente à família Myrtaceae cujos OE's são descritos por apresentar uma ampla variedade de propriedades farmacológicas. A busca por alternativas terapêuticas eficazes e com baixa toxicidade para o tratamento de doenças não-transmissíveis e infecciosas, dentre elas as doenças neurodegenerativas e negligenciadas, respectivamente, ainda é um desafio. Visto que, os fármacos disponíveis para o tratamento apresentam várias limitações. Neste contexto, o presente estudo teve por objetivo avaliar o potencial biológico do óleo essencial da casca do fruto de *M. floribunda* (MfEO). Assim, foi determinada a composição química do óleo e investigado seus parâmetros farmacocinéticos e toxicológicos através de ensaios *in silico*. Posteriormente, testes de interações molecular entre os principais compostos majoritários do MfEO com as enzimas acetilcolinesterase e esterol 14-alfa desmetilase foram avaliados. Também, foram analisadas as atividades citotóxicas, de inibição enzimática e antiparasitária do OE. Os resultados revelaram a presença de 26 compostos (96,86%) por cromatografia gasosa acoplada a espectrometria de massa, dos quais os principais componentes majoritários foram: δ -Cadineno (26.8%), γ -Cadineno (15.69%), γ -Muuroleno (6.21%), α -Selineno (6.11%), α -Muuroleno (6.11%) e (E)-Cariofileno (5.54%). Os compostos majoritários do óleo apresentaram propriedades favoráveis para a interação com as enzimas avaliadas e o OE foi capaz de inibir a acetilcolinesterase, demonstrando resultados promissores através do ensaios *in silico* e *in vitro*. MfEO apresentou concentração citotóxica (CC50) de 260.9 e 332.9 $\mu\text{g/ml}$ para célula Vero e macrófago J774A.1, respectivamente. MfEO demonstrou significativa atividade leishmanicida para as formas promastigotas (IC50: 55,84 $\mu\text{g/ml}$) e amastigotas de *Leishmania amazonensis* (IC50: 7,54 $\mu\text{g/ml}$), com um índice de seletividade (44,1) para amastigotas intracelulares do parasita. Este estudo foi pioneiro na descrição da composição química e do potencial biotecnológico do óleo essencial das cascas do fruto de *M. floribunda*, proporcionando uma nova perspectiva para o uso das cascas do fruto no desenvolvimento de aplicações farmacológicas de baixo custo.

Palavras-chave: Cambuí. *Myrciaria floribunda*. Fitoterapia.

ABSTRACT

Essential oils (OE's) are volatile compounds obtained from aromatic plants that can be promising in biological activities. *Myrciaria floribunda* (H. West ex Willd.) O. Berg is a species native to Brazil belonging to the family Myrtaceae whose OE's are described for having a wide variety of pharmacological properties. The search for new effective therapeutic alternatives with low toxicity for the treatment of non-communicable and infectious diseases, including neurodegenerative and neglected diseases, respectively, is still a challenge. Since, the drugs available for treatment have several limitations. In this context, the present study aimed to assess the biological potential of the essential oil of the peel of the fruit of *M. floribunda* (MfEO). The chemical composition of the oil was determined and its pharmacokinetic and toxicological parameters were investigated through silica tests. Subsequently, tests for molecular interactions between the major majority compounds of MfEO with the enzymes acetylcholinesterase, and sterol 14- α demethylase. Also, the cytotoxic, enzymatic and antiparasitic inhibition activities of the OE were analyzed. The results revealed the presence of 26 compounds (96.86%) by gas chromatography coupled with mass spectrometry, of which the main major components were: δ -Cadinene (26.8%), γ -Cadinene (15.69%), γ -Muurolene (6.21%), α -Selinene (6.11%), α -Muurolene (6.11%) and (E)-Karyophyllene (5.54%). The major compounds of the oil showed favorable properties for the interaction with the evaluated enzymes and OE was able to inhibit acetylcholinesterase, showing promising results through *in silico* and *in vitro* assays. MfEO showed cytotoxic concentration (CC₅₀) of 260.9 and 332.9 μ g/ ml for Vero cell and macrophage J774A.1, respectively. MfEO demonstrated significant leishmanicidal activity for the promastigotes (IC₅₀: 55.84 μ g/ml) and amastigotes of *Leishmania amazonensis* (IC₅₀: 7.54 μ g/ml), with a selectivity index (44.1) for intracellular amastigotes of the parasite. This study was a pioneer in the description of the chemical composition and biotechnological potential of the essential oil of the peels of the fruit of *M. floribunda*, providing a new perspective for the use of the peels of the fruit in the development of low-cost pharmacological applications.

Keywords: Cambuí. *Myrciaria floribunda*. Phytotherapy.

LISTA DE ILUSTRAÇÕES

Figura 1 –	Folhas, flores e frutos de <i>Myrciaria floribunda</i>	22
Quadro 1 –	Doenças Neurodegenerativas: principais características e sintomas.....	24
Figura 2 –	Síntese e liberação de acetilcolina na fenda sináptica	25
Figura 3 –	Estrutura característica da enzima acetilcolinesterase	27
Figura 4 –	Estruturas de inibidores de acetilcolinesterase.....	28
Quadro 2 –	Lista de doenças tropicais negligenciadas consideradas pela OMS	30
Figura 5 –	Ilustração do ciclo evolutivo da <i>Leishmania amazonensis</i>	32
Figura 6 –	Áreas endêmicas de Leishmaniose Cutânea.....	33
Figura 7 –	Lesão de Leishmaniose Cutânea Localizada	34
Figura 8 –	Lesão de Leishmaniose Cutânea Difusa.....	35
Figura 9 –	Lesão de Leishmaniose Mucocutânea.....	35
Figura 10 –	Áreas endêmicas de Leishmaniose Visceral.....	36
Gráfico 1 –	Casos de Leishmaniose Visceral por regiões brasileiras, 2008 a 2017.....	36
Figura 11 –	Leishmaniose Visceral e Leishmaniose dérmica Pós-kala-azar.....	37
Figura 12 –	Effects of MfEO on mammalian cells after 48 hours of treatment.....	51
Figura 13 –	The effects of MfEO on promastigote forms of <i>Leishmania amazonensis</i> after 24 and 48 hours of treatment.....	52
Figura 14 –	Effect of MfEO on intracellular amastigotes forms of <i>L. amazonensis</i>	53
Figura 15 –	The effects of MfEO on <i>Leishmania amazonensis</i> ultrastructure as observed by scanning electron microscopy.....	55
Figura 16 –	Molecular docking of δ -Cadinene, γ -Cadinene and Fluconazole over to the LiCYP51 (A, C and E), respectively.....	59

ARTIGO

Figura 1 –	Chemical structure of the major components of the essential oil of <i>M. floribunda</i>	87
Figura 2 –	Mass spectrometry of δ -Cadinene in the essential oil (A), reference standard of δ -Cadinene (B), γ -Cadinene in the essential oil (C), reference standard γ -Cadinene (D).	87
Figura 3 –	Interaction of δ (A) and γ (B) cadinene with human AChE. Binding and related amino acid residue in molecular docking (C, D).....	90
Figura 4 –	Determination of inhibition activity of MfEO (A, B) and neostigmine (C, D) on <i>Crassostrea rhizophorae</i> and <i>Electrophorus electricus</i> AChE, respectively.....	91

LISTA DE TABELAS

Tabela 1 –	Óleos essenciais da família Myrtaceae e suas atividades biológicas	18
Tabela 2 –	Principais formas clínicas de leishmaniose cutânea.....	31
Tabela 3 –	Medicamentos utilizados no tratamento da Leishmaniose	38
Tabela 4 –	Leishmanicidal and cytotoxic effects of essentials oil of <i>M. floribunda</i>	54
Tabela 5 –	Interaction profile MfEO major constituents, δ -Cadinene (δ -Cad) and γ -Cadinene (γ -Cad) with the enzyme sterol 14-alpha demethylase (<i>LiCYP51</i>)	57

ARTIGO

Tabela 1 –	Identified chemical constituents of MfEO obtained by GC/MS	86
Tabela 2 –	<i>In silico</i> ADMET analysis of major constituents of MfEO and neostigmine.....	88
Tabela 3 –	Interaction profile between major oil compounds with acetylcholinesterase enzyme.....	89

LISTA DE ABREVIATURAS E SIGLAS

ACh	Acetilcolina
AChE	Acetilcolinesterase
AChEIs	Inibidores de acetilcolinesterase
ADMET	Absorção, distribuição, metabolismo, excreção e toxicidade
CaCl ₂	Cloreto de cálcio
CAS	Sítio ativo catalítico
DA	Doença de Alzheimer
DH	Doença de Huntington
DP	Doença de Parkinson
DN	Doenças Neurodegenerativas
DTN	Doenças tropicais negligenciadas
ELA	Esclerose Lateral Amiotrófica
EM	Esclerose Múltipla
IC ₅₀	Índice de concentração inibitória de 50%
MfEO	Óleo essencial da casca do fruto de <i>Myrciaria floribunda</i>
MG	Miastemia gravis
OE's	Óleos essenciais
ODS	Objetivos de desenvolvimento sustentável
OMS	Organização Mundial de Saúde
LC	Leishmaniose Cutânea
LCL	Leishmaniose cutânea localizada
LCD	Leishmaniose Cutânea Difusa
LMC	Leishmaniose mucocutânea
LV	Leishmaniose Visceral
mAChRs	Receptores muscarínicos de acetilcolina
nAChRs	Receptores nicotínicos de acetilcolina

SUMÁRIO

1	INTRODUÇÃO	15
1.1	OBJETIVOS	16
1.1.1	Objetivo Geral	16
1.1.2	Objetivos Específicos.....	16
2	REFERENCIAL TEÓRICO	17
2.1	ÓLEOS ESSENCIAIS.....	17
2.1.1	Família Myrtaceae	18
2.1.2	<i>Myrciaria floribunda</i> (H. West ex Willd.) O. Berg	21
2.1.3	Frutos e seus benefícios para a saúde	22
2.2	DOENÇAS NEURODEGENERATIVAS	23
2.2.1	Sistema Colinérgico	25
2.2.2	Acetilcolinesterase e neurodegeneração	27
2.2.3	Produtos naturais versus doenças neurodegenerativas.....	28
2.3	DOENÇAS TROPICAIS NEGLIGENCIADAS (DTN)	29
2.3.1	Leishmaniose	30
2.4	AGENTE ETIOLÓGICO, CICLO DE VIDA E VETOR	31
2.4.1	Leishmaniose Cutânea (LC)	33
2.4.2	Leishmaniose Cutânea Localizada (LCL)	33
2.4.3	Leishmaniose Cutânea Difusa (LCD)	34
2.4.5	Leishmaniose mucocutânea (LMC)	35
2.5	LEISHMANIOSE VISCERAL – LV	36
2.6	DIAGNÓSTICO E TRATAMENTO	37
3	METODOLOGIA	40
3.1	OBTENÇÃO DO ÓLEO ESSENCIAL	40
3.2	CARACTERIZAÇÃO QUÍMICA	40
3.3	ANÁLISES IN SILICO	41
3.3.1	ADMET	41
3.3.2	Docking Molecular	41
3.4	ATIVIDADE DE INIBIÇÃO ENZIMÁTICA	41
3.4	ENSAIO DE CITOTOXICIDADE	42
3.5	ATIVIDADE LEISHMANICIDA	42

3.5.1	Efeito do MfEO em formas promastigotas.....	42
3.5.2	Efeito do MfEO em formas amastigotas	42
3.6	ANÁLISE ULTRAESTRUTURAL	43
4	RESULTADOS	44
4.1	THE BIOLOGICAL ACTIVITY OF ESSENTIAL OIL FROM FRUIT PEEL OF <i>MYRCIARIA FLORIBUNDA</i> (H. WEST EX WILLD.) O. BERG ON <i>LEISHMANIA AMAZONENSIS</i>	44
5	CONCLUSÃO	67
	REFERÊNCIAS	67
APÊNDICE A –	CHEMICAL COMPOSITION AND ACETYLCHOLINESTERASE INHIBITORY POTENTIAL, <i>IN SILICO</i> , OF <i>MYRCIARIA FLORIBUNDA</i> (H. WEST EX WILLD.) O. BERG FRUIT PEEL ESSENTIAL OIL	83

1 INTRODUÇÃO

O estudo sobre as propriedades dos óleos essenciais (OE's) tem sido crescente ao longo dos anos, levando em consideração que a indústria tende à adaptar suas formulações para as exigência de diferentes públicos e normas específicas para o comércio de produtos (IRSHAD et al., 2019). Devido as suas propriedades, os OEs apresentam vantagens por serem de fácil obtenção, sustentáveis e biodegradáveis, tornando-os produtos bem aceitos entre os consumidores (FIGUEIREDO, PEDRO & BARROSO, 2017).

O Brasil é um país rico pela sua diversidade de plantas, fator consideravelmente importante para a realização de estudos e aplicações biotecnológicas utilizando os OE's (MENDES et al., 2016). Dentre as famílias que compreendem as espécies vegetais produtoras de óleos, a família Myrtaceae se destaca pela ampla variedade de espécies. No País, diversos gêneros pertencentes a esta família apresentam grande importância econômica como por exemplo, *Plinia* (jabuticabeira), *Eugenia* (pitangueira), *Psidium* (goiabeira) e *Myrciaria* (cambuizeiro) (SERAGLIO et al., 2018).

Myrciaria floribunda (H. West ex Willd.) O. Berg. é uma planta nativa do Brasil, conhecida popularmente como cambuí, seus frutos podem ser consumidos “*in natura*” ou após o processamento, na forma de licores, geleias e doces, ressaltando assim, o valor econômico da espécie (WU, LONG & KENNELLY, 2013; TNG et al., 2019). Além da importância econômica, essa espécie tem chamado atenção da comunidade científica por conta das suas propriedades no campo biomédico, como ação antimicrobiana, inseticida (TIETBOHL et al., 2014; TIETBOHL et al., 2019) e de inibição enzimática (TIETBOHL et al., 2017; OLIVEIRA et al., 2018; FEDER et al., 2019). No entanto, a investigação do potencial biológico do óleo essencial de *M. floribunda* ainda é rara e nenhum relato sugere a utilização da casca do fruto para investigação científica, que por vezes é descartada como material sem utilidade.

A utilização da casca do fruto de *M. floribunda* como possibilidade de aplicação biotecnológica é inovadora e compreende um campo aberto para estudo nas áreas alimentícia, cosmética e farmacêutica. No campo farmacêutico, a busca por alternativas terapêuticas para o tratamento de doenças crônicas não-transmissíveis e infecciosas ainda é necessária, visto que os medicamentos utilizados nos tratamentos convencionais apresentam limitações como diminuição da efetividade medicamentosa a longo prazo e efeitos colaterais (MENEZES et al., 2015; BURČUL et al., 2019), alto custo, resistência (SAVOIA, 2015), entre outros. Nesse contexto, as doenças neurodegenerativas, como doença de Alzheimer e Parkinson; e doenças tropicais negligenciadas, como a Leishmaniose Cutânea merecem destaque, pelo alto índice de

indivíduos acometidos e medidas terapêuticas ineficazes e tóxicos. Dessa forma, este estudo investigou o potencial biológico do óleo essencial da casca do fruto de *Myrciaria floribunda* (H. WEST EX WILLD.) O. BERG.

1.1 OBJETIVOS

1.1.1 Objetivo Geral

Avaliar o potencial biológico do óleo essencial da casca do fruto de *Myrciaria floribunda* (MfEO).

1.1.2 Objetivos específicos

- Obter e caracterizar o óleo essencial;
- Determinar os parâmetros farmacocinéticos e toxicológicos *in silico* e docking molecular dos compostos majoritários do óleo;
- Verificar o potencial de inibição enzimática da AChE;
- Determinar a citotoxicidade do OE em linhagens celulares;
- Verificar o efeito do óleo sobre promastigota e amastigota de *Leishmania amazonensis* e descrever às alterações ultraestruturais.

2 REFERENCIAL TEÓRICO

2.1 ÓLEOS ESSENCIAIS

Óleos essenciais (OE's) são um complexo de compostos funcionais de origem natural que podem ser extraídos de diferentes partes da planta, como: flores, folhas, cascas e frutos (PENG, BISHOP & QUEK, 2019). De uma forma geral, os OE's são constituídos principalmente pelos compostos terpênicos e de acordo com a distribuição de sua sequência química, eles podem ser classificados em: monoterpenos ($C_{10}H_{16}$), sequiterpenos ($C_{15}H_{24}$), diterpenos ($C_{20}H_{32}$) e triterpenos ($C_{30}H_{40}$) (CHOUHAN et al., 2017). Além das classes de terpenos, outros grupos funcionais como álcool, aldeído, éster, éter, cetona, ésteres e óxidos fenólicos são encontrados em OE's (BURČUL et al., 2019), essa diversidade de compostos químicos oferecem uma amplitude de aplicações na indústria de alimentos, cosméticos e farmacêutica, sendo de grande importância o estudo e identificação de suas propriedades (WINKELMAN, 2018; KHARBACH et al., 2019).

OE's são obtidos a partir de um produto vegetal que serve de matéria-prima para sua extração. Alguns dos métodos convencionais utilizados para obtenção destes são: hidrodestilação, destilação a vapor e extração por solvente (DHIFI et al., 2016), outros métodos relatados como inovadores e promissores no processo de obtenção são extração por fluído supercrítico, extração assistida por micro-ondas e extração por ultrassom (JING et al., 2019). Ao longo dos anos, a investigação de aplicações dos OE's em saúde, agricultura e meio ambiente tem aumentado (MANION & WIDDER, 2017; BAHMANI & SCHMIDT, 2018; HASSAN, MANZOOR & SALEEM, 2020).

Diversos estudos demonstram que os OE's podem ser promissores em várias atividades biológicas, entre elas: antimicrobiana (CORREA et al., 2019; RUIZ-RICO, MORENO & BARAT, 2020), antibiofilme (ARTINE et al., 2018; GAO et al., 2020), larvicida (PANDIYAN, MATHEW, and MUNUSAMY 2019; BENELLI et al., 2020), leishmanicida (SILVA et al. 2018; SAMPAIO et al., 2019), tripanocida (AZEREDO and SOARES 2013; PEREIRA et al., 2017), fungicida (MEDEIROS et al., 2016; SANTOS et al. 2018), anti-doenças autoimune (COCK and CHEESMAN, 2019), anti-inflamatória (CHOU et al. 2018; ASCARI et al., 2019); moduladora do sistema neurológico (ARRUDA et al., 2012; ZARRAD et al., 2015); Inibição enzimática (OLIVEIRA et al., 2019; FRATERNALE, FLAMINI & ASCRIZZI, 2019), antioxidante (GEDIKOĞLU, SÖKMEN & ÇIVIT, 2019; DENG et al., 2020; HENNIA et al., 2020) e aromaterapia (ALI et al., 2015; HASSAN, MANZOOR & SALEEM, 2020).

2.1.1 Família Myrtaceae

Myrtaceae é uma das grandes famílias de angiospermas que abrange cerca de 145 gêneros e cerca de 5970 espécies, distribuídas nas regiões tropicais e subtropicais do mundo (THE PLANT LIST, 2013). No Brasil, é uma das famílias mais representativas, apresentando cerca de 1000 espécies, das quais 22 são nativas e está entre as 10 famílias com maior riqueza de espécies no país (MENDES et al., 2016).

A família Myrtaceae caracteriza-se por apresentar desde arbustos a árvores altas e ser uma das principais famílias de plantas frutíferas, com numerosos exemplos de frutos comestíveis e de sabor raro (STEFANELLO, PASCOAL & SALVADOR, 2011). Alguns exemplos de gêneros que pertencem a família cujos frutos são comercializados incluem, espécies dos gêneros *Psidium* (goiabas), *Eugenia* (pitangas), *Plinia* (jabuticabas) e *Syzygium* (jambo e jamelão). Além de especiarias como o gênero *Syzygium* (cravo-da-índia); *Eucalyptus* e *Corymbia* são importantes fontes de madeira e óleos essenciais que contribuem no desenvolvimento econômico (REYNERTSON et al., 2008; SERRALHO et al., 2018; FARIAS et al., 2020).

Ao longo dos anos, diversos estudos relatam o potencial dos óleos essenciais de espécies da família Myrtaceae como uma fonte promissora de compostos bioativos e propriedades biológicas, como demonstra a tabela 1 nos últimos cinco anos.

Tabela 1 – Óleos essenciais da família Myrtaceae e suas atividades biológicas

<i>Espécie</i>	<i>Parte da planta</i>	<i>Propriedades</i>	<i>Referência</i>
<i>Calypttranthes restingae</i>	Folhas	Antinoceptivo	Passos et al., 2016
<i>Calypttranthes grandifolia</i>	Folhas	Leishmanicida	Kauffmann et al., 2016
<i>Calypttranthes tricona</i>			
<i>Eugenia arenosa</i>	Folhas	Leishmanicida	Kauffmann et al., 2016
<i>Eugenia pyriformis</i>			
<i>Eugenia dysenterica</i>	Folhas	Antidiarréico	Galheigo et al., 2016
<i>Eugenia hiemalis</i> Cambess.	Folhas	Antimicoplasmático	Zatelli et al., 2016

<i>Myrcia lundiana</i>	Folhas	Antifúngico	Alves et al., 2016
<i>Myrcia sylvatica</i>	Folhas	Antimicrobiano	Silva et al., 2016
<i>Pimenta racemosa</i>	Folhas	Antimicrobiano	Contreras-Moreno et al., 2016
<i>Syzygium zeylanicum</i>	Folhas	Larvicida	Govindarajan & Benelli, 2016
<i>Syzygium lanceolatum</i> (Lam.)	Folhas	Antimicrobiano e antioxidante	Muthumperumal et al., 2016
<i>Eucalyptus camaldulensis</i>	Folhas	Antifúngico	Yangui et al., 2017
<i>Eugenia brejoensis</i>	Folhas	Tripanocida	Souza et al., 2017
<i>Eugenia candolleana</i>	Folhas	Larvicida	Neves et al., 2017
<i>Eugenia caryophyllata</i>	Flores	Anti-inflamatório	Han & Parker, 2017
<i>Eugenia dysenterica</i>	Folhas	Antioxidante e anticolinesterásico	Feitosa et al., 2017
<i>Eugenia klotzschiana</i>	Folhas e flores	Antimicrobiano e antioxidante	Carneiro et al., 2017
<i>Eugenia pitanga</i>	Folhas	Leishmanicida	Kauffmann et al., 2017
<i>Leptospermum citratum</i>	Flores	Inseticida	Park et al., 2017
<i>Myrcia splendens</i>	Folhas	Antitumorais e antimicrobiano	Scalvenzi et al., 2017
<i>Myrtus communis</i>	Folhas	Antifúngico	Yangui et al., 2017
<i>Blepharocalyx salicifolius</i>	Folhas	Broncodilatador, Antitussígeno e antiespasmódico	Hernández et al., 2018
<i>Eucalyptus citriodora</i>	Folhas	Antimicrobiano	Tolba et al.,

			2018
<i>Eugenia uniflora</i>	Folhas	Antifúngico	Santos et al., 2018
<i>Melaleuca alternifolia</i>	Folhas	Antioxidante e antimicrobiano	Zhang et al., 2018
<i>Myrciaria floribunda</i>	Frutos	Antioxidante	Oliveira et al., 2018
<i>Myrcia oblongata</i>	Folhas	Antimicrobiano	Santana et al., 2018
<i>Myrcia rostrata</i>	Folhas	Antinociceptivo	Silva et al., 2018
<i>Psidium guineense</i>	Folhas	Antioxidante, anti-inflamatório, antiproliferativo e antimicobactéria	Nascimento et al., 2018
<i>Syzygium guineense</i>	Folhas	Antioxidante e antimicrobiano	Okhale et al., 2018
<i>Campomanesia guazumifolia</i>	Folhas	Antioxidante	Santos et al., 2019
<i>Corymbia citriodora</i> <i>Myrciaria dubia</i>	Folhas	Inseticida	Negrini et al., 2019
<i>Eucalyptus globulus</i>	Folhas	Antibacteriano e anticâncer	Adnan, Mohd. 2019
<i>Eucalyptus globulus</i> <i>Melaleuca citrina</i>	Folhas	Inibidor de acetilcolinesterase	Petrachaianan et al., 2019
<i>Eugenia dysenterica</i>	Folhas	Antifúngico	Silva et al., 2019
<i>Eugenia pyriformis</i>	Partes aéreas	Antifúngico, Leishmanicida e antitumoral	Durazzini et al., 2019
<i>Myrciaria floribunda</i>	Folhas	Inseticida	Tietbohl et al., 2019
<i>Myrciaria plinioides</i>	Folhas	Antileishmania	Kauffmann et al., 2019
<i>Psidium myrtoides</i>	Folhas	Antibacteriano	Dias et al.,


		e antitumoral	2019
<i>Syzygium aromaticum</i>	Folhas	Antifúngico	Tančinová et al., 2019
<i>Eucalyptus cloeziana</i>			
<i>Eucalyptus umbellata</i>	Folhas	Repelente, inseticida,	Tian et al., 2020
<i>Eucalyptus benthamii</i>		antibacteriano	
<i>Eugenia caryophyllus</i>	Flores	Inseticida	Matos et al., 2020
<i>Eugenia stipitata</i>	Folhas	Antinociceptivo, anti-inflamatório e antipirético	Costa et al., 2020
<i>Melaleuca sp.</i>	Folhas	Antibacteriano e antioxidante	Siddique et al., 2020

2.1.2 *Myrciaria floribunda* (H. West ex Willd.) O. Berg

Myrciaria floribunda (H. West ex Willd.) O. Berg. conhecida popularmente como cambuí ou camboin é uma espécie nativa do Brasil, encontrada nos domínios fitogeográficos da Amazônia, Floresta Atlântica, Caatinga e Cerrado (MAIA, 2019). Em relação aos seus aspectos botânicos trata-se de um arbusto com altura variando de 3 – 16 m, folhas elípticas e flores sésseis com brácteas, seus frutos são bagas que pode variar de 0,4 - 0,8 cm (Figura 1) e apresentam-se nas colorações verde vermelho, vinho, ou laranja de acordo com o grau de maturação (SANTOS et al., 2018).

Os frutos de *M.floribunda* podem ser apreciados tanto “*in natura*”, como processados na forma de licores, geleias e doces (WU, LONG & KENNELLY 2013; TNG et al., 2019). Segundo estudos de Santos et al. (2017) e Oliveira et al. (2018) os frutos *M. floribunda* são fontes nutricionais que apresentam concentrações significativas de β -criptoxantina (pró-vitamina A) e ácidos fenólicos relatados por apresentarem potencial antioxidante.

Figura 1 – Folhas, flores e frutos de *Myrciaria floribunda*



1A – Ramos com flores e frutos (Desenhado por: Nolán Iglesias Martínez. Fonte: Ramos, Pendás & Urra, 2015); 1B – flor (Fonte: Ramos, Pendás & Urra, 2015); 1C - frutos de *M. floribunda* (Fonte: Autor).

Estudos avaliando as propriedades farmacológicas de extratos das folhas de *M. floribunda* relataram potencial antitumoral (TIETBOHL et al., 2017), antioxidante e antimicrobiana (AZEVEDO et al., 2019). Enquanto que, o óleo essencial das folhas demonstrou-se como um promissor inseticida (TIETBOHL et al., 2014; TIETBOHL et al., 2019; FEDER et al., 2019) e apresentou leve inibição da enzima acetilcolinesterase (TIETBOHL et al., 2012). No entanto, ainda são raros os estudos avaliando as propriedades biológicas da espécie e nenhum relato sugere a utilização da casca do fruto para investigação, que por vezes é desprezada como matéria sem utilidade. Dessa forma, pesquisas científicas que forneçam informações sobre o potencial de espécies naturais e seus resíduos em aplicações biotecnológicas são de grande importância para o desenvolvimento de produtos sustentáveis que ofereçam vantagens econômicas e ambientais (TREICHEL et al., 2020).

2.1.3 Frutos e seus benefícios para a saúde

As frutas e vegetais contêm uma variedade de micronutrientes específicos para a função física e mental. São altamente recomendados, tendo em vista as contribuições benéficas que esses alimentos oferecem para uma vida saudável (BROOKIE et al., 2018). Eles apresentam uma grande variedade de constituintes fitoquímicos, entre eles minerais e vitaminas que desempenham um papel fundamental na proteção e bom funcionamento do corpo (YAHIA, GARCÍA-SOLÍS & CELIS, 2019).

As vitaminas (C, A e E), flavonoides, antocianinas e compostos fenólicos presentes em frutas são componentes descritos como potenciais antioxidantes, que atuam neutralizando espécies reativas de oxigênio e nitrogênio, responsáveis pelo estresse oxidativo (BARBOSA, SILVA & CORREIA, 2019). O estresse oxidativo é a causa e/ou progressão de várias doenças, entre elas: doenças cardiovasculares, câncer, doença inflamatória crônica, formas de depressão e doenças neurodegenerativas (PATEL et al., 2019).

Estudos comparativos avaliando as propriedades nutricionais das cascas e polpas de frutas relatam que, as cascas são fontes promissoras de compostos bioativos (flavonoides, antocianinas, minerais e vitaminas) e em grande parte dos casos excedem o valor nutricional da polpa (ABBASI et al., 2017; SAIDANI et al., 2017). No entanto, no consumo de frutas muitas vezes as cascas são descartadas como resíduos não utilizáveis e de pouco valor, porém, deve ser dada atenção às suas propriedades como alimento funcional e uma fonte de matéria-prima para as indústrias alimentícia e farmacêutica (CZECH et al., 2019). Vários produtos naturais obtidos de plantas medicinais, frutas e vegetais demonstram ser potenciais agentes terapêuticos no desenvolvimento de novas formulações para o tratamento de doenças, dentre elas doenças neurodegenerativas (SOLAYMAN et al., 2017; Silva & Pogačnik, 2020) e doenças tropicais negligenciadas (CHEUKA et al., 2017; VARELA & FERNANDES, 2019).

2.2 DOENÇAS NEURODEGENERATIVAS

Distúrbios mentais como demência e depressão são condições altamente prevalentes na população mundial, além de serem achados comuns em doenças neurodegenerativas (RÉUS et al., 2016; KOVASC, 2018; GALTS et al., 2019). De acordo com a organização mundial de saúde (OMS) cerca de 50 milhões de pessoas no mundo apresentam demência e projeta-se que esse valor triplique até 2050, para um valor de 152 milhões de casos (WHO, 2017). Estimativas recentes, abordam que mais de 264 milhões de pessoas vivem com depressão no mundo (WHO, 2020). Ambos transtornos mentais costumam ser fatais e resultam em altos gastos para o sistema de saúde (WHO, 2017; POHL & LIN, 2018; KAMAL et al., 2019).

As doenças Neurodegenerativas (DN) são uma das causas mais comuns de morbidade e mortalidade em todo mundo, principalmente em idosos (Erkkinen et al., 2018). A neurodegeneração é um fenômeno de perda progressiva da estrutura ou função dos neurônios, resultando em comprometimentos mentais e funcionais, devido à alterações no processo de neurotransmissão e a incapacidade de renovação celular (WINNER & WINKLER, 2015; CHEN, ZHANG & HUANG, 2016).

O diagnóstico precoce em combinação com o tratamento adequado são de grande importância para retardar a progressão da doença, que geralmente é diagnosticada com base na avaliação neuropatológica (KOIKKALAINEN et al., 2016). As DN podem ser classificadas de acordo com as características clínicas primárias (demência, parkinsonismo, distúrbios em neurônios motores), distribuição anatômica de neurodegeneração (degeneração frontotemporais, distúrbios extrapiramidais ou degenerações espinocerebelares) ou anormalidades moleculares (KOVACS & BUDKA, 2010; DUGGER & DICKSON, 2017). Contudo, a etiologia das DN permanece em investigação.

Doença de Alzheimer (SPIERS-JONES, ATTEMS & THAL, 2017), Doença de Parkinson (FU, HARDY & DUFF, 2018), Doença de Huntington (COLGAN & TABRIZI, 2018), Esclerose Lateral Amiotrófica (HARDIMAN et al., 2017), Esclerose múltipla (NIEDZIELSKA et al., 2016) e Miastemia grave (PHILLIPS & VINCENT, 2016) são exemplos de DN. O quadro 1 resume as principais características encontradas nestas doenças, que estão relacionadas à distúrbios no sistema nervoso central (SNC), sistema nervoso periférico (SNP) e acometimento do sistema colinérgico.

Quadro 1 – Doenças Neurodegenerativas: principais características e sintomas

Doenças Neurodegenerativas	Características	Principais sintomas
Doença de Alzheimer (DA)	Atrofia da substância cinzenta, acúmulo de placas amiloides e emaranhados neurofibrilares	Demência
Doença de Parkinson (DP)	Perda de substância nigra e de neurônios dopaminérgicos	Perda de movimentos
Doença de Huntington (DH)	Perda de neurônios GABAérgicos	Distúrbios cognitivos, motores e psiquiátricos
Esclerose Lateral Amiotrófica (ELA)	Perda de neurônios motores superiores e inferiores	Fraqueza e paralisia muscular
Esclerose Múltipla (EM)	Distúrbio desmielinizante imuno-mediado do SNC	Alterações na mobilidade, equilíbrio, visão e cognição
Miastemia Grave (MG)	Doença autoimune que afeta a junção neuromuscular	Fraqueza e fadiga muscular


Fonte: Elaborado pelo autor

2.2.1 Sistema Colinérgico

O sistema colinérgico está envolvido em importantes funções do organismo, incluindo cognição; aprendizado e memória; processamento sensorial e motor; sono e estresse; processamento e regulação emocional (OFEK & SOREQ, 2013; SZUTOWICZ ET AL., 2013; PEPEU & GIOVANNINI, 2017). Ele atua sobre o sistema nervoso periférico (SNP), incluindo nervos motores, órgãos do sistema autônomo e sistema nervoso central (SNC), na propagação excitatória e comunicação entre células nervosas (MU & HUANG, 2019). O sistema colinérgico é formado por uma rede de neurônios que sintetizam e liberam acetilcolina (ACh), neurotransmissor que desempenha papel crucial na manutenção da homeostase e funções cerebrais (BAXTER & CRIMINIS, 2018).

A molécula de ACh é constituída a partir de um éster de colina e ácido acético por ação da acetiltransferase. Após sua síntese, a ACh é armazenada em vesículas sinápticas e encaminhada para a membrana do neurônio pré-sináptico (Figura 2) quando um impulso nervoso é propagado há liberação da ACh na fenda sináptica (BROWN, 2019). Esse neurotransmissor irá atuar sobre o neurônio pós-sináptico, através da ligação com receptores colinérgicos, assim, o impulso nervoso é regenerado e propagado para o neurônio seguinte, resultando na transmissão da mensagem excitatória (AKAIKE et al., 2018).

Figura 2 – Síntese e liberação de acetilcolina na fenda sináptica




Os receptores de ACh de uma forma geral são divididos em receptores nicotínicos (nAChRs) e receptores muscarínicos (mAChRs) (WESSLER & KIRKPATRICK, 2008). Os nAChRs são formados por combinações de subunidades α e β , encontrados no cérebro, junções neuromuscular, regiões ganglionares e células não-neuronais (WONNACOTT et al., 2018; ZOLI ET AL., 2018). Os mAChRs são receptores acoplados a proteína G, classificados em cinco subtipos (M1, M2, M3, M4 e M5) e são encontrados no SNP; órgãos autônomos e glândulas exócrinas (LANGMEAD et al., 2008). Após, a condução da mensagem excitatória, a ACh é degradada rapidamente pela ação da acetilcolinesterase (AChE), que desempenha um papel essencial na neurotransmissão (AKAIKE et al., 2018).

AChE é uma serino-hidrolase responsável pela finalização da transmissão dos impulsos nervosos nas sinapses colinérgicas, através da hidrólise da ACh presente na fenda sináptica em colina e ácido acético (CONCEIÇÃO PETRONILHO et al., 2011). É uma das enzimas mais eficientes do sistema nervoso, com capacidade de hidrolisar 6×10^5 moléculas de ACh por minuto. Encontra-se presente em tecidos condutores, nervos, músculos, SNC e SNP; fibras motoras e sensoriais; sistema simpático e parassimpático; sistema colinérgico e não-colinérgico; e junções neuromusculares (TRIPATHI & SRIVASTAVA, 2010).

A estrutura tridimensional da AChE demonstra que a enzima possui dois sítios para ligação, um sítio ativo catalítico (CAS) localizado inferiormente a região de abertura e o sítio aniônico periférico (PAS) localizado a cerca de 15 Å acima do CAS, Figura 3 (SOREQ & SEIDMAN, 2001; SAXENA & DUBEY, 2019). O sítio catalítico é subdividido em dois subsítios: esterático e aniônico. O subsítio esterático é composto por uma tríade catalítica de ácido glutâmico (E202), serina (S203) e histidina (H447). Enquanto que, o subsítio aniônico é constituído por triptofano (W86) (PETRONILHO, PINTO & VILLAR, 2011). A tríade catalítica é a responsável pela hidrólise da acetilcolina, enquanto o nitrogênio quaternário da fração colina interage com o triptofano (W86) no subsítio aniônico. Já o sítio aniônico periférico (PAS), associa-se a compostos bis-quaternários e pode estar envolvido na ação de inibidores da enzima ou na inibição por excesso de substrato (SCHMATZ, 2009; SAXENA & DUBEY, 2019).

Figura 3 – Estrutura característica da enzima acetilcolinesterase



Fonte: Soreq & Seidman (2001)

2.2.2 Acetilcolinesterase e neurodegeneração


As vias de sinalização colinérgicas tem sido estudadas em doenças neurodegenerativas com a finalidade de melhorar o quadro fisiopatológico nesses distúrbios neurológicos e psiquiátricos (VENTURA et al., 2010; PEPEU & GIOVANNINI, 2017). Para restaurar os níveis de ACh nas sinapses colinérgicas e melhorar a função cognitiva e motora, consequentemente a qualidade de vida, tem sido retratado efeitos benéficos de inibidores de acetilcolinesterase (AChEIs) no tratamento da Doença de Parkinson (MATSUNAGA et al., 2016) e Doença de Alzheimer (DA) (WANG & ZHANG, 2019).

Na DA a degeneração dos neurônios colinérgicos tem sido um achado primário e constante em pacientes (STANCIU et al., 2020). Outros acometimentos como alterações genéticas na expressão de receptores muscarínicos e nicotínicos; diminuição da síntese e liberação de ACh e acúmulo relativo de AChE na fenda sináptica são problemas relacionados ao sistema colinérgico que comprometem a neurotransmissão (OZ, PETROIANU & LORKE, 2016). Os AChEIs tem sido preconizados no tratamento farmacológico da DA por apresentarem propriedades neuroprotetoras e anti-inflamatórias, além de reduzir as fibrilas tóxicas na DA e restaurar os níveis de ACh (SANTOS et al., 2018; BENFANTE et al., 2019). Atuam também no tratamento dos sintomas comportamentais e psicológicos, como a demência, reduzindo a necessidade de psicotrópicos e ansiolíticos, principalmente em doses altas (TAN et al., 2020). A Figura 4 apresenta as estruturas químicas de alguns AChEIs utilizados no tratamento da DA.

Medicamentos como rivastigmina, neostigmina, tacrina e donepezil são utilizados no tratamento da disfunção cognitiva e de memória associada a DA. Contudo, estes compostos

cursam com efeitos adversos como, alterações gastrointestinais, náuseas, vômito e problemas associados a sua biodisponibilidade, como por exemplo, baixa seletividade (BURČUL et al., 2019). Diante disso, existe a necessidade de novos compostos que apresentem menos efeitos adversos. Nesse contexto, os produtos naturais são candidatos promissores para a investigação de compostos bioativos que possam atuar no combate e/ou prevenção de doenças neurodegenerativas (KHATOON, REHMAN & RAHMAN, 2018).

Figura 4 - Estruturas de inibidores de acetilcolinesterase



Legenda: 1 – fisostigmina, 2 - rivastigmina, 3 - neostigmina,
4 - carbaril, 5 - tacrina, 6 - galantamina, 7 – donepezil.

Fonte: Burčul et al. (2019).

2.2.3 Produtos naturais *versus* doenças neurodegenerativas

Os produtos extraídos de plantas podem atingir diferentes vias de sinalização metabólicas envolvidas na patogênese de doenças, devido a ação de vários fitoconstituintes que encontram-se presentes em produtos naturais (DEY et al., 2016). Estudos abordam que compostos bioativos presentes em produtos naturais como antocianinas, carotenoides, resveratrol, alfa tocoferol, quercitina, 7,8-di-hidroxifavona entre outros compostos da classe de polifenóis apresentam efeitos benéficos para a prevenção de doenças neurodegenerativas (SOLANKI et al., 2015; ELUMALAI & LAKSHMI, 2016; SHAHIDI & YEO, 2018; MAHER, 2019). Alguns mecanismos apresentados pelos produtos naturais na neuroproteção são: redução da fosforilação da proteína Tau (ESSA et al., 2012), inibição de agregação proteica

(CUANALO-CONTRERA & MORENO-GONZALEZ, 2019), potencial antioxidante, ação sobre a neuroinflamação (JIN et al., 2019) e inibição da acetilcolinesterase (SILVA & POGACNIK, 2020).

A galantamina (alcaloide natural) e a rivastigmina (alcaloide sintético) são inibidores de acetilcolinesterase aprovados clinicamente que possuem como base produtos naturais (GONZÁLEZ et al., 2019). Atualmente, não existe terapias eficazes para a maioria das doenças neurodegenerativas que baseiam-se em reduzir os sintomas comportamentais e cognitivos, sem alterar de forma significativa a progressão da doença (CUNY, 2012; SATHEESHKUMAR et al., 2016).

Novas terapias mais eficazes que possa prevenir a progressão destas doenças são necessárias, nesse contexto, os óleos essenciais são ótimas estratégias para o planejamento de novos medicamentos e avaliação das atividades cerebrais (XU et al., 2014; RANJAN & KUMARI, 2017). Estudos com óleos essenciais demonstraram ser eficazes em modelos de doenças neurodegenerativas *in vitro* e *in vivo*, atuando como neuroprotetores e na redução do comprometimento neuronal (AYAZ et al., 2017; AUMEERUDDY-ELALFI et al., 2018; PETRACHAIANAN et al., 2018; POHL & LIN, 2018; BENNY & JAYA, 2019; EFTEKHARI et al., 2019).

2.3 DOENÇAS TROPICAIS NEGLIGENCIADAS (DTN)

Doenças tropicais negligenciadas são um grupo diversificado de doenças transmissíveis prevalentes em países tropicais e subtropicais. Atualmente, a OMS reconhece 17 infecções relacionados à DTN (HOTEZ et al., 2016) quadro 2. Estas doenças continuam sendo um problema de saúde pública mundial, que afeta mais de um bilhão de pessoas, principalmente populações que residem em condições de pobreza, falta de saneamento básico e em contato próximo com vetores infectados (WHO, 2020).

Medidas com o propósito de combater as DTN estão entre os desafios estabelecidos pela ONU. De acordo com os objetivos de desenvolvimento sustentável (ODS), até 2030 países desenvolvidos e em desenvolvimento devem realizar intervenções para cobertura universal das DTN na atenção primária à saúde, principalmente em áreas de extrema pobreza. E também, realizar intervenções que impeçam a transmissão de doenças negligenciadas, cuja finalidade de ambas medidas é promover equidade e eliminar problemas de saúde relacionados à pobreza (UNITED NATIONS, 2015; ENGELS & ZHOU, 2020).

Quadro 2 – Lista de doenças tropicais negligenciadas consideradas pela OMS

Doenças Tropicais Negligenciadas (DTN)	
Úlcera de Buruli	Tracoma
Teníase e Neurocisticercose	Micetoma
Doença de Chagas	Bouba
Dracunculíase	Oncocercose
Dengue	Hanseníase
Equinococose	Esquistossomose
Raiva	Tripanossomíase humana africana
Filariose Linfática	Helmintíase transmitida pelo solo
Leishmaniose	

Fonte: adaptado de Santos (2019)

Fatores importantes estão envolvidos no surgimentos e disseminação das DTN, dentre elas a Leishmaniose. Condições socioeconômicas (pobreza), ambientais (desmatamento e mudanças climáticas), migrações para áreas endêmicas, resistência a medicamentos, falta de controle dos reservatórios e vetores são exemplos de fatores que estão diretamente envolvidos com o aumento de casos de Leishmaniose (ORYAN & AKBARI, 2016).

2.3.1 Leishmaniose

A leishmaniose é uma doença tropical negligenciada causada por protozoários do gênero *Leishmania* que continua sendo uma epidemia recorrente, responsável por casos de morbidade e mortalidade (VALERO & URIARTE, 2020). Apresenta distribuição mundial, sendo encontrada principalmente em países da Europa, Ásia, África e América. Anualmente, cerca de um milhão de novos casos são relatados por ano e em média 65.000 mortes (WHO, 2019). No Brasil, a Leishmaniose Cutânea (LC) e Leishmaniose Visceral (LV) estão incluídas na lista nacional de doenças e agravos de notificação compulsória, de acordo com dados do Sistema de Informação de Agravos de Notificação (SINAN) em 2018 foram registrados 17.119 casos de LC e 3.376 casos de LV (SINAN, 2018).

2.4 AGENTE ETIOLÓGICO, CICLO DE VIDA E VETOR

Os protozoários do gênero *Leishmania* pertencem a ordem Kinetoplastida e a família Trypanosomatidae são os agentes etiológicos da Leishmaniose. Estes podem ser classificados em dois subgêneros: *Viannia* e *Leishmania*, de acordo com o local de desenvolvimento do protozoário no hospedeiro. As espécies responsáveis por causar infecções pertencem a estes dois grupos e cerca de 20 espécies são conhecidas por causarem infecções em humanos, sendo 10 delas de grande importância para a saúde pública, tabela 2 (HURRELL et al., 2016; STEVERDING, 2017).

Tabela 2 – Principais formas clínicas de leishmaniose cutânea


Síndrome Clínica	Espécies ¹	Manifestações Clínicas
Leishmaniose Cutânea Localizada (LCL)	<i>L. (L.) major</i>	
	<i>L. (L.) mexicana</i>	Número único ou limitado de
	<i>L. (L.) amazonensis</i>	lesões; úlceras formadas podem ser
	<i>L. (V.) braziliensis</i>	molhadas ou secas com borda
	<i>L. (L.) tropica</i>	crateriforme elevada. Cargas
	<i>L. (L.) aethiopica</i>	moderadas de parasitas em biópsias
	<i>L. (V.) panamanensis</i>	da borda da úlcera; resposta DTH ²
	<i>L. (L.) infantum</i>	positiva
	<i>L. (L.) donovani</i>	
Leishmaniose Cutânea Difusa (LCD)	<i>L. (L.) amazonensis</i>	Lesões nodulares múltiplas, disseminadas e não ulcerativas; muitos parasitas em lesões; resposta DTH ausente (anergia)
	<i>L. (L.) mexicana</i>	
	<i>L. (V.) pifanoi</i>	
	<i>L. (L.) aethiopica</i>	
	<i>L. (L.) major</i>	
Leishmaniose Mucocutânea (LCM)	<i>L. (V.) braziliensis</i>	Lesões altamente inflamatórias envolvendo membranas de mucosas; pode ser desfigurante. Formas raras de parasitas presentes em biópsias; forte resposta de DTH
	<i>L. (V.) panamanensis</i>	
	<i>L. (V.) guyanensis</i>	
	<i>L. (L.) amazonensis</i>	

¹ (L.) denota o subgênero *Leishmania*. (V.) denota o subgênero *Viannia*. ² DTH refere-se a uma resposta de hipersensibilidade tardia ao antígeno de *Leishmania*, um teste que também é chamado de teste cutâneo de *Leishmania* (LST) ou teste de Montenegro. Fonte: Adaptado de Scorza, Carvalho & Wilson, 2017.

Os parasitos causadores da leishmaniose apresentam ciclo heteroxênico e duas formas evolutivas distintas: promastigota e amastigota. A promastigota é a forma extracelular, flagelada e móvel. Enquanto que, a forma amastigota é obrigatoriamente intracelular, imóvel e sem flagelo livre (figura 5). A transmissão da leishmaniose para homem ocorre através da picada de flebotomíneos fêmeas do gênero *Lutzomyia* (novo mundo) e *Phlebotomus* (velho mundo), que atuam como vetores no processo de infecção.

Quando os flebotomíneos infectados realizam o repasto sanguíneo, injetam a forma promastigota metacíclica (forma infectante) no hospedeiro vertebrado. O sistema imune inato do hospedeiro na tentativa de combater o processo infeccioso, recruta macrófagos que fagocitam os parasitas. Estes permanecem internalizados no vacúolo parasitóforo, região em que ocorre a conversão da forma promastigota para amastigota e multiplicação celular (SUNTER & GULL, 2017). Após, intensa multiplicação, a membrana do macrófago é rompida e os amastigotas são liberados no tecido. Esses podem ser fagocitados por novos macrófagos ou serem ingeridos por flebotomíneos durante novo repasto sanguíneo. Caso seja ingeridos pelo vetor, no intestino médio do inseto, as formas amastigotas se diferenciam em promastigota metacíclica e migram para a região estomacal, onde ocorre a diferenciação para a forma infectante, quando o flebotomíneo se alimentar de um novo hospedeiro o ciclo evolutivo recomeça (TEIXEIRA et al., 2013).

Figura 5 – Ilustração do ciclo evolutivo da *Leishmania amazonensis*




Fonte: Teixeira et al. 2013

2.4.1 Leishmaniose Cutânea (LC)

A Leishmaniose Cutânea (LC) também denominada de Leishmaniose Tegumentar (LT) foi descrita pela primeira vez no Velho Mundo pelos pesquisadores Lewis e Cunningham, em 1876. Mundialmente, 89 países são endêmicos para LC e 90 % dos casos ocorrem no Afeganistão, Argélia, Brasil, Paquistão, Peru, Arábia Saudita, Arábia e Síria, figura 6 (REITHINGER et al., 2007; WHO, 2019).

Figura 6 - Áreas endêmicas de Leishmaniose Cutânea



Fonte: WHO, 2018

As espécies comumente responsável pelos casos de leishmaniose cutânea no Brasil são a *Leishmania brasilienses* e *Leishmania amazonensis*. As diferentes apresentações clínicas da doença variam de acordo com a resposta imune do hospedeiro e aspectos do parasita; e com base nas formas clínicas a LC pode ser classificada em: localizada, difusa ou mucocutânea (MASMOUDI et al., 2013).

2.4.2 Leishmaniose cutânea localizada (LCL)

A LCL caracteriza-se por uma pápula eritematosa assintomática, com tamanho variando de 1 a 10 mm de diâmetro, apresentando região ulcerada e bordas nodulares grossas ou pontiagudas (figura 7). As regiões do corpo mais acometidas são: orelhas, nariz, lábios, bochechas, pernas, mãos e antebraços, cujo período de incubação pode variar de 1 a 4 semanas (TORRES-GUERRERO, 2017).

Figura 7 - Lesão de Leishmaniose Cutânea Localizada



Fonte: Torres-Guerrero et al. (2017)

A LC pode curar espontaneamente em até 4 anos, quando isso acontece, a cura progride da periferia para o centro da lesão. A cicatrização espontânea deixa uma placa com pigmentação irregular e cicatrizes retráteis, bem como deformidade local devido à grande extensão do dano tecidual. Por outro lado, quando não há uma resposta imune celular do hospedeiro frente à infecção pode haver uma piora do quadro e estabelecimento da Leishmaniose Cutânea Difusa (TORRES-GUERRERO et al.2017; ANVERSA et al., 2018).

2.4.3 Leishmaniose Cutânea Difusa (LCD)

A LCD é decorrente da ausência de resposta imune frente aos antígenos do parasita, o que resulta na disseminação tecidual, linfática e sanguínea. As lesões são caracterizadas por múltiplos nódulos ou pápulas que se desenvolvem lentamente e sem ulcerações, envolvendo todo corpo e em alguns casos mucosas. Nessa forma clínica de leishmaniose não há cura espontânea e casos de recidivas são frequentes após o tratamento, figura 8 (HAILU, DAGNE & BOELAERT, 2016).

Figura 8 – Lesão de Leishmaniose Cutânea Difusa



Fonte: Torres-Guerrero et al. (2017)

2.4.4 Leishmaniose mucocutânea (LMC)

A LMC têm como principal característica o acometimento de mucosas, principalmente a mucosa nasal e oral. Os sintomas iniciais são inespecíficos, dificultando o diagnóstico. A princípio as lesões são superficiais e progridem lentamente formando crostas com aspecto necrótico que levam a desfiguração facial do palato, septos nasais e lábios (Figura 9), ocorre também linfadenopatia acentuada e, quando não tratada, pode levar à morte (GOTO & LINDOSO, 2012; STEVERDING, 2017).

Figura 9 – Lesão de Leishmaniose Mucocutânea




Fonte: Gomes et al. (2004)

2.5 LEISHMANIOSE VISCERAL – LV


A LV também conhecida como Calazar é a forma mais grave da leishmaniose, na maioria dos casos é fatal. Cerca de 76 países são endêmicos, e no continente americano em pelo ao menos 12 deles (Figura 10). No Brasil é descrita em vários municípios, com média de 3500 casos registrados anualmente e coeficiente de incidência de 2,0 casos/100.000 habitantes. De acordo com dados do Ministério da Saúde (OMS), a região nordeste apresenta uma grande prevalência de caso ao longo dos anos, gráfico 1 (MINISTÉRIO DA SAÚDE, 2017; WHO, 2018).

Figura 10 - Áreas endêmicas de Leishmaniose Visceral



Fonte: WHO (2018).

Gráfico 1- Casos de Leishmaniose Visceral por regiões brasileiras, 2008 a 2017



Fonte: Ministério da Saúde (2017).

A LV é causada pelas espécies *Leishmania donovani* (na Índia e África) e *Leishmania infantum* (Mediterrâneo e Américas). Manifesta-se como uma doença sistêmica, que, quando não tratada, pode evoluir para óbito em mais de 90 % dos casos (MINISTÉRIO DA SAÚDE, 2016). As manifestações clínicas caracteriza-se por febre prolongada, pancitopenia, linfadenopatia, perda de peso, hepatomegalia, esplenomegalia, anemia e globulinemia (SUDAN et al., 2019). A LV pode evoluir, se não tratada para uma forma crônica denominada leishmaniose dérmica pós-kala-azar (PKDL) caracterizada por nódulos endurecidos ou máculas despigmentadas, Figura 11 (SUNDAR & CHAKRAVARTY, 2018).

Figura 11 - Leishmaniose Visceral e Leishmaniose dérmica Pós-kala-azar



A - Leishmaniose Visceral; B - Leishmaniose dérmica Pós-kala-azar

Fonte: WHO (2020).

2.6 DIAGNÓSTICO E TRATAMENTO

O diagnóstico da leishmaniose envolve aspectos clínicos e laboratoriais. O diagnóstico laboratorial direto é realizado através da identificação microscópica de amastigotas em esfregaços de biópsias, raspagens ou impressões corados com Giemsa. Os testes sorológicos para detecção de anticorpos *anti-leishmania* como a reação intradérmica de Montenegro, Elisa, imunofluorescência, citometria de fluxo, testes rápidos e testes de aglutinação são métodos imunológicos para detecção do parasito. A detecção de DNA do parasita por PCR é um método bastante sensível, no entanto, não é uma prática em países em desenvolvimento (ELMAHALLAWY et al., 2014). O tratamento da Leishmaniose baseia-se em três classes de

medicamentos: antimoniais pentavalentes, pentamidina e anfotericina B. No entanto, todos os quimioterápicos disponíveis apresentam limitações, dentre elas: alta toxicidade, reações adversas e casos de resistência, como demonstra a tabela 3 (MENEZES et al., 2015; SAVOIA, 2015; KASHANI, KHAMESIPOUR & FIROOZ, 2018).

Tabela 3 – Medicamentos utilizados no tratamento da Leishmaniose

Medicamento	Via de Administração	Toxicidade	Comentário
Antimoniais pentavalentes	IM IV IL	Cardiotoxicidade grave, Pancreatite, Nefrotoxicidade, Hepatotoxicidade	Medicamentos de primeira linha, mas com altas incidências de resistência; resposta variável em diferentes espécies que causam LC
Anfotericina B	IV	Nefrotoxicidade grave, Reações relacionadas à infusão, hipocalemia, febre alta	Toxicidade grave; necessidade de hospitalização prolongada; medicamento de primeira linha para LV na Índia, onde há resistência antimonial
Anfotericina B lipossomal	IV	Rigidez e calafrios leves durante a infusão Nefrotoxicidade leve (infrequente e leve)	Alto custo
Miltefosina	Oral	Vômitos e diarreia, nefrotoxicidade, hepatotoxicidade, teratogenicidade	Eficaz por via oral, mas sua meia-vida longa pode incentivar o surgimento de resistência em uso prolongado; eficaz para LV e contra algumas espécies que causam LC;

			contraindicado na gravidez como teratogênico em ratos
Paromomicina	IM (LV) ou tópico (LC)	Nefrotoxicidade grave, Ototoxicidade, Hepatotoxicidade	Baixo custo; falta de eficácia na África Oriental; formulação tópica disponível para CL
Pentamidina	IM	Alta taxa de hiperglicemia, como resultado de dano pancreático; hipotensão, taquicardia e alterações eletrocardiográficas	Apenas para formas específicas de CL na América do Sul; primeira linha de tratamento de CL na Guiana Francesa

IV: administração intravenosa; IM: administração intramuscular; IL: administração intralinfática.

Fonte: Adaptado de Menezes et al. (2015)

Não existe vacinas para a leishmaniose e a terapia medicamentosa apresenta muitas limitações. Nesse contexto, a busca por alternativas terapêuticas eficazes, menos tóxicas e de baixo custo para o tratamento da CL é necessária. Assim, a prospecção de produtos naturais para o tratamento de doenças parasitárias consiste numa medida promissora para investigação e desenvolvimento de formulações úteis no tratamento da CL (Luna et al., 2019; Soni et al., 2019).

3 METODOLOGIA

3.1 OBTENÇÃO DO ÓLEO ESSENCIAL

Os frutos de *Myrciaria floribunda* foram coletados na cidade de Exú, estado de Pernambuco, Brasil, em 2018 (Latitude:-7.355809029182327; longitude:-39.887568331218304). A espécie foi identificada pelo botânico Dr. Alexandre Gomes da Silva e o voucher 92722 foi depositado no Herbário do Instituto Agronômico de Pernambuco (IPA). A extração do MfEO foi realizada pelo método de hidrodestilação (aparelho de Clevenger). Para obtenção do óleo 200 g da casca do fruto foram misturados a 2,5 L de água destilada e submetido a hidrodestilação por 3 horas. Após a extração, o óleo foi armazenado a 5°C.

3.2 CARACTERIZAÇÃO QUÍMICA

A análise química do óleo essencial foi realizada por cromatógrafo gasoso Thermo Trace GC Ultra (Thermo Scientific, Milão, Itália), através de um detector de ionização de chama (FID). Uma coluna capilar de sílica fundida VB-5 5 (ValcoBond 30 m × 0,25 mm x 0,25 mm) foi utilizada para separação dos constituintes (Valco Instruments Company Inc., Houston, TX, EUA) e nitrogênio a uma vazão de 1 L/min e pressão de entrada de 30 psi foi utilizado como gás de arraste. O gradiente inicial de temperatura foi 40°C durante 2 min, e aumento de 4°C/min até 230°C foi mantido durante 5 min. As temperaturas do injetor e detector foram ajustadas para 250 °C e 280 °C, respectivamente. A amostra (1µl) foi injetada e a quantidade relativa de cada componente estimada pela área do pico correspondente e expressa como uma porcentagem da área total do cromatograma. Os espectros de massa foram realizados a 70 eV (no modo EI) com uma velocidade de 1.0 varreduras de m / z 35-350. A identificação dos componentes individuais foi realizada em comparação com os valores de índices de retenção de uma série de n-alcanos de acordo com a literatura (VAN DEN DOOL E KRATZ, 1963); os dados disponíveis na biblioteca espectral de massa do sistema GC-MS (MassFinder 4, Hochmuth, Hamburgo, Alemanha); Biblioteca Espectral de Massa NIST08 (ChemSW Inc. Fairfield, CA, EUA); Wiley Registry TM da Relação Espectral de Massa 9ª Edição (Wiley, Hoboken, NJ, EUA) e dados espectrais de massa publicados (ADAMS, 2017).

3.3 ANÁLISES *IN SILICO*

3.3.1 ADMET

Para prever as propriedades farmacocinéticas semelhantes a drogas dos compostos majoritários do MfEO, foram utilizadas as seguintes plataformas on-line: Swiss ADME, Swiss Target Prediction (SIB., Lausanne, Suíça) PROTOX-II Server (Universidade Charité, Berlim, Alemanha), Molinspiration (Molinspiration Cheminformatics, Nova Ulica, República Eslovaca), Osiris Property Explorer, Osiris Data Warrior (Actelion Pharmaceuticals Ltd., Allschwil, Suíça) e pKCSM (Pires, Blundell e Ascher 2015). Informações sobre o medicamento de referência, a Neostigmina (PubChem CID: 4456), utilizada como parâmetro comparativo para as análises foram obtidas no banco de dados PubChem (<https://pubchem.ncbi.nlm.nih.gov/>).

3.3.2 Docking Molecular

A abordagem de docking molecular utilizada neste estudo teve como objetivo identificar a ligação dos compostos majoritários com enzimas envolvidas em doenças neurodegenerativas (acetilcolinesterase PDB:4PQE) e Leishmaniose (esterol 14-alfa desmetilase PDB:3L4D). As estruturas correspondentes às proteínas foram obtidas no Protein Data Bank (Berman, Henrick and Nakamura 2003) e os resultados sobre os valores de energias de ligação, eletrostática, intermolecular e superfície de interação foram determinadas e analisadas usando o algoritmo genético Lamarckiano (López-Camacho et al. 2015).

3.4 ATIVIDADE DE INIBIÇÃO ENZIMÁTICA

A avaliação do potencial de inibição enzimática da acetilcolinesterase foi determinada em microplaca por método espectrofotométrico (ASSIS et al., 2012; SOUZA et al., 2018). As enzimas utilizadas para os ensaios foram acetilcolinesterase (AChE) extraída de *Crassostrea rhizophorae* e AChE comercial *Electrophorus electricus* (Sigma). A incubação foi realizada adicionando 10 µl da AChE e 10 µl do MfEO em diferentes concentrações (0,0001 a 1 mg/ml) considerando-se a ausência de óleo (0,0 mg/mL) como controle negativo (100% de atividade). Foram utilizados como branco DMSO + tampão (Tris-HCl 0,5 mM pH 8,0); e Neostigmina como controle positivo (inibidor padrão). A placa foi incubada por 1h em temperatura de 25°C. Após, o período de incubação foram adicionados 200µl do reagente cromogênico DNTB

(0,25mM) e 20 µl do substrato (ASCh) a leitura foi realizada em comprimento de onda de 405 nm nos tempos 0 e 180 segundos. O percentual de inibição enzimática foi determinado com base nos controles. O ensaio foi realizado em quadruplicata e os cálculos utilizando o programa Microsoft Excel.

3.4 ENSAIO DE CITOTOXICIDADE

O potencial citotóxico do MfEO foi avaliado de acordo com o protocolo estabelecido por Aliança, et al. (2017) com pequenas modificações. Resumidamente, os modelos de células Vero e macrófago J774A.1 foram plaqueados (5×10^5 células/poço) em placa de 96 poços em meio 100 µL de meio RPMI, suplementado com 10% SFB inativado e incubado após 3h a 37° C em CO₂ a 5%. Após esse período, as células não aderentes foram removidas, as células Vero e os macrófagos aderidos foram cultivados por 48 h em RPMI na ausência ou presença de diferentes concentrações do MfEO (31.25 a 500 µg/mL). Posteriormente, as células tratadas e não tratadas foram lavadas e incubadas em meio de cultura RPMI com 5 mg/mL de brometo de 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazólio (MTT, Sigma-Aldrich, St. Louis, MO, EUA), por 3 horas a 37 ° C. Em seguida, o precipitado de cristais de formazan derivado da redução do MTT foi solubilizado em solução de isopropanol (100 µL / poço) e a leitura das absorbâncias da placa foi avaliada em espectrofotômetro a 540 nm. A concentração citotóxica do MfEO (CC₅₀) foi determinada por análise de regressão utilizando o software SPSS 8.0.

3.5 ATIVIDADE LEISHMANICIDA

3.5.1 Efeito do MfEO em formas promastigotas

Para avaliar os efeitos do MfEO nas formas promastigotas de *Leishmania amazonensis* (LTB0016), 10^6 parasitas/mL foram cultivados em meio Schneider suplementado com 10 % SFB, na ausência ou presença de diferentes concentrações do MfEO (25 a 200 µg/mL) e incubados à 26 °C por 48 h. A viabilidade celular dos parasitas foi avaliada pelo kit CellTiter-Glo® Luminescent Cell Viability Assay nos tempos 24 e 48 h, e a concentração do MfEO capaz de inibir 50 % do crescimento celular (IC₅₀) foi determinada por análise de regressão usando o software SPSS 8.0.

3.5.2 Efeito do MfEO em formas amastigotas

Para verificar a ação do MfEO sobre as formas amastigotas intracelular de *L. amazonensis*, os macrófagos J774A.1 (1×10^6 células/mL) foram plaqueados em placa de 24 poços contendo meio RPMI com 10 % SFB. Deixou-se os macrófagos aderirem durante 3 horas a 37°C em 5% de CO₂, e posteriormente foram infectados com promastigotas de *L. amazonensis* utilizando uma razão 20:1 de parasitas/ célula a 37 °C durante 14 horas. Os parasitas não-interiorizados foram removidos por lavagem e as células aderidas foram incubados por 24 h nas condições de incubação estabelecidas anteriormente com 1/8 X, ¼ X, ½ X e 1X o valor do IC₅₀ do MfEO para as formas promastigotas. Células não tratadas e células tratadas com os fármacos de referência (antimoniato de meglumina e anfoterina B) foram utilizados como controles. Após, o período de incubação, as células foram lavadas em PBS, fixadas com álcool e coradas com coloração panótica; e a porcentagem de células infectadas foi determinada pela contagem de 150 macrófagos aleatoriamente em duplicada. O índice de sobrevivência foi determinado pela multiplicação da porcentagem de macrófagos infectados pelo número médio de parasitas por célula infectada e a IC₅₀ do MfEO para as formas amastigotas foi determinada por análise de regressão como já descrito. O índice de seletividade (SI) do MfEO para promastigotas e amastigotas foi determinado pela razão da CC₅₀ em macrófagos e a IC₅₀ para as duas formas dos protozoários.

3.6 ANÁLISE ULTRAESTRUTURAL

Para verificar as alterações na ultraestrutura, promastigotas de *L. amazonensis* foram tratadas com 1x e 2x o valor da IC₅₀, por 48h. Como controle, foram utilizadas células não tratadas. Posteriormente, as células foram fixadas por 2h em temperatura ambiente em uma solução contendo 2.5% de glutaraldeído / 4% paraformaldeído em 0,1 M de tampão fosfato pH 7.2. Após lavagem no mesmo tampão, as células foram pós-fixadas durante 1 h com 1% de tetróxido de ósmio / 0.8% de ferricianeto de potássio / CaCl₂ 5 mM em tampão cacodilato 0.1 M, pH 7.2. Após lavagem com tampão cacodilato, as células foram aderidas em lamínulas revestidas com poli-L-lisina. As amostras foram desidratadas em etanol, secas em ponto crítico HCP-2 (Hitachi, Tóquio, Japão), revestidas com uma camada de ouro de 20 nm de espessura e observadas em um Microscópio Eletrônico de Varredura JEOL T-200.

4 RESULTADOS

O resultado desta pesquisa gerou um segundo artigo que será submetido em um Journal de Fitoterapia.

4.1 The biological activity of essential oil from fruit peel of *Myrciaria floribunda* (H. West ex Willd.) O. Berg on *Leishmania amazonensis*

Deyzi Caroline da Silva Barbosa¹; Vanderlan Nogueira Holanda^{1,2}; Welson Vicente da Silva¹; Márcia Vanusa da Silva²; Maria Tereza dos Santos Correia²; Regina Celia Bressan Queiroz de Figueiredo^{1,*}

¹ Instituto Aggeu Magalhães, Departamento de Microbiologia, Avenida Professor Moraes Rego, 1235, 50670-901 Recife, PE, Brazil.

²Departamento de Bioquímica, Centro de Biociências, Universidade Federal de Pernambuco, Avenida Professor Moraes Rego, 1235, 50670-901 Recife, PE, Brazil.

***Corresponding author:**

Dr. Regina Celia B. Q. Figueiredo

Laboratório de Biologia Celular de Patógenos, Departamento de Microbiologia, Instituto Aggeu Magalhães – IAM/FIOCRUZ-PE, Avenida Professor Moraes Rego s/n 50670-420, Recife, Pernambuco, Brazil. E-mail address: rcbqf01@gmail.com (R. C. B. Q. Figueiredo).

Maria Tereza dos Santos Correia and Regina Celia Bressan Queiroz de Figueiredo contributed equally to this work.

Abstract

Cutaneous Leishmaniasis (CL) is a neglected disease characterized by high rates of morbidity and mortality worldwide. The treatment available for CL has several limitations including serious side effects and resistance to treatment. Herein we aimed to evaluate the activity of essential oil from the peel of *Myrciaria floribunda* fruits (MfEO) on *Leishmania amazonensis*. The cytotoxic potential of MfEO on host mammalian cells was evaluated by MTT. *In vitro* leishmanicidal effects of MfEO were investigated on promastigote and intracellular amastigote forms. The ultrastructural changes induced by MfEO were evaluated by Scanning Electron Microscopy (SEM). Molecular docking of δ -cadinene and γ -cadinene, the major compounds of MfEO onto the enzyme sterol 14- α demethylase (CYP51) was analyzed. Our results showed that MfEO presented a CC₅₀ of 260.9 and 332.9 μ g/mL for Vero and macrophages, respectively. The MfEO inhibited the growth of promastigote and the survival of intracellular amastigotes, with IC₅₀ of 55.84 and 7.54 μ g/mL, respectively. MfEO presented high selectivity towards amastigote forms, being 44.1 times more toxic for this form than to macrophages. The Molecular docking analysis showed that both major compounds interacted with the active site of *Leishmania* CYP51, suggesting a putative role of cadinenes as inhibitor of CYP51 of this parasite.

Keywords: Cutaneous Leishmaniasis; *Leishmania amazonensis*; essential oil; *Myrciaria floribunda*; phytotherapy; molecular docking

1. Introduction

Leishmaniasis, caused by protozoa of the genus *Leishmania*, are severe neglected tropical diseases (NTDs), responsible for high rates of morbidity and mortality. These diseases are dispersed worldwide, being present in 89 countries, with 90% of cases occurring in Afghanistan, Algeria, Brazil, Pakistan, Peru, Saudi Arabia and Syria (WHO, 2020; Valero & Uriarte, 2020). Depend on the species of *Leishmania* involved and the immune response of the host, leishmaniasis can assume different clinical manifestations ranging from the localized cutaneous to the visceral form with potentially fatal outcomes (Torres-Guerrero et al, 2017). Cutaneous Leishmaniasis (CL) stands out for its high prevalence and potential to cause physical deformities (Holanda et al. 2019). In Brazil, *Leishmania amazonensis* is considered the most relevant epidemiological specie, due to its wide geographical distribution and its ability to cause different forms of cutaneous leishmaniasis (Christensen et al., 2019).

Currently, there are no vaccines for leishmaniasis and the chemotherapy for the treatment of this illness is still based on the parenteral administration of pentavalent antimonials (Menezes et al., 2015). Meglumine antimoniate and sodium stibogluconate are the first-line drugs. However, these drugs have various disadvantages, such as a long therapeutic regimen, variations in effectiveness, appearance of resistance (Sundar, Chakravarty & Meena, 2018) and severe side effects, including cardiotoxicity, hepatotoxicity and nephrotoxicity (Scott & Novais, 2016; Taheri, Rad & Molkara, 2019; Marques et al., 2019). Pentamidine and Amphotericin B have been used as second-line drugs. However, these drugs also present high toxicity and adverse side effects that limit their use (Iqba et al., 2016; Oliveira et al., 2017). In this regard, the search for effective, less toxic and low-cost therapeutic alternatives for the treatment of CL is still necessary.

Natural products have been used for the treatment of infectious disease since ancient times, especially in developing countries (García et al., 2017). Among them, Essential Oils (EOs) have been shown promising bio/pharmacological properties, including antimicrobial (Santana et al., 2018; Correa et al., 2019), anti-inflammatory (Han & Parker, 2017), antioxidant (Santos et al., 2019; Hennia et al., 2020) and leishmanicidal (Medeiros et al., 2011; Ramos et al., 2014) activities. Furthermore, the hydrophobic nature of EOs constituents makes them permeable to cells, which is a desirably feature for developing agents against intracellular pathogens (García et al., 2017). EOs are a complex mixture of compounds obtained from different plants parts, such as flowers, leaves, fruits, roots and seeds. EOs extracted from the

Myrtaceae family have attracted attention due to their promising pharmacological properties (Durazzini et al., 2019; Kauffmann et al., 2019).

Myrciaria floribunda (H. West Ex Willd.) O. Berg, a plant from Myrtaceae family, popularly known as Cambuí, presents insecticidal (Tietbohl et al., 2014; Tietbohl et al., 2019), antibacterial and antioxidant activities (Azevedo et al., 2019). This plant also has demonstrated to inhibit the enzymes acetylcholinesterase from *Electrophorus electricus* and *Crassostrea rhizophorae* (Tietbohl et al., 2012; Barbosa et al., 2020). In a previous study we have elucidate the chemical composition of EO from fruit peels of *Myrciaria floribunda* (MfEO) and demonstrated the good pharmacokinetic and toxicological profiles of their major constituents (Barbosa et al., 2020). However, the knowledge on the biological potential of the MfEO against trypanosomatids is lacking and, at the best of our knowledge, there is no reports on the use of MfEO against leishmaniasis. Therefore, in this study we investigated for the first time, the leishmanicidal activity *Myrciaria floribunda* essential oil on promastigote and amastigote forms of *L. amazonensis*. We also used molecular docking approach to model putative interactions of their main compounds onto the sterol 14- α demethylase, a key enzyme for *Leishmania* survival and replication.

2. Material and Methods

2.1 Essential Oil - *Myrciaria floribunda* fruits were collected at Exú municipality, in the state of Pernambuco, Brazil (voucher number: 92722). The MfEO was extracted from fruit peels by hydrodistillation using a Clevenger apparatus, as described previously (Silva et al., 2015). The chemical characterization was performed through GC/MS analysis, as described by Barbosa et al. (2020). For *in vitro* analysis, MfEO was initially dissolved in dimethyl sulfoxide (DMSO) (Sigma–Aldrich, St. Louis, MO, USA), at a concentration of 50 mg/mL and stored at -20°C, protected from light. This stock solution is diluted again to obtain a work solution, at final concentration of DMSO never exceeding 0.1 % v/v that is considered as nontoxic for parasites and mammalian cells.

2.2. Mammalian Cells - Vero Cells and macrophages were maintained by weekly passages in RPMI medium supplemented with 10% inactivated bovine fetal serum (iFBS) and 1% streptomycin-penicillin solution (Sigma-Aldrich, USA), at 37 ° C and 5% CO₂ atmosphere.

2.3 Cytotoxicity Assay - The cytotoxic potential of MfEO was evaluated according to the protocol established by Aranda-Souza, et al. (2019). Briefly, Vero cells or macrophages were seeded in 96-well plates (5×10^5 cells/well) containing 100 μ L of RPMI medium, supplemented with 10% of iFBS, and incubated for 3 hours at 37 °C in 5% CO₂. After this time, non-adherent cells were washed out and the remaining adhered cells were incubated for 48 hours in RPMI in the absence or presence of the different concentrations of MfEO (31.25 to 500 μ g/mL). Treated and untreated cells (negative control) were washed and incubated in fresh RPMI culture medium, containing 5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO, USA), for additional 3 h at 37 °C. After the incubation, the cells were solubilized in DMSO (100 μ L/well) and the formazan precipitate derived from MTT reduction was determined spectrophotometrically at 540 nm. The concentration able to reduce the cell viability by 50% (CC₅₀) was determined by regression analysis using the software SPSS 8.0 for Windows.

2.4 Leishmanicidal Activity Assay - Promastigote forms of *Leishmania amazonensis* (LTB0016), were cultured in Schneider's medium supplemented with 10% iFBS, in the absence (control) or presence of different concentrations of MfEO (25-200 μ g/mL) and incubated at 26 °C for 48 hours. The cell viability of the parasites was evaluated by the CellTiter-Glo® Luminescent Cell Viability Assay kit at 24 and 48 hours. The concentration of MfEO able of inhibiting 50% of cell viability (IC₅₀) was determined as described for mammalian cells. To investigate the effects of MfEO on the intracellular amastigote forms of *L. amazonensis*, J774A.1 macrophages (1×10^6 cells/mL) were seeded in 24-well plates containing a coverslip on the bottom. The cells were cultivated in RPMI medium, supplemented with 10% iFBS. Adhered macrophages were infected with *L. amazonensis* promastigotes (20:1 promastigotes/macrophage) at 37 °C for 14 hours. The non-internalized parasites were removed by washing in RPMI and the samples were incubated in the absence or presence of MfEO for 24 hours, at concentrations ranging from $1/8$ IC₅₀ to IC₅₀ values, obtained for promastigote forms. Infected cells treated with the reference drugs (Meglumine antimoniate or Amphotericin B) were used as positive controls. After treatment, the cells were washed in PBS, and submitted to panoptical fast staining kit (Laborclin, São Paulo, Brazil). The percentage of infected cells was determined by counting of 150 randomly chosen macrophages in duplicate. The survival index was determined by multiplying the percentage of infected macrophages by the average number of parasites per infected cell. The IC₅₀ for amastigote forms was determined by regression analysis as described above. The selectivity index (SeI) of MfEO for promastigotes

and amastigotes was determined by the ratio of CC_{50} macrophages to IC_{50} of these developmental stages of *L. amazonensis*.

2.5 Ultrastructural assay - To verify the effects of MfEO on the ultrastructure of *L. amazonensis*, promastigote forms were treated with 1x and 2x IC_{50} value of MfEO for 48 hours. Untreated promastigotes were used as a control. After incubation with this essential oil, the parasites were fixed for 2 hours at room temperature in a solution containing 2.5% glutaraldehyde/ 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.2. After washing in the same buffer, the cells were post-fixed for 1 hour with 1% osmium tetroxide/0.8% potassium ferrocyanide/5 mM $CaCl_2$ in 0.1 M cacodylate buffer, pH 7.2. The parasites were then washed in 0.1 M cacodylate buffer and allowed to adhere to coverslips, previously coated with poly-L-lysine. The samples were dehydrated in ethanol, dried at a critical point HCP-2 (Hitachi, Tokyo, Japan), coated with a 20 nm thick gold layer and observed in a JEOL T-200 Scanning Electron Microscope.

2.6 Molecular Docking - The X-ray crystallographic structures of sterol 14- α demethylase) from *Leishmania infantum* (Lepesheva et al., 2011), obtained from protein databank (PDB), was used in our docking analysis. To verify the homology of LiCYP51 from *L. infantum* and hypothetical proteins of *L. amazonensis*, the FASTA sequence of LiCYP51, (PDB: 3L4D) was used for local alignment of the protein sequence using BLAST server (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) (Altschul, 2005). The molecular docking of δ -cadinene and γ -cadinene onto LiCYP51 was carried out using AutoDock 4.2 software. The smiles from chemical structure of cadinenes were applied to obtain the compounds in PDB format, using the Open Babel GUI program (<https://openbabel.org/docs/dev/GUI/GUI.html>). Water molecules were removed, hydrogens, Kollman, and Gasteiger charge were added. The protein and ligand structures were saved in the PDBQT file format. For each ligand-protein complex 10-docking poses were generated using Lamarckian Genetic Algorithm (López-Camacho et al., 2015). The pose with the lowest binding energy was selected as the final docking result. The interactions of the target-ligand complex were analyzed and rendered using Discovery Studio 2020 (Discovery Studio Modeling Environment, Release 2017, San Diego: Dassault Systèmes, 2016).

2.7 Statistical analysis- Linear regression analysis was performed using SPSS 8.0 software (IBM Co., New York, USA). Nonparametric data were analyzed using one-way analysis of


variance (ANOVA) followed by Bonferroni test. Statistical analysis was performed using the Prism 5.0 software (GraphPad, San Diego, CA, USA). All statistical analyzes were performed at the level of significance $p < 0.05$.

3. Results and Discussion

Essential oils are a mixture of compounds rich in active molecules, which present interesting biological characteristics for the development of new drugs against neglected diseases (Prado et al., 2018; Oliveira et al., 2020). In this study we exploited the *in vitro* potential of the essential oil from peel of *M. floribunda* fruits (MfEO) on *Leishmania amazonensis*, the main etiological agent of CL in Brazil.

One of the main desirable characteristics for a promising leishmanicidal compound is its selective toxicity towards the parasite without causing damage to the host cells (Santos et al., 2008). In this regard, the cytotoxic potential of MfEO on mammalian cells was evaluated in Vero cells and J774A.1 macrophages, using the MTT methodology. Our results showed that MfEO inhibited significantly the viability of both cell models (Figure 12), with a CC_{50} of 260.9 and 332.9 $\mu\text{g/mL}$, for Vero cell and macrophages, respectively (Table 4). According to Ríos et al. (2008), EOs having CC_{50} between 100 and 500 $\mu\text{g/mL}$ are considered moderately toxic. Our results showed that macrophages were more resistant to the treatment with MfEO compared to the Vero cells. These results are particularly important because macrophages are the main cell target of *Leishmania* spp. infection. The higher resistance of macrophages to MfEO could be attributed to its well-known ability to neutralize potentially toxic compounds (Chowdhary, Chowdhary & Kashaw 2016; Wu & Lu, 2020).


Figure 12. Effects of MfEO on mammalian cells after 48 hours of treatment. (A) Vero cell, (B) Macrophage. The bars represent the mean $\pm$ SD of three independent experiments in triplicate. * Significant difference compared to the control group ($p < 0.05$).



Because MfEO presented moderate cytotoxicity to mammalian cells, we further investigated the effects of this essential oil on promastigote viability by measuring the ATP production by these cells. The quantification of the amount of ATP present is considered as a molecular indicator of metabolically active cells. The CellTiter-Glo® assay generated a “glow-type” luminescent signal produced by luciferase that was proportional to the percentage of living cells (El-Obeid et al., 2020). Our results showed that the treatment with MfEO inhibited significantly the parasite viability. Although there is no statistic difference compared to the control cells, at 25 µg/mL the viability of treated cells, mainly at 24 hours of cultivation, was slightly higher than untreated cells. This effected could be due to a shift on cellular metabolism in an attempt to circumvent the stress induced by treatment with EO (Monzote et al., 2018). After 24 hours of treatment, a significant decrease in the viability of promastigote forms was observed for concentration up to 100 µg/mL, whereas in cells treated for 48 hours, this inhibitory effect is earlier observed, for concentrations up to 50 µg/mL (Figure 13). The estimated $IC_{50}/48$ hours for promastigote forms was 55.84 µg (Table 4).

When the cytotoxicity of MfEO for mammalian cells was compared with the leishmanicidal effect on promastigote we found that this essential oil was almost 6 and 5 times more toxic for the parasite than to the macrophages and Vero cells, respectively. It is interesting to note that at the concentration of 200 µg/mL, the parasite viability was almost completely abolished (Figure 13).


Figure 13. The effects of MfEO on promastigote forms of *Leishmania amazonensis* after 24 and 48 hours of treatment. The bars represented the mean $\pm$ SE of three independent experiments in triplicate. * Significant difference when compared to the control group ($p < 0.05$).



In the view of our promising results of MfEO on the promastigote forms of *L. amazonensis*, we further investigated the action of this essential oil on the most relevant intracellular amastigote forms. Because amastigotes are responsible for the clinical manifestation of leishmaniasis in mammalian host, the evaluation of drug candidates on this developmental stage of parasite is the most effective way to relate the anti-leishmania activity *in vitro* and *in vivo* (Russel & Talamas-Rohana, 1989). The treatment of infected-macrophages with both MfEO and Amb significantly reduced the number of amastigotes inside these cells, in a dose-dependent way, when compared to untreated-infected ones (Figure 14A). At lower concentration of MfEO (6.98 µg/mL), the inhibitory effect on amastigotes was comparable to those found for amphotericin B (the reference drug) at a concentration of 9.75 µg/mL (Figure 14A-B). The inhibitory effect of MfEO on the macrophage infection by *L. amazonensis* is consistent with the decrease of survival index of amastigote inside these cells (Figure 14B). The lower values of Survival Index at higher concentration of MfEO (near to zero, at 55.84 µg/mL of MfEO) indicated that this essential oil was able, not only to significantly decrease the number of intracellular amastigotes, but also to reduce the number of infected cells. The effects of MfEO on macrophage infection could be better visualized by light microscopy (Figure 14C). The analysis of untreated-infected cells showed a high rate of infection with numerous internalized amastigotes inside large parasitophorous vacuoles (PVs). In some cells the number of amastigotes/PV was higher than 10 (Figure 14C). As expected, the treatment of infected cells with MfEO or the reference drugs Glucantime (Glu) and Amphotericin B (Amb), induced a

significant decrease in the number of amastigote/parasitophorous vacuole and consequently, in the rate of infection. At higher tested concentration of MfEO, the morphology of macrophages was compared with non-infected cells (Figure 14C) and no detectable PVs could be observed. The effects of MfEO on macrophage infection could be related to the direct action of essential oil components on the amastigote. However, we cannot rule out the possibility of MfEO is also acting on macrophages, making them more competent to fight the parasite (Ueda-Nakamura et al., 2006; Jihene et al., 2020).

Figure 14. Effect of MfEO on intracellular amastigotes forms of *L. amazonensis*. (A) Inhibitory effect of MfEO on the total number of amastigotes within infected-macrophages in 150 cells; (B) Survival index of amastigotes inside J774A.1 macrophages. Each bar represents the mean $\pm$ SD of three independent experiments performed in duplicate. (*) Significant difference compared to the control group ($p < 0.05$). (C) Light microscopy of macrophage-infected cultures, stained with Giemsa treated or not (negative control, NC) with MfEO, Glucantime (Glu) or Amphotericin B (AmB). The arrows indicate the intracellular amastigote inside PVs. Note the presence of empty PVs in treated cells (black asterisk).



Our results showed that the MfEO was more selective for amastigotes than to macrophages, with SeI of 44.1 (Table 4). This value was considerably higher than those reported for reference drugs, which are very toxic to mammalian cells. Previous studies have shown that meglumine antimoniate (Glucantime) and Amphotericin B have low selectivity for *L. amazonensis* with SeI values of 2.46 and 0.15 respectively (Carvalho et al., 2017). The intracellular amastigote forms were also more susceptible to the treatment with MfEO than free-promastigotes, with an IC₅₀ value of 7.54 µg/mL which was about 7.4 times lower than the IC₅₀ value for promastigote.

It is usually assumed that the effect of EOs on trypanosomatids is due to the isolated or combined action of their major compounds. In a previous work we identified the sesquiterpenes δ-cadinene (26.8%), γ-cadinene (15.69%), γ-muurolene (6.21%), α-selinene (6.11 %), α-muurolene (6.11 %) and (E)-caryophyllene (5.54%) as the main constituents of MfEO (Barbosa et al., 2020). These compounds were also present in other EOs with leishmanicidal activity (Santos et al., 2008; Andrade et al., 2016; Macedo et al., 2020). The effect of MfEO on promastigotes and amastigotes may be related to the lipophilic nature its constituents, facilitating cell penetration and interaction with intracellular targets (Cortes et al., 2020). In our previous study, we used *in silico* approaches to predict the ADMET properties of the six most abundant constituents of MfEO. Our results showed that these molecules presented high lipophilicity with ClogP > 4.0 (Barbosa et al., 2020). This finding was particularly interesting because, to exert their effects on amastigotes, which live and proliferate intracellularly, the MfEO constituents must have to cross host cells membranes (plasma membrane and PVs) (Muylder et al., 2011).

Table 4. Leishmanicidal and cytotoxic effects of essentials oil of *M. floribunda*.


Cell Type	MfEO (µg/mL)				
	CC ₅₀	IC ₅₀		SeI	
		Pro	Ama	Pro	Ama
Vero	260.9 ± 6.3	-	-	4.67	n.d
J774	332.9 ± 13.1	-	-	5.96	44.15
<i>L. braziliensis</i>	-	55.84 ± 1.1	7.54 ± 0.6		

CC₅₀ - concentration required to reduce cell viability by 50%; IC₅₀ - Inhibitory concentration for 50% of parasites; SeI – Selectivity Index; Pro – promastigote; Ama - amastigotes; n.d. not

determined. The Data represent the mean $\pm$ SD of three independent experiments performed in triplicate.

It has been shown that terpenes, present in essential oils, are able to interact with liposaccharides, fatty acids, phospholipids of *Leishmania*, impairing key metabolic pathways for parasite survival (Díaz et al., 2019). In order to investigate the effects of MfEO on plasma membrane and overall ultrastructure of *L. amazonensis* promastigotes, scanning electron microscopy analysis was performed (Figure 15). Control cells showed typical morphology, with a spindle-shaped cell body, a preserved elongated free-flagellum and a smooth plasma membrane (Figure 15A-B). On the other hand, the treatment with MfEO induced significant ultrastructural changes such as: the wrinkling of the plasma membrane, increased cell volume, with a shortening of both the cell body and flagellum (Figure 15C-F). In some drastically affected cells, it was possible to observe the presence of membrane perforations (Figure 15 C, arrow), indicative of damaged plasma membrane. Atypical dividing cells were also usually found in samples treated with MfEO (Figure 15E-4F), which is suggestive of arresting of cell cycle in cytokinesis stage (Silva et al., 2015). The injury in the plasma membrane can ultimately lead to loss of cell viability and parasite death (Tiuman et al., 2005; Silva et al., 2018). Treated cells presented higher exocytic activity when compared to untreated control cells (Figure 15C). The release of vesicles from the membrane can be stimulated by stress conditions. It has been reported that *L. amazonensis* promastigotes and *T. cruzi* epimastigotes budding blebs after treatment with enzyme inhibitors involved in sterol biosynthesis (Adade & Souto-Padrón, 2010).

Figure 15. The effects of MfEO on *Leishmania amazonensis* ultrastructure as observed by scanning electron microscopy. (A-B) Untreated promastigotes showing typical spindle-shaped morphology and elongated flagellum (C-D). Promastigotes treated with 55.84 $\mu\text{g/mL}$ MfEO. (C) Note the presence of perforations on the plasma membrane (arrow). (D) Detail of exocytic vesicles budding from cell surface (arrowhead). (E-F) Atypical dividing promastigotes treated with 111.68 $\mu\text{g/mL}$ MfEO.



Based on our ultrastructural results, we hypothesized that the major constituents of MfEO could be acting on key enzymes or other molecules that are essential for survival and proliferation of *L. amazonensis*. In the last decades, the identification and validation of biochemical pathways present in trypanosomatids but absent or divergent from their host has been provide promissory targets for the rational design of novel drugs against *Leishmania* spp. (Romero and López, 2017). Among these validated targets, the enzyme sterol 14- α demethylase (CYP51) have a pivotal role in the physiology of *Leishmania* spp. as well as other trypanosomatids (Mukherjee et al., 2020). It has been shown that disruption of CYP51 results

in changes in the ultrastructure of several organelles, decline of endogenous sterols in the parasites, and an accumulation of various 14- α -methyl sterols with major cytostatic and cytotoxic consequences (Chen et al., 2010). Thus, in the search of putative inhibitor of this key enzyme, we decided to carry out a theoretical molecular docking of δ - and γ -cadinene, the major compounds of MfEO, over CYP51. Because the crystal structure of CYP51 of *L. amazonensis* was not available on the protein data bank (PDB) we used the CYP51 of *L. infantum* (LiCYP51 protein data bank entry: 3L4D) as a template for molecular docking assays. Our BLAST analysis showed that this protein presented 97% of amino acid sequence similarity with two hypothetical orthologue protein of *L. amazonensis* (GenBank: BAE79802.1) (data not shown). Molecular docking analysis revealed that both isomers δ - and γ -cadinene presented higher binding energy with LiCYP51 of -7.17 e -7.31 kcal/mol, respectively when compared to fluconazole (-6.28 kcal/mol), a standard inhibitor of this enzyme (Table 5).


Table. 5. Interaction profile MfEO major constituents, δ -Cadinene (δ -Cad) and γ -Cadinene (γ -Cad) with the enzyme sterol 14- α demethylase (LiCYP51).

	CYP51		
	δ -Cad	γ -Cad	Fluconazole
BE (kcal/mol)	-7.17	-7.31	-6.28
LE	-0.48	-0.49	-0.29
IC (μ M)	5.59	4.38	24.72
IE	-7.46	-7.61	-8.07
VDW-Hb (DE)	-7.46	-7.61	-8.04
EE	0.0	0.0	-0.03
TI	-0.31	-0.28	-1.70
TE	0.3	0.3	1.79
UnE	-0.31	-0.28	-1.70
Rseed 1/2	None	None	None

BE: binding energy; LE: ligand efficiency; IC: inhibition constant; IE: intermolecular energy; VDW-Hb (DE): van der Waals-Hydrogen bond (dissolve energy); EE: electrostatic energy; TI: total Internal; TE: torsional-energy; UnE: unbound-energy; Rseed: seeds of specific random numbers used for fitting the current conformation.

CYP51 is key enzyme of sterol biosynthesis in trypanosomatids and therefore, plays an important role in the maintenance of membrane structure, growth and development process. Consistently, our ultrastructural analysis showed defects on cell division and damage of plasma membrane which are also observed in *Leishmania* treated with sterol inhibitors (Macedo-Silva et al., 2015). CYP51 is a cytochrome P450 monooxygenase (CYP51 gene family), the heme-thiolate protein that catalyses a unique three-step reaction of oxidative removal of the 14 α -methyl group from the sterol core (Lepesheva & Waterman, 2011). The chemical interaction between both cadinene isomers and *Li*CYP51 is due to interactions of these compounds with hydrophobic amino acids residues of *Li*CYP51, mainly by van der Waals (VAL 42, PHE 41, LEU 214 and TRP 216) and alkyl (PRO 221, LEU 220, PHE 41 and TRP 216) bounds. Our molecular docking analysis revealed that the interaction profile between cadinenes and *Li*CYP51 was similar to those observed for fluconazole, a standard inhibitor of this enzyme. Both cadinenes isomers interacts with 15 amino acids in the active site of *Li*CYP51, 13 of which were found to also bind to Fluconazole. These results suggested that both δ -Cad and γ -Cad bind to the same active site of CYP41 which is inhibited by fluconazole (Figure 16).

Figure 16. Molecular docking of δ -Cadinene, γ -Cadinene and Fluconazole over to the *LiCYP51* (A, C and E), respectively. Interactions of cadinenes and fluconazole with the amino acid residues of the enzyme (B, D and F).



4. Conclusion

Essential oil from fruit peel of *Myrciaria floribunda* was evaluated for antiparasitic potential against *L. amazonensis* and for cytotoxicity in Vero cells and macrophages. Our results showed for the first time that MfEO was effective against promastigote and amastigote forms, with high selectivity against the intracellular forms of parasite (SeI=44.15) and moderate

cytotoxicity towards mammalian cells. The treatment with MfEO induced a significant decrease in promastigotes viability and morphological changes compatible with damage to plasma membrane. It is important to mention that MfEO reduced the number of both infected cells and intracellular amastigotes. Our molecular docking analysis showed that the main compounds of MfEO, δ -cadinene and its isomer γ -cadinene, interact with the enzyme sterol 14-alpha demethylase (CYP51), which are essential for the survival and proliferation of *Leishmania* spp. Because CYP51 plays an important role in sterol biosynthetic pathway in this parasite, it is possible that δ -cadinene and γ -cadinene, caused a disturbance in the cell membrane which ultimately, can lead the parasite to death. Further studies are necessary to determine the exact mechanism of action of these compounds alone or in association. Our results points to the possibility of the use of cadinene as a scaffold for the development of novel chemotherapeutic agent for the treatment of cutaneous leishmaniasis.

5. References

- Altschul, S. F., Wootton, J. C., Gertz, E. M., Agarwala, R., Morgulis, A., Schäffer, A. A., & Yu, Y. K. (2005). Protein database searches using compositionally adjusted substitution matrices. *The FEBS journal*, 272(20), 5101-5109. DOI: 10.1111/j.1742-4658.2005.04945.x.
- Adade, M. C., & Souto-Padrón, T. (2010). Contributions of ultrastructural studies to the cell biology of Trypanosomatids: targets for anti-parasitic drugs. *The Open Parasitology Journal*, 4, 178-187.
- Aranda-Souza, M. Â., Lorena, V. M. B., Santos Correia, M. T., Pereira-Neves, A., & de Figueiredo, R. C. B. Q. (2019). A C-type lectin from *Bothrops leucurus* snake venom forms amyloid-like aggregates in RPMI medium and are efficiently phagocytosed by peritoneal macrophages. *Toxicon*, 157, 93-100. DOI: 10.1016/j.toxicon.2018.11.309.
- Andrade, M. A., Santos Azevedo, C., Motta, F. N., Santos, M. L., Silva, C. L., Santana, J. M., & Bastos, I. M. (2016). Essential oils: in vitro activity against *Leishmania amazonensis*, cytotoxicity and chemical composition. *BMC Complementary and Alternative Medicine*, 16(1), 444. DOI: 10.1186/s12906-016-1401-9.
- Azevedo, M. M. L., Cascaes, M. M., Guilhon, G. M. S., Andrade, E. H. A., Zoghbi, M. D. G. B., da Silva, J. K. R., & Silva, S. H. M. (2019). Lupane triterpenoids, antioxidant potential and antimicrobial activity of *Myrciaria floribunda* (H. West ex Willd.) O. Berg. *Natural Product Research*, 33(4), 506-515. DOI: 10.1080/14786419.2017.1402311.

- Barbosa, D.C.S., Holanda, V. N., Assis, C.R.A., Aguiar, J. C. R. O. L., Nascimento, P. H., Silva, W. V., Navarro, D. M. A. F., Silva, M. V., Lima, V. L. M., & Correia, M. T. S. (2020). Chemical composition and acetylcholinesterase inhibitory potential, in silico, of *Myrciaria floribunda* (H. West ex Willd.) O. Berg fruit peel essential oil. *Industrial Crops and Products*, 151. DOI: 10.1016/j.indcrop.2020.112372.
- Carvalho, C. E. S., Sobrinho-Junior, E. P. C., Brito, L. M., Nicolau, L. A. D., Carvalho, T. P., Moura, A. K. S., & Carvalho, F. A. A. (2017). Anti-leishmania activity of essential oil of *Myracrodruon urundeuva* (Engl.) Fr. All.: composition, cytotoxicity and possible mechanisms of action. *Experimental Parasitology*, 175, 59-67. DOI: /10.1016/j.exppara.2017.02.012.
- Chen, C-K, Leung, S. S. F., Guilbert, G., Jacobson, M. P., McKerrow, J. H., & Podust L.M. (2017) *Trypanosoma brucei* bound to the antifungal drugs posaconazole and fluconazole. *PLoS Neglected Tropical Disease*. 4, e651. DOI:10.1371/journal.pntd.0000651.
- Chowdhary, S. J., Chowdhary, A. M. I. T., & Kashaw, S. U. S. H. I. L. (2016). Macrophage targeting: a strategy for leishmaniasis specific delivery. *International Journal of Pharmacy and Pharmaceutical Sciences*, 8(11), 16-26.
- Christensen, S. M., Belew, A. T., El-Sayed, N. M., Tafuri, W. L., Silveira, F. T., & Mosser, D. M. (2019). Host and parasite responses in human diffuse cutaneous leishmaniasis caused by *L. amazonensis*. *PLoS Neglected Tropical Diseases*, 13(3). DOI: 10.1371/journal.pntd.0007152.
- Correa, M. S., Schwambach, J., Mann, M. B., Frazzon, J., Frazzon, A. P. G. (2019). Antimicrobial and antibiofilm activity of the essential oil from dried leaves of *Eucalyptus staigeriana*. *Arquivos do Instituto Biológico*, 86. DOI: 10.1590/1808-1657000202018.
- Cortes, S., Sousa, C. B., Lago, T. M. J., & Campino, L. (2020). Potential of the natural products against leishmaniasis in old world - a review of in-vitro studies. *Pathogens and Global Health*, 1-13. DOI: 10.1080/20477724.2020.1754655.
- Díaz, J. G., Arranz, J. C. E., Batista, D. D. G. J., Fidalgo, L. M., Costa, J. D. L. V., Macedo, M. B., & Cos, P. (2018). Antileishmanial potentialities of *Croton linearis* leaf essential oil. *Natural Product Communications*, 13(5). DOI: 10.1177/1934578X1801300527.
- Durazzini, A. M., Machado, C. H., Fernandes, C. C., Willrich, G. B., Crotti, A. E., Candido, A. C., & Martins, C. H. (2019). *Eugenia pyriformis* Cambess: a species of the Myrtaceae family with bioactive essential oil. *Natural Product Research*, 1-5. DOI:10.1080/14786419.2019.1669031.

- El-Obeid, A., Alajmi, H., Harbi, M., Yahya, W. B., Al-Eidi, H., Alaujan, M., & Ajlouni, A. W. (2020). Distinct anti-proliferative effects of herbal melanin on human acute monocytic leukemia THP-1 cells and embryonic kidney HEK293 cells. *BMC Complementary Medicine and Therapies*, 20, 1-12. DOI: doi.org/10.1186/s12906-020-02944-1.
- García, M., Scull, R., Satyal, P., Setzer, W. N., & Montoze, L. (2017). Chemical characterization, antileishmanial activity, and cytotoxicity effects of the essential oil from leaves of *Pluchea carolinensis* (Jacq.) G. Don. (Asteraceae). *Phytotherapy Research*, 31(9), 1419-1426. DOI: 10.1002/ptr.5869.
- Han, X., & Parker, T. L. (2017). Anti-inflammatory activity of clove (*Eugenia caryophyllata*) essential oil in human dermal fibroblasts. *Pharmaceutical Biology*, 55(1), 1619-1622. DOI: 10.1080/13880209.2017.1314513.
- Hennia, A., Nemmiche, S., Guerreiro, A., Faleiro, M. L., Antunes, M. D., Aazza, S., & Miguel, M. G. (2020). Antioxidant and antiproliferative activities of *Myrtus communis* L. essential oils from different Algerian regions. *Journal of Essential Oil Bearing Plants*, 1-12. DOI: 10.1080/0972060X.2019.1687335.
- Holanda, V. N., Silva, W. V., Nascimento, P. H., Oliveira, R. N., Menezes Lima, V. L. & Figueiredo, R. C. B. Q. (2019). Desafios e perspectivas no tratamento da leishmaniose tegumentar: revisão de literatura. *Revista Interfaces: Saúde, Humanas e Tecnologia*, 6(17), 140-157.
- Iqbal, H., Ishfaq, M., Wahab, A., Abbas, M. N., Ahmad, I., Rehman, A., & Zakir, M. (2016). Therapeutic modalities to combat leishmaniasis, a review. *Asian Pacific Journal of Tropical Disease*, 6(1):1-5. DOI: 10.1016/S2222-1808(15)60975-6.
- Jihene, A., Rym, E., Ines, K. J., Madji, H., Olfa, T., & Abderrabba, M. (2020). Antileishmanial potential of propolis essential oil and its synergistic combination with Amphotericin B. *Natural Product Communications*, 15(1):1-8. DOI: 10.1177/1934578X19899566.
- Kauffmann, C., Giacomini, A. C., Arossi, K., Pacheco, L. A., Hoehne, L., Freitas, E. M. D., & Ethur, E. M. (2019). Antileishmanial *in vitro* activity of essential oil from *Myrciaria plinioides*, a native species from Southern Brazil. *Brazilian Journal of Pharmaceutical Sciences*, 55. DOI: 10.1590/s2175-97902019000217584.
- Lepesheva, G.I., Hargrove, T.Y., Wawrzak, Z., Waterman, M.R. (2011). Crystal structure of sterol 14- α demethylase (CYP51) from *Leishmania infantum* in complex with fluconazole. *Protein Data Bank*. DOI: 10.2210/pdb3L4D/pdb.

- Lepesheva, G. I., & Waterman, M. R. (2011). Sterol 14 α -demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis. *Current Topics in Medicinal Chemistry*, 11: 2060-2071. DOI: 10.2174/156802611796575902.
- López-Camacho, E., Godoy, M. J. G., García-Nieto, J., Nebro, A. J., Aldana-Montes, J. F. (2015). Solving molecular flexible docking problems with metaheuristics: A comparative study. *Applied Soft Computing*, 28, 379-393. DOI:10.1016/j.asoc.2014.10.049
- Macedo-Silva, S. T., Visbal, G., Urbina, J. A., Souza, W., Rodrigues, J. C. F. (2015). Potent in vitro antiproliferative synergism of combinations of ergosterol biosynthesis inhibitors against *Leishmania amazonensis*. *Antimicrobial Agents and Chemotherapy*, 59(10). DOI: 10.1128/AAC.01150-15.
- Macedo, C. G., Fonseca, M. Y., Caldeira, A. D., de Castro, S. P., Lima, W. P., Borsodi, M. P. G., & Castro, K. C. F. (2020). Leishmanicidal activity of *Piper marginatum* Jacq. from Santarém-PA against *Leishmania amazonensis*. *Experimental Parasitology*, 107847. DOI: 10.1016/j.exppara.2020.107847.
- Marques, S. A., Merlotto, M. R., Ramos, P. M., & Marques, M. E. A. (2019). American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure. *Anais Brasileiros de Dermatologia*, 94(3), 355-357. DOI: 10.1590/abd1806-4841.20198388.
- Medeiros, M. D. G. F., Da Silva, A. C., Citó, A. M. D. G. L., Borges, A. R., De Lima, S. G., Lopes, J. A. D., & Figueiredo, R. C. B. Q. (2011). In vitro antileishmanial activity and cytotoxicity of essential oil from *Lippia sidoides* Cham. *Parasitology International*, 60(3), 237-241. DOI: 10.1016/j.parint.2011.03.004.
- Menezes, J. P. B., Guedes, C. E. S., Petersen, A. L. O. A., Fraga, D. B. M., & Veras, P. S. T. (2015). Advances in development of new treatment for leishmaniasis. *BioMed Research International*. DOI: 10.1155/2015/815023.
- Monzote, L., Geroldinger, G., Tonner, M., Scull, R., De Sarkar, S., Bergmann, S., ... & Gille, L. (2018). Interaction of ascaridole, carvacrol, and caryophyllene oxide from essential oil of *Chenopodium ambrosioides* L. with mitochondria in *Leishmania* and other eukaryotes. *Phytotherapy Research*, 32(9), 1729-1740. DOI: doi.org/10.1002/ptr.6097.
- Muylder, G., Ang, K. K. H., Chen, S., Arkin, M., Engel, J. C. & McKerrow, J. H. (2011). A Screen against *Leishmania* intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. *PLoS Neglected Tropical Diseases*, 5(7): e1253. DOI: 10.1371/journal.pntd.0001253.

- Mukherjee, S., Moitra, S., Xu, W., Hernandez, V., & Zhang, K. (2020). Sterol 14- α -demethylase is vital for mitochondrial functions and stress tolerance in *Leishmania major*. *PLoS Pathogens*, 16(8), e1008810. DOI: 10.1371/journal.ppat.1008810.
- Oliveira, L. F. G., Pereira, B. A. S., Gilbert, B., Corrêa, A. L., Rocha, L., & Alves, C. R. (2017). Natural products and phytotherapy: an innovative perspective in leishmaniasis treatment. *Phytochemistry Reviews*, 16(2), 219-233. DOI: 10.1007/s11101-016-9471-3.
- Oliveira, D. M., Furtado, F. B., Gomes, A. A., Belut, B. R., Nascimento, E. A., Morais, S. A., & Cunha, L. C. (2020). Chemical constituents and antileishmanial and antibacterial activities of essential oils from *Scheelea phalerata*. *ACS Omega*. DOI: 10.1021/acsomega.9b01962.
- Prado, A. C., Garces, H. G., Bagagli, E., Rall, V. L. M., Furlanetto, A., Fernandes Junior, A., & Furtado, F. B. (2018). *Schinus molle* essential oil as a potential source of bioactive compounds: antifungal and antibacterial properties. *Journal of Applied Microbiology*, 126(2), 516-522. DOI: 10.1111/jam.14157.
- Ramos, E. H., Moraes, M. M., Nerys, L. L. D. A., Nascimento, S. C., Militão, G. C., de Figueiredo, R. C., & Silva, T. G. (2014). Chemical composition, leishmanicidal and cytotoxic activities of the essential oils from *Mangifera indica* L. var. rosa and espada. *BioMed Research International*. DOI: 10.1155/2014/734946.
- Ríos, Y. K., Otero, A. C., Muñoz, D. L., Echeverry, M., Robledo, S. M., & Yepes, M. A. (2008). Actividad citotóxica y leishmanicida in vitro del aceite esencial de manzanilla (*Matricaria chamomilla*). *Revista Colombiana de Ciencias Químico-Farmacéuticas*, 37(2).
- Romero & López (2017). In silico molecular docking studies of new potential 4-phthalazinyl-hydrazones on selected *Trypanosoma cruzi* and *Leishmania* enzyme targets. *Journal of Molecular Graphics and Modelling*, 76: 313-329. DOI: 10.1016/j.jmgm.2017.07.013.
- Russell, D. G., & Talamas-Rohana, P. (1989). *Leishmania* and the macrophage: a marriage of inconvenience. *Immunology Today*, 10(10), 328-333. DOI: 10.1016/0167-5699(89)90188-6.
- Santana, C. B., Lara Souza, J. G., Coracini, M. D. A., Walerius, A. H., Soares, V. D., da Costa, W. F., & Silva Pinto, F. G. (2018). Chemical composition of essential oil from *Myrcia oblongata* DC and potencial antimicrobial, antioxidant and acaricidal activity against *Dermanyssus gallinae* (Degeer, 1778). *Bioscience Journal*, 34(4). DOI: 10.14393/BJ-v34n1a2018-39599.

- Santos, D. O., Coutinho, C. E. R., Madeira, M. F., Bottino, C. G., Vieira, R. T., Nascimento, S. B., Bernardinho, A., Bourguignon, S. C., Corte-Real, S., Pinho, R. T., Rodrigues, C. R., & Castro, H. C. (2008). Leishmaniasis treatment—a challenge that remains: a review. *Parasitology Research*, 103, 1-10. DOI: 10.1007/s00436-008-0943-2.
- Santos, A. O., Ueda-Nakamura, T., Dias Filho, B. P., Junior, V. F. V., Pinto, A. C., & Nakamura, C. V. (2008). Effect of brazilian copaiba oils on *Leishmania amazonensis*. *Journal of Ethnopharmacology*, 120(2), 204-208. DOI: 10.1016/j.jep.2008.08.007.
- Santos, A. L., Polidoro, A. D. S., Cardoso, C. A., Batistote, M., do Carmo Vieira, M., Jacques, R. A., & Caramão, E. B. (2019). GC×GC/qMS analyses of *Campomanesia guazumifolia* (Cambess.) O. Berg essential oils and their antioxidant and antimicrobial activity. *Natural Product Research*, 33(4), 593-597. DOI: 10.1080/14786419.2017.1399383.
- Scott, P., & Novais, F. O. (2016). Cutaneous leishmaniasis: immune responses in protection and pathogenesis. *Nature Reviews Immunology*, 16(9), 581-592. DOI: 10.1038/nri.2016.72.
- Silva, A. G., Alves, R. C. C., Filho, C. M. B., Bezerra-Silva, P. C., Santos, L. M. M., Foglio, M.A., Navarro, D. M. A. F., Silva, M. V., & Correia, M. T. S. C. (2015). Chemical composition and larvicidal activity of the essential oil from leaves of *Eugenia brejoensis* Mazine (Myrtaceae). *Journal of Essential Oil Bearing Plants*, 18(6). DOI: 10.1080/0972060X.2014.1000390.
- Silva, R. R. P., Silva, B. J. M., Rodrigues, A. P. D., Farias, L.H. S., Silva, M. N. S., Alves, D.T.V., Bastos, G. N. T., Nascimento, J. L. M., & Silva, E. O. (2015). In vitro biological action of aqueous extract from roots of *Physalis angulata* against *Leishmania (Leishmania) amazonensis*. *BMC Complementary and Alternative Medicine*, 15 (249). DOI: 10.1186/s12906-015-0717-1.
- Silva, V. D., Almeida-Souza, F., Teles, A. M., Neto, P. A., Mondego-Oliveira, R., Mendes Filho, N. E., & Mouchrek Filho, V. E. (2018). Chemical composition of *Ocimum canum* Sims. essential oil and the antimicrobial, antiprotozoal and ultrastructural alterations it induces in *Leishmania amazonensis* promastigotes. *Industrial Crops and Products*, 119, 201-208. DOI: 10.1016/j.indcrop.2018.04.005.
- Taheri, A. R., Sabouri Rad, S., & Molkara, S. (2019). Systemic treatments of leishmaniasis: A narrative review. *Reviews in Clinical Medicine*, 6(3), 91-97. DOI: 10.22038/RCM.2019.42632.1287.
- Tietbohl, L. A., Lima, B. G., Fernandes, C. P., Santos, M. G., Silva, F. E., Denardin, E. L., Rocha, L. (2012). Comparative study and anticholinesterasic evaluation of essential oils from

- leaves, stems and flowers of *Myrciaria floribunda* (H. West ex Willd.) O. Berg. *Latin American Journal of Pharmacy*, 31(4), 637-641.
- Tietbohl, L. A., Barbosa, T., Fernandes, C. P., Santos, M. G., Machado, F. P., Santos, K. T., & Rocha, L. (2014). Laboratory evaluation of the effects of essential oil of *Myrciaria floribunda* leaves on the development of *Dysdercus peruvianus* and *Oncopeltus fasciatus*. *Revista Brasileira de Farmacognosia*, 24(3), 316-321. DOI: 10.1016/j.bjp.2014.07.009.
- Tietbohl, L. A., Mello, C. B., Silva, L. R., Dolabella, I. B., Franco, T. C., Enríquez, J. J., & Azambuja, P. (2019). Green insecticide against Chagas disease: effects of essential oil from *Myrciaria floribunda* (Myrtaceae) on the development of *Rhodnius prolixus* nymphs. *Journal of Essential Oil Research*, 1-11. DOI: 10.1080/10412905.2019.1631894.
- Tiuman, T. S., Ueda-Nakamura, T., Cortez, D. A. G., Dias Filho, B. P., Morgado-Díaz, J. A., de Souza, W., & Nakamura, C. V. (2005). Antileishmanial activity of parthenolide, a sesquiterpene lactone isolated from *Tanacetum parthenium*. *Antimicrobial Agents and Chemotherapy*, 49(1), 176-182. DOI: 10.1128/AAC.49.11.176-182.2005.
- Torres-Guerrero, E., Quintanilla-Cedillo, M. R., Quintanilla-Cedillo, J., Arenas, R. (2017). Leishmaniasis: a review. *F1000Research*, 6. DOI: 10.12688/f1000research.11120.1.
- Ueda-Nakamura, T., Mendonça-Filho, R. R., Morgado-Díaz, J. A., Maza, P. K., Filho, B. P. D., Cortez, D. A. G., Alviano, D. S., Rosa, M. S. S., Lopes, A. H. C. S., Alviano, C. S., & Nakamura, C. V. (2006). Antileishmanial activity of Eugenol-rich essential oil from *Ocimum gratissimum*. *Parasitology International*, 55(2), 99-105. DOI: 10.1016/j.parint.2005.10.006.
- Valero, N. N. H & Uriarte, M. (2020). Environmental and socioeconomic risk factors associated with visceral and cutaneous leishmaniasis: a systematic review. *Parasitology Research*, 1-20. DOI: 10.1007/s00436-019-06575-5.
- World Health Organization, (2020). Global Health Observatory (GHO) data leishmaniasis. http://www.who.int/gho/neglected_diseases/leishmaniasis/en/.
- Wu, M. Y., & Lu, J. H. (2020). Autophagy and macrophage functions: inflammatory response and phagocytosis. *Cells*, 9(1), 70. DOI: 10.3390/cells9010070.

5 CONCLUSÃO

A utilização da casca do fruto de *M. floribunda* como possibilidade de aplicação biotecnológica é inovadora e compreende um campo aberto para estudo nas áreas alimentícia, cosmética e farmacêutica. O MfEO apresentou propriedades biológicas promissoras como inibidor de acetilcolinesterase e atividade anti-leishmania, sendo um potencial bioativo para o desenvolvimento de novas formulações farmacológicas mais efízes, menos tóxicas e de baixo custo, que atenda as limitações dos fármacos disponíveis para o tratamento de doenças neurodegenerativas e negligenciadas. Este estudo foi pioneiro na descrição da composição química e aplicações biológicas para óleo essencial da casca do fruto de *M. floribunda*.

REFERÊNCIAS

- ABBASI, Arshad Mehmood et al. Phytochemical composition, cellular antioxidant capacity and antiproliferative activity in mango (*Mangifera indica* L.) pulp and peel. **International journal of food science & technology**, v. 52, n. 3, p. 817-826, 2017.
- ADNAN, Mohd. Bioactive potential of essential oil extracted from the leaves of *Eucalyptus globulus* (Myrtaceae). **Journal of Pharmacognosy and Phytochemistry**, v. 8, n. 1, p. 213-216, 2019.
- AKAIKE, Akinori; SHIMOHAMA, Shun; MISU, Yoshimi. Nicotinic Acetylcholine Receptor Signaling in Neuroprotection. **Springer Singapore**: 2018.
- ALI, Babar et al. Essential oils used in aromatherapy: A systemic review. **Asian Pacific Journal of Tropical Biomedicine**, v. 5, n. 8, p. 601-611, 2015.
- ALVES, Mércia Freitas et al. *Myrcia lundiana* Kiaersk native populations have different essential oil composition and antifungal activity against *Lasiodiplodia theobromae*. **Industrial Crops and Products**, v. 85, p. 266-273, 2016.
- ANASTASIOU, Charis; BUCHBAUER, Gerhard. Essential oils as immunomodulators: some examples. **Open Chemistry**, v. 15, n. 1, p. 352-370, 2017.
- ANVERSA, Laís et al. Human leishmaniasis in Brazil: A general review. **Revista da Associação Médica Brasileira**, v. 64, n. 3, p. 281-289, 2018.
- ARRUDA, Miguel et al. Anti-acetylcholinesterase and antioxidant activity of essential oils from *Hedychium gardnerianum* Sheppard ex Ker-Gawl. **Molecules**, v. 17, n. 3, p. 3082-3092, 2012.
- ARTINI, Marco et al. Antimicrobial and antibiofilm activity and machine learning classification analysis of essential oils from different mediterranean plants against *Pseudomonas aeruginosa*. **Molecules**, v. 23, n. 2, p. 482, 2018.

ASCARI, Jociani et al. Chemical composition, antioxidant and anti-inflammatory activities of the essential oils from male and female specimens of *arr* (Asteraceae). **Journal of ethnopharmacology**, v. 234, p. 1-7, 2019.

AUMEERUDDY-ELALFI, Zaahira et al. Selected essential oils inhibit key physiological enzymes and possess intracellular and extracellular antimelanogenic properties *in vitro*. **Journal of food and drug analysis**, v. 26, n. 1, p. 232-243, 2018.

AYAZ, Muhammad et al. Neuroprotective and anti-aging potentials of essential oils from aromatic and medicinal plants. **Frontiers in aging neuroscience**, v. 9, p. 168, 2017.

AZEREDO, Camila MO; SOARES, Maurilio J. Combination of the essential oil constituents citral, eugenol and thymol enhance their inhibitory effect on *Crithidia fasciculata* and *Trypanosoma cruzi* growth. **Revista Brasileira de Farmacognosia**, v. 23, n. 5, p. 762-768, 2013.

AZEVEDO, Maycow Marcos L. et al. Lupane triterpenoids, antioxidant potential and antimicrobial activity of *Myrciaria floribunda* (H. West ex Willd.) O. Berg. **Natural product research**, v. 33, n. 4, p. 506-515, 2019.

BAHMANI, Mohsen; SCHMIDT, Olaf. Plant essential oils for environment-friendly protection of wood objects against fungi. Maderas. **Ciencia y tecnología**, v. 20, n. 3, p. 325-332, 2018.

BARBOSA, Deyzi Caroline; SILVA, Welson Vicente; CORREIA, Maria Tereza. Atividade antioxidante de óleos essenciais da família Myrtaceae pelo método de dpph: uma revisão de literatura. **Revista Interfaces: Saúde, Humanas e Tecnologia**, v. 7, n. 2, p. 325-338, 2019.

BAXTER, Mark G.; CRIMINS, Johanna L. Acetylcholine Receptor Stimulation for Cognitive Enhancement: Better the Devil You Know?. **Neuron**, v. 98, n. 6, p. 1064-1066, 2018.

BENELLI, Giovanni et al. Insecticidal and mosquito repellent efficacy of the essential oils from stem bark and wood of *Hazomalania voyronii*. **Journal of ethnopharmacology**, v. 248, p. 112333, 2020.

BENFANTE, Roberta et al. Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders. **Aging clinical and experimental research**, p. 1-12, 2019.

BENNY, Anju; THOMAS, Jaya. Essential oils as treatment strategy for Alzheimer's disease: Current and future perspectives. **Planta medica**, v. 85, n. 03, p. 239-248, 2019.

BEZERRA, F. W. F. et al. Extraction of bioactive compounds. In: Green Sustainable Process for Chemical and Environmental Engineering and Science. **Elsevier**, 2020. p. 149-167.

BROOKIE, Kate L.; BEST, Georgia I.; CONNER, Tamlin S. Intake of raw fruits and vegetables is associated with better mental health than intake of processed fruits and vegetables. **Frontiers in psychology**, v. 9, p. 487, 2018.

BROWN, Robert H.; AL-CHALABI, Ammar. Amyotrophic lateral sclerosis. **New England Journal of Medicine**, v. 377, n. 2, p. 162-172, 2017.

BROWN, David A. Acetylcholine and cholinergic receptors. **Brain and Neuroscience Advances**, v. 3, p. 2398212818820506, 2019.

BROWNLEE, Wallace J. et al. Diagnosis of multiple sclerosis: progress and challenges. **The Lancet**, v. 389, n. 10076, p. 1336-1346, 2017.

BURČUL, Franko et al. Terpenes, phenylpropanoids, sulfur and other essential oil constituents as inhibitors of cholinesterases. **Current medicinal chemistry**, 2019.

ÇAKALOĞLU, Büşra; ÖZYURT, Vasfiye Hazal; ÖTLEŞ, Semih. Cold press in oil extraction. A review. **Ukrainian Food Journal**, v. 7, n. 4, p. 640-654, 2018.

CARNEIRO, Nargella S. et al. Chemical composition, antioxidant and antibacterial activities of essential oils from leaves and flowers of *Eugenia klotzschiana* Berg (Myrtaceae). **Anais da Academia Brasileira de Ciências**, v. 89, n. 3, p. 1907-1915, 2017.

CHAKRAVARTY, Jaya; SUNDAR, Shyam. Current and emerging medications for the treatment of leishmaniasis. **Expert opinion on pharmacotherapy**, v. 20, n. 10, p. 1251-1265, 2019.

CHEMAT, Farid; BOUTEKEDJIRET, Chahrazed. Extraction//Steam Distillation. **Reference module in Chemistry Molecular Sciences and Chemical Engineering**, p. 1-11, 2016.

CHEN, Wei-Wei; ZHANG, X. I. A.; HUANG, Wen-Juan. Role of neuroinflammation in neurodegenerative diseases. **Molecular medicine reports**, v. 13, n. 4, p. 3391-3396, 2016.

CHEUKA, Peter Mubanga et al. The role of natural products in drug discovery and development against neglected tropical diseases. **Molecules**, v. 22, n. 1, p. 58, 2017.

CHOU, Su-Tze et al. Chemical composition, antioxidant, anti-melanogenic and anti-inflammatory activities of *Glechoma hederacea* (Lamiaceae) essential oil. **Industrial Crops and Products**, v. 122, p. 675-685, 2018.

CHOUHAN, Sonam; SHARMA, Kanika; GULERIA, Sanjay. Antimicrobial activity of some essential oils—present status and future perspectives. **Medicines**, v. 4, n. 3, p. 58, 2017.

COCK, Ian Edwin; CHEESMAN, Matthew. The potential of plants of the genus *Syzygium* (Myrtaceae) for the prevention and treatment of arthritic and autoimmune diseases. In: Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases. **Academic Press**, p. 401-424, 2019.

COLGAN, Peter; TABRIZI, Sarah J. Huntington's disease: a clinical review. **European journal of neurology**, v. 25, n. 1, p. 24-34, 2018.

CONDE-HERNÁNDEZ, Lilia A. et al. CO₂-supercritical extraction, hydrodistillation and steam distillation of essential oil of rosemary (*Rosmarinus officinalis*). **Journal of food engineering**, v. 200, p. 81-86, 2017.

CONTRERAS-MORENO, Billmary Z. et al. Antimicrobial activity of essential oil of *Pimenta racemosa* var. *racemosa* (Myrtaceae) leaves. **Journal of Pharmacy & Pharmacognosy Research**, v. 4, n. 6, p. 224-230, 2016.

CORREA, Marcos Saldanha et al. Antimicrobial and antibiofilm activity of the essential oil from dried leaves of *Eucalyptus staigeriana*. **Arquivos do Instituto Biológico**, v. 86, 2019.

COSTA, Wêndeo Kennedy et al. Essential oil from *Eugenia stipitata* McVaugh leaves has antinociceptive, anti-inflammatory and antipyretic activities without showing toxicity in mice. **Industrial Crops and Products**, v. 144, p. 112059, 2020.

CUANALO-CONTRERAS, Karina; MORENO-GONZALEZ, Ines. Natural Products as Modulators of the Proteostasis Machinery: Implications in Neurodegenerative Diseases. **International journal of molecular sciences**, v. 20, n. 19, p. 4666, 2019.

CUNY, Gregory D. Neurodegenerative diseases: challenges and opportunities. **Future medicinal chemistry**, v. 4, n. 13, p. 1647-1649, 2012.

CZECH, Anna et al. Mineral Content of the Pulp and Peel of Various Citrus Fruit Cultivars. **Biological trace element research**, v. 193, n. 2, p. 555-563, 2020.

DENG, Weihui et al. Chemical Composition, Antimicrobial, Antioxidant, and Antiproliferative Properties of Grapefruit Essential Oil Prepared by Molecular Distillation. **Molecules**, v. 25, n. 1, p. 217, 2020.

DEY, Abhijit et al. Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions. **Biotechnology advances**, v. 35, n. 2, p. 178-216, 2017.

DHIFI, Wissal et al. Essential oils' chemical characterization and investigation of some biological activities: a critical review. **Medicines**, v. 3, n. 4, p. 25, 2016.

DIAS, Alline LB et al. Chemical composition and in vitro antibacterial and antiproliferative activities of the essential oil from the leaves of *Psidium myrtilloides* O. Berg (Myrtaceae). **Natural product research**, v. 33, n. 17, p. 2566-2570, 2019.

DUGGER, Brittany N.; DICKSON, Dennis W. Pathology of neurodegenerative diseases. **Cold Spring Harbor perspectives in biology**, v. 9, n. 7, p. a028035, 2017.

DURÃES, Emanuelle Rosário Brito et al. Phytochemical study, toxicity and antimicrobial activity of *Psidium myrsinites* DC.(Myrtaceae) leaves. **Bioscience Journal**, v. 33, n. 5, 2017.

DURAZZINI, Ana MS et al. *Eugenia pyriformis* Cambess: a species of the Myrtaceae family with bioactive essential oil. **Natural product research**, p. 1-5, 2019.

DO, Thi Kieu Tiên et al. Authenticity of essential oils. **TrAC Trends in Analytical Chemistry**, v. 66, p. 146-157, 2015.

EFTEKHARI, Mahdiah et al. *Oliveria decumbens*, a bioactive essential oil: chemical composition and biological activities. **Iranian journal of pharmaceutical research: IJPR**, v. 18, n. 1, p. 412, 2019.

ELMAHALLAWY, Ehab Kotb et al. Diagnosis of leishmaniasis. **The Journal of Infection in Developing Countries**, v. 8, n. 08, p. 961-972, 2014.

ELUMALAI, Preetham; LAKSHMI, Sreeja. Role of quercetin benefits in neurodegeneration. In: The Benefits of Natural Products for Neurodegenerative Diseases. **Springer, Cham**, 2016. p. 229-245.

ENGELS, Dirk; ZHOU, Xiao-Nong. Neglected tropical diseases: an effective global response to local poverty-related disease priorities. **Infectious Diseases of Poverty**, v. 9, n. 1, p. 1-9, 2020.

ERKKINEN, Michael G.; KIM, Mee-Ohk; GESCHWIND, Michael D. Clinical neurology and epidemiology of the major neurodegenerative diseases. **Cold Spring Harbor perspectives in biology**, v. 10, n. 4, p. a033118, 2018.

ESSA, Musthafa M. et al. Neuroprotective effect of natural products against Alzheimer's disease. **Neurochemical research**, v. 37, n. 9, p. 1829-1842, 2012.

FARIAS, David et al. A critical review of some fruit trees from the Myrtaceae family as promising sources for food applications with functional claims. **Food chemistry**, p. 125630, 2020.

FEDER, Denise et al. Exploring the Insecticide and Acaricide Potential of Development Regulators obtained from Restinga vegetation from Brazil. **Anais da Academia Brasileira de Ciências**, v. 91, n. 1, 2019.

FEITOSA, Chistiane Mendes et al. Antioxidant and anticholinesterase activities of the essential oil of *Eugenia dysenterica* DC. **African Journal of Pharmacy and Pharmacology**, v. 11, n. 19, p. 241-249, 2017.

FIGUEIREDO, A. Cristina; PEDRO, Luis G.; BARROSO, José G. Voláteis e óleos essenciais. **Parte I/II. Agrotec**, v. 24, p. 14-17, 2017.

FRATERNALE, Daniele; FLAMINI, Guido; ASCRIZZI, Roberta. In Vitro Anticollagenase and Antielastase Activities of Essential Oil of *Helichrysum italicum* subsp. italicum (Roth) G. Don. **Journal of medicinal food**, 2019.

FU, Hongjun; HARDY, John; DUFF, Karen E. Selective vulnerability in neurodegenerative diseases. **Nature neuroscience**, v. 21, n. 10, p. 1350-1358, 2018.

GALHEIGO, Maria Raquel Unterkircher et al. Antidiarrhoeic effect of *Eugenia dysenterica* DC (Myrtaceae) leaf essential oil. **Natural product research**, v. 30, n. 10, p. 1182-1185, 2016.

GAO, Zhipeng et al. Chemical composition and anti-biofilm activity of essential oil from *Citrus medica* L. var. *sarcodactylis* Swingle against *Listeria monocytogenes*. **Industrial Crops and Products**, v. 144, p. 112036, 2020.

GALTS, Ciaran PC et al. Depression in neurodegenerative diseases: common mechanisms and current treatment options. **Neuroscience & Biobehavioral Reviews**, 2019.

GAYAS, Bazilla; KAUR, Gagandeep. Novel oil extraction methods in food industry: A review. **Journal of Oilseed Brassica**, v. 1, n. 1, p. 1-11, 2017.

GEDIKOĞLU, Ayça; SÖKMEN, Münevver; ÇIVIT, Ayşe. Evaluation of *Thymus vulgaris* and *Thymbra spicata* essential oils and plant extracts for chemical composition, antioxidant, and antimicrobial properties. **Food science & nutrition**, v. 7, n. 5, p. 1704-1714, 2019.

GIARETTA, Augusto et al. Diversidade de Myrtaceae na Reserva Natural Vale. Floresta Atlântica de Tabuleiro: diversidade e endemismo na Reserva Natural Vale. Rona, Belo Horizonte, p. 247-257, 2016.

GONZÁLEZ, M. P. et al. Plants with evidence-based therapeutic effects against neurodegenerative diseases. **Pharm Pharmacol Int J**, v. 7, n. 5, p. 221-227, 2019.

GONÇALVES, Sandra; ROMANO, Anabela. Application of supercritical CO₂ for enhanced oil recovery. In: Green Sustainable Process for Chemical and Environmental Engineering and Science. **Elsevier**, 2020. p. 67-84.

GOTO, Hiro; LINDOSO, José Angelo Lauletta. Cutaneous and mucocutaneous leishmaniasis. **Infectious Disease Clinics**, v. 26, n. 2, p. 293-307, 2012.

GOVINDARAJAN, Marimuthu; BENELLI, Giovanni. α -Humulene and β -elemene from *Syzygium zeylanicum* (Myrtaceae) essential oil: highly effective and eco-friendly larvicides against *Anopheles subpictus*, *Aedes albopictus*, and *Culex tritaeniorhynchus* (Diptera: Culicidae). **Parasitology research**, v. 115, n. 7, p. 2771-2778, 2016.

HAILU, Asrat; DAGNE, Daniel Argaw; BOELAERT, Marleen. Leishmaniasis. In: Neglected Tropical Diseases-Sub-Saharan Africa. **Springer**, Cham, 2016. p. 87-112.

HAN, Xuesheng; PARKER, Tory L. Anti-inflammatory activity of clove (*Eugenia caryophyllata*) essential oil in human dermal fibroblasts. **Pharmaceutical biology**, v. 55, n. 1, p. 1619-1622, 2017.

HARDIMAN, Orla et al. Amyotrophic lateral sclerosis. **Nature Reviews Disease Primers**, v. 3, n. 1, p. 1-19, 2017.

HASSAN, Sohaib; MANZOOR, Muhammad Arfan; SALEEM, Muhammad Aamir. Using essential oils of weeds in aromatherapy for healing and medication. **Journal of Research in Weed Science**, v. 3, n. 1. pp. 1-119, p. 71-80, 2020.

HENNIA, Aicha et al. Antioxidant and Antiproliferative Activities of *Myrtus communis* L. Essential Oils from Different Algerian Regions. **Journal of Essential Oil Bearing Plants**, p. 1-12, 2020.

HERNÁNDEZ, Jehison Jiménez et al. Antitussive, antispasmodic, bronchodilating and cardiac inotropic effects of the essential oil from *Blepharocalyx salicifolius* leaves. **Journal of ethnopharmacology**, v. 210, p. 107-117, 2018.

HOTEZ, Peter J. et al. Eliminating the neglected tropical diseases: translational science and new technologies. **PLoS neglected tropical diseases**, v. 10, n. 3, 2016.

HURRELL, Benjamin P.; REGLI, Ivo B.; TACCHINI-COTTIER, Fabienne. Different *Leishmania* species drive distinct neutrophil functions. **Trends in parasitology**, v. 32, n. 5, p. 392-401, 2016.

IRSHAD, Muhammad et al. Biological Importance of Essential Oils. In: Essential Oils-Oils of Nature. **IntechOpen**, 2019.

JIN, Xin et al. Produtos naturais como potencial modulador da polarização microglial em doenças neurodegenerativas. **Pesquisa farmacológica**, 2019.

JING, Chang-Liang et al. Variation in Chemical Composition and Biological Activities of Flos *Chrysanthemi indicis* Essential Oil under Different Extraction Methods. **Biomolecules**, v. 9, n. 10, p. 518, 2019.

- KAMAL, Mehnaz et al. Natural products and their active principles used in the treatment of neurodegenerative diseases: a review. **Oriental Pharmacy and Experimental Medicine**, p. 1-23, 2019.
- KASHANI, Mansour Nassiri; KHAMESIPOUR, Ali; FIROOZ, Alireza. Leishmaniose cutânea. In: *Pele étnica pigmentada e dermatoses importadas*. **Springer**, Cham, 2018. p. 95-101.
- KAUFFMANN, Carla et al. Potential antileishmanial activity of essential oils of native species from southern Brazil. *Environ. Nat. Resour. J.*, v. 64, p. 18, 2016.
- KAUFFMANN, Carla et al. Chemical composition and evaluation preliminary of antileishmanial activity in vitro of essential oil from leaves of *Eugenia pitanga*, a native species of southern of Brazil. **Journal of Essential Oil Bearing Plants**, v. 20, n. 2, p. 559-569, 2017.
- KAUFFMANN, Carla et al. Antileishmanial in vitro activity of essential oil from *Myrciaria plinioides*, a native species from Southern Brazil. **Brazilian Journal of Pharmaceutical Sciences**, v. 55, 2019.
- KHARBACH, Mourad et al. Recent advances in untargeted and targeted approaches applied in herbal-extracts and essential-oils fingerprinting-A review. **Journal of pharmaceutical and biomedical analysis**, p. 112849, 2019.
- KHATOON, Syeda S.; REHMAN, M.; RAHMAN, A. The role of natural products in Alzheimer's and Parkinson's disease. In: *Studies in Natural Products Chemistry*. **Elsevier**, p. 69-127, 2018.
- KOIKKALAINEN, Juha et al. Diagnóstico diferencial de doenças neurodegenerativas usando dados estruturais de RM. **NeuroImage: Clinical**, v. 11, p. 435-449, 2016.
- KOVACS, G. G.; BUDKA, H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. **Clin Neuropathol**, v. 29, n. 5, p. 271-288, 2010.
- KOVACS, Gabor G. Conceitos e classificação de doenças neurodegenerativas. In: *Manual de neurologia clínica*. **Elsevier**, 2018. p. 301-307.
- LANGMEAD, Christopher J.; WATSON, Jeannette; REAVILL, Charlie. Muscarinic acetylcholine receptors as CNS drug targets. **Pharmacology & therapeutics**, v. 117, n. 2, p. 232-243, 2008.
- LE, Thanh Binh et al. Anti-protozoal activity of essential oils and their constituents against *Leishmania*, *Plasmodium* and *Trypanosoma*. **Phytochimie**, v. 1, p. 1-33, 2018.
- LEMOES, EEP et al. *Myrciaria floribunda*: cambuí. Embrapa Agroindústria Tropical-Capítulo em livro técnico (INFOTECA-E), 2018.
- MACEDO, Caroline Gomes et al. Leishmanicidal activity of *Piper marginatum* Jacq. from Santarém-PA against *Leishmania amazonensis*. **Experimental Parasitology**, p. 107847, 2020.
- MAHMOUDVAND, Hossein et al. In vitro and in vivo antileishmanial activities of *Pistacia vera* essential oil. **Planta Medica**, v. 82, n. 04, p. 279-284, 2016.

- MAHER, Pamela. The potential of flavonoids for the treatment of neurodegenerative diseases. **International journal of molecular sciences**, v. 20, n. 12, p. 3056, 2019.
- MAIA, Valéria Cid. Insect galls on Myrtaceae: richness and distribution in brazilian restingas. **Biota Neotropica**, v. 19, n. 1, 2019.
- MANION, Chelsea R.; WIDDER, Rebecca M. Essentials of essential oils. **American Journal of Health-System Pharmacy**, v. 74, n. 9, p. e153-e162, 2017.
- MASMOUDI, Abderrahmen et al. Old World cutaneous leishmaniasis: diagnosis and treatment. **Journal of dermatological case reports**, v. 7, n. 2, p. 31, 2013.
- MATOS, Luana Ferreira et al. Chemical composition and insecticidal effect of essential oils from *Illicium verum* and *Eugenia caryophyllus* on *Callosobruchus maculatus* in cowpea. **Industrial Crops and Products**, v. 145, p. 112088, 2020.
- MATSUNAGA, Shinji et al. Cholinesterase inhibitors for Lewy body disorders: a meta-analysis. **International Journal of Neuropsychopharmacology**, v. 19, n. 2, 2016.
- MEDEIROS, Fernando CM et al. Fungicidal activity of essential oils from Brazilian Cerrado species against wood decay fungi. **International Biodeterioration & Biodegradation**, v. 114, p. 87-93, 2016.
- MENDES, Luiza Alves et al. Óleos essenciais em Myrtaceae. **Tópicos Especiais em Produção Vegetal VI**, p. 110, 2016.
- MENEZES, Juliana Perrone Bezerra et al. Advances in development of new treatment for leishmaniasis. **BioMed research international**, v. 2015, 2015.
- MINISTÉRIO DA SAÚDE, 2016. Leishmaniose visceral. Disponível em: <https://portalarquivos2.saude.gov.br/images/pdf/2016/novembro/18/Guia-LV-2016.pdf>. Acesso em: 31 de Jan. 2020.
- MINISTÉRIO DA SAÚDE, 2017. Leishmaniose visceral. Disponível em: <https://portalarquivos2.saude.gov.br/images/pdf/2019/janeiro/28/leishvisceral-17-novo-layout.pdf>. Acesso em: 31 de Jan. 2020.
- MIRANDA, C. A. S. F. et al. Essential oils from leaves of various species: antioxidant and antibacterial properties on growth in pathogenic species. **Revista Ciência Agronômica**, v. 47, n. 1, p. 213-220, 2016.
- MU, Ping; HUANG, Yanhua H. Cholinergic system in sleep regulation of emotion and motivation. *Pharmacological research*, 2019.
- MUTHUMPERUMAL, Chellam et al. Chemical profiling of leaf essential oil, Antioxidant potential and Antibacterial activity of *Syzygium lanceolatum* (Lam.) Wt. & Arn.(Myrtaceae). **Free Radicals & Antioxidants**, v. 6, n. 1, 2016.
- NASCIMENTO, Kamilla Felipe et al. Antioxidant, anti-inflammatory, antiproliferative and antimycobacterial activities of the essential oil of *Psidium guineense* Sw. and spathulenol. **Journal of ethnopharmacology**, v. 210, p. 351-358, 2018.
- NEGRINI, Marcelo et al. Insecticidal activity of essential oils in controlling fall armyworm, *Spodoptera frugiperda*. **Arquivos do Instituto Biológico**, v. 86, 2019.

- NEVES, Ilzenayde de A. et al. Composition and larvicidal activity of essential oil of *Eugenia candolleana* DC. (Myrtaceae) against *Aedes aegypti*. **Revista virtual de Química**, v. 9, p. 2305-2315, 2017.
- NIEDZIELSKA, Ewa et al. Oxidative stress in neurodegenerative diseases. **Molecular neurobiology**, v. 53, n. 6, p. 4094-4125, 2016.
- NORRIS, Jeremiah et al. Social and economic impact review on neglected tropical diseases. Economic Policy/Briefing Paper. **Washington DC: Hudson Institute**, 2012.
- OFEK, K.; SOREQ, H. Cholinergic involvement and manipulation approaches in multiple system disorders. **Chemico-biological interactions**, v. 203, n. 1, p. 113-119, 2013.
- OKHALE, Samuel Ehiabhi et al. Chemical Characterization, Antioxidant and Antimicrobial Activities of the Leaf Essential Oil of *Syzygium guineense* (Willd.) DC. var. *guineense* (Myrtaceae) from Nigeria. **International Journal of Pharmacognosy and Phytochemistry Research**, v. 10, n. 11, p. 341-349, 2018.
- OLIVEIRA, Luiz Filipe Gonçalves et al. Natural products and phytotherapy: an innovative perspective in leishmaniasis treatment. **Phytochemistry reviews**, v. 16, n. 2, p. 219-233, 2017.
- OLIVEIRA, Luciana Mouta et al. Chemical characterization of *Myrciaria floribunda* (H. West ex Willd) fruit. **Food chemistry**, v. 248, p. 247-252, 2018.
- OLIVEIRA, Mozaniel Santana et al. Phytochemical profile, antioxidant activity, inhibition of acetylcholinesterase and interaction mechanism of the major components of the Piper divaricatum essential oil obtained by supercritical CO₂. **The Journal of Supercritical Fluids**, v. 145, p. 74-84, 2019.
- OLIVEIRA, Luciana Mouta et al. Chemical characterization of *Myrciaria floribunda* (H. West ex Willd) fruit. **Food chemistry**, v. 248, p. 247-252, 2018.
- ORYAN, A.; AKBARI, M. Worldwide risk factors in leishmaniasis. **Asian Pacific Journal of Tropical Medicine**, v. 9, n. 10, p. 925-932, 2016.
- OZ, Murat; PETROIANU, Georg; LORKE, Dietrich E. α 7-nicotinic acetylcholine receptors: new therapeutic avenues in Alzheimer's disease. In: *Nicotinic Acetylcholine Receptor Technologies*. Humana Press, New York, NY, p. 149-169, 2016.
- PANDIYAN, G. Navaneetha; MATHEW, Nisha; MUNUSAMY, Sundharesan. Larvicidal activity of selected essential oil in synergized combinations against *Aedes aegypti*. **Ecotoxicology and environmental safety**, v. 174, p. 549-556, 2019.
- PARK, Chung et al. Myrtaceae plant essential oils and their β -triketone components as insecticides against *Drosophila suzukii*. **Molecules**, v. 22, n. 7, p. 1050, 2017.
- PASSOS, L. O. et al. A New B-triketone and antinociceptive effect from the essential oil of the leaves of *Calyptanthus restingae* Sobral (Myrtaceae). **Med Aromat Plants**, v. 5, n. 249, p. 2167-0412.100024, 2016.
- PATEL, Sarvesh et al. Review on Bioactive and Antioxidant Potential of Coloured Fruits and Vegetables. **Journal of Drug Delivery and Therapeutics**, v. 9, n. 2, p. 433-441, 2019.

- PEPEU, Giancarlo; GIOVANNINI, Maria Grazia. The fate of the brain cholinergic neurons in neurodegenerative diseases. **Brain research**, v. 1670, p. 173-184, 2017.
- PENG, Yaoyao; BISHOP, Karen Suzanne; QUEK, Siew Young. Compositional Analysis and Aroma Evaluation of Feijoa Essential Oils from New Zealand Grown Cultivars. **Molecules**, v. 24, n. 11, p. 2053, 2019.
- PETRACHAIANAN, Tipsara et al. Screening of acetylcholinesterase inhibitory activity in essential oil from Myrtaceae. **Thai Journal of Pharmaceutical Sciences**, v. 43, n. 1, 2019.
- PETRONILHOA, Elaine; PINTOB, Angelo C.; VILLARA, José Daniel Figueroa. Acetilcolinesterase: Alzheimer E Guerra Química. **Ciência e Tecnologia**, p. 3, 2011.
- PHILLIPS, William D.; VINCENT, Angela. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. **F1000Research**, v. 5, 2016.
- POHL, Franziska; KONG THOO LIN, Paul. O uso potencial de produtos naturais e extratos vegetais com propriedades antioxidantes para a prevenção / tratamento de doenças neurodegenerativas: ensaios in vitro, in vivo e clínicos. **Molecules**, v. 23, n. 12, p. 3283, 2018.
- RAMOS, Zenia Acosta; PENDÁS, Enrique González; URRRA, Niuris Varela. Notas taxonómicas sobre el género *Myrciaria Berg* (Myrtaceae) en Cuba. **Revista Ecvoda**, v. 5, n. 2, p. 283-289, 2015.
- RANJAN, Navi; KUMARI, Manorma. Acetylcholinesterase inhibition by medicinal plants: A Review. **Annals of Plant Sciences**, v. 6, n. 06, p. 1640-4, 2017.
- REITHINGER, Richard et al. Cutaneous leishmaniasis. **The Lancet infectious diseases**, v. 7, n. 9, p. 581-596, 2007.
- RENARD, Pierre-Yves; JEAN, Ludovic. Probing the cholinergic system to understand neurodegenerative diseases. 2017.
- RÉUS, Gislaine Z. et al. Neurochemical correlation between major depressive disorder and neurodegenerative diseases. **Life sciences**, v. 158, p. 121-129, 2016.
- REYNERTSON, Kurt A. et al. Quantitative analysis of antiradical phenolic constituents from fourteen edible Myrtaceae fruits. **Food chemistry**, v. 109, n. 4, p. 883-890, 2008.
- REYES-JURADO, Fatima et al. Essential oils in vapor phase as alternative antimicrobials: A review. **Critical reviews in food science and nutrition**, p. 1-10, 2019.
- RODRIGUES, Klinger Antonio et al. Syzygium cumini (L.) Skeels essential oil and its major constituent α -pinene exhibit anti-Leishmania activity through immunomodulation in vitro. **Journal of ethnopharmacology**, v. 160, p. 32-40, 2015.
- ROSA, Ana Claudia Santos da et al. Obtaining oil from macauba kernels by ultrasound-assisted extraction using ethyl acetate as the solvent. **Brazilian Journal of Food Technology**, v. 22, 2019.
- RUIZ-RICO, María; MORENO, Yolanda; BARAT, José M. In vitro antimicrobial activity of immobilised essential oil components against *Helicobacter pylori*. **World Journal of Microbiology and Biotechnology**, v. 36, n. 1, p. 3, 2020.

- SAIDANI, Fayza et al. Phenolic, sugar and acid profiles and the antioxidant composition in the peel and pulp of peach fruits. **Journal of Food Composition and Analysis**, v. 62, p. 126-133, 2017.
- SALOMÃO, Luiz CC et al. Jabuticaba—*Myrciaria spp.* In: Exotic Fruits. **Academic Press**, 2018. p. 237-244.
- SAMPAIO, Mariana et al. Chemical composition, antioxidant and antiprotozoal activity of *Eugenia gracilima* Kiaersk. leaves essential oil. **Natural product research**, p. 1-5, 2019.
- SANTANA, Camila Beatriz et al. Chemical composition of essential oil from *Myrcia oblongata* DC and potencial antimicrobial, antioxidant and acaricidal activity against *Dermanyssus gallinae* (Degeer, 1778). **Bioscience Journal**, v. 34, n. 4, 2018.
- SANTOS, Everton Ferreira et al. Caracterização Físico-química, compostos bioativos e atividade antioxidante total de frutos de cambuizeiro (*Myrciaria floribunda* O. Berg). **Revista Ouricuri**, v. 7, n. 1, p. 064-079, 2017.
- SANTOS, Joycy Francely Sampaio et al. Chemical composition, antifungal activity and potential anti-virulence evaluation of the *Eugenia uniflora* essential oil against *Candida spp.* **Food chemistry**, v. 261, p. 233-239, 2018.
- SANTOS, Thaiane Coelho dos et al. Naturally occurring acetylcholinesterase inhibitors and their potential use for Alzheimer's disease therapy. **Frontiers in pharmacology**, v. 9, p. 1192, 2018.
- SANTOS, Everton Ferreira dos et al. Caracterização fenológica e morfológica de plantas e qualidade pós-colheita de frutos de acessos de cambuizeiro (*Myrciaria floribunda* O. Berg) do **banco ativo de germoplasma do CECA-UFAL**. 2018.
- SANTOS, Anaí L. et al. GC× GC/qMS analyses of *Campomanesia guazumifolia* (Cambess.) O. Berg essential oils and their antioxidant and antimicrobial activity. **Natural product research**, v. 33, n. 4, p. 593-597, 2019.
- SANTOS, Gustavo Rafael de Albuquerque et al. O desequilíbrio fatal: reflexão sobre as doenças negligenciadas. 2019.
- SAREEDENCHAI, V. et al. (2019). Screening of acetylcholinesterase inhibitory activity in essential oil from Myrtaceae. **Thai Journal of Pharmaceutical Sciences** (TJPS), 43(1).
- SATHEESHKUMAR et al. Spices: Potential Therapeutics for Alzheimer's Disease. In: Essa M., Akbar M. Guillemin G. (eds) *The Benefits of Natural Products for Neurodegenerative Diseases*. Advances in Neurobiology, vol 12. **Springer**, Cham, 2016.
- SAVOIA, Dianella. Recent updates and perspectives on leishmaniasis. **The Journal of Infection in Developing Countries**, v. 9, n. 06, p. 588-596, 2015.
- SAXENA, Mridula; DUBEY, Ragini. Target enzyme in Alzheimer's disease: Acetylcholinesterase inhibitors. **Current topics in medicinal chemistry**, v. 19, n. 4, p. 264-275, 2019.

SCALVENZI, Laura et al. *Myrcia splendens* (Sw.) DC. (syn. *M. fallax* (Rich.) DC.) (Myrtaceae) essential oil from Amazonian Ecuador: A chemical characterization and bioactivity profile. **Molecules**, v. 22, n. 7, p. 1163, 2017.

SCHMATZ, Roberta et al. Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. **European journal of pharmacology**, v. 610, n. 1-3, p. 42-48, 2009.

SCORZA, Breanna M.; CARVALHO, Edgar M.; WILSON, Mary E. Cutaneous manifestations of human and murine leishmaniasis. **International journal of molecular sciences**, v. 18, n. 6, p. 1296, 2017.

SCOTT, Phillip; NOVAIS, Fernanda O. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. **Nature Reviews Immunology**, v. 16, n. 9, p. 581-592, 2016.

SERAGLIO, Siluana Katia Tischer et al. Nutritional and bioactive potential of Myrtaceae fruits during ripening. **Food chemistry**, v. 239, p. 649-656, 2018.

SHAHIDI, Fereidoon; YEO, JuDong. Bioactivities of phenolics by focusing on suppression of chronic diseases: A review. **International journal of molecular sciences**, v. 19, n. 6, p. 1573, 2018.

SHAH, Krupal A. et al. Extraction of essential oil from Patchouli leaves using hydrodistillation: Parametric studies and optimization. **Indian Journal of Chemical Technology (IJCT)**, v. 24, n. 4, p. 405-410, 2017.

STRATAKOS, Alexandros Ch; KOIDIS, Anastasios. Methods for extracting essential oils. In: *Essential Oils in Food Preservation, Flavor and Safety*. **Academic Press**, 2016. p. 31-38.

STEFANELLO, Maria Élide Alves; PASCOAL, Aislan CRF; SALVADOR, Marcos J. Essential oils from neotropical Myrtaceae: chemical diversity and biological properties. **Chemistry & biodiversity**, v. 8, n. 1, p. 73-94, 2011.

STEVERDING, Dietmar. The history of leishmaniasis. **Parasites & vectors**, v. 10, n. 1, p. 82, 2017.

SIDDIQUE, Saima et al. Chemical composition, antibacterial and antioxidant activities of essential oils from leaves of three *Melaleuca* species of Pakistani flora. **Arabian Journal of Chemistry**, v. 13, n. 1, p. 67-74, 2020.

SILVA, Leomara A. et al. Composition and Antimicrobial Activity of Leaf Essential Oils of *Myrcia sylvatica* (G. Mey.) DC. **European Journal of Medicinal Plants**, p. 1-9, 2016.

SILVA, Aline do Nascimento et al. Composição Química E Atividade antinociceptiva em modelo animal do óleo essencial de *Myrcia rostrata* DC. (Myrtaceae). **Química Nova**, v. 41, n. 9, p. 982-988, 2018.

SILVA, E. A. J. et al. Antibacterial and antiproliferative activities of the fresh leaf essential oil of *Psidium guajava* L.(Myrtaceae). **Brazilian Journal of Biology**, v. 79, n. 4, p. 697-702, 2019.

SILVA, Sandra et al. Wound Healing Effect of Essential Oil Extracted from *Eugenia dysenterica* DC (Myrtaceae) Leaves. **Molecules**, v. 24, n. 1, p. 2, 2019.

SILVA, Rui FM; POGAČNIK, Lea. Polyphenols from Food and Natural Products: Neuroprotection and Safety. **Antioxidants**, v. 9, n. 1, p. 61, 2020.

SINAN. Doenças e Notificação de agravos. Disponível em: <<http://www2.datasus.gov.br/DATASUS/index.php?area=0203&id=29878153>>. Acesso em 02 de Fev. de 2020

SOUZA, Larissa Isabela Oliveira et al. The chemical composition and trypanocidal activity of volatile oils from Brazilian Caatinga plants. **Biomedicine & Pharmacotherapy**, v. 96, p. 1055-1064, 2017.

SOLAYMAN, Md et al. Natural products combating neurodegeneration: Parkinson's disease. **Current drug metabolism**, v. 18, n. 1, p. 50-61, 2017.

SOLANKI, Isha et al. Flavonoid-based therapies in the early management of neurodegenerative diseases. **Advances in nutrition**, v. 6, n. 1, p. 64-72, 2015.

SPIRES-JONES, Tara L.; ATTEMS, Johannes; THAL, Dietmar Rudolf. Interactions of pathological proteins in neurodegenerative diseases. **Acta neuropathologica**, v. 134, n. 2, p. 187-205, 2017.

STANCIU, Gabriela Dumitrita et al. Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement. **Biomolecules**, v. 10, n. 1, p. 40, 2020.

SUNDAR, Shyam; CHAKRAVARTY, Jaya. Visceral leishmaniasis. In: Drug Resistance in Leishmania Parasites. **Springer**, Cham, p. 159-176, 2018.

SUNDAR, Shyam; SINGH, Bhawana. Emerging therapeutic targets for treatment of leishmaniasis. **Expert opinion on therapeutic targets**, v. 22, n. 6, p. 467-486, 2018.

SUNDAR, Shyam; CHAKRAVARTY, Jaya; MEENA, Lalit P. Leishmaniasis: treatment, drug resistance and emerging therapies. **Expert Opinion on Orphan Drugs**, v. 7, n. 1, p. 1-10, 2019.

SUNTER, Jack; GULL, Keith. Shape, form, function and Leishmania pathogenicity: from textbook descriptions to biological understanding. **Open biology**, v. 7, n. 9, p. 170165, 2017.

SZUTOWICZ, Andrzej et al. Acetyl-CoA the key factor for survival or death of cholinergic neurons in course of neurodegenerative diseases. **Neurochemical research**, v. 38, n. 8, p. 1523-1542, 2013.

TAN, Edwin CK et al. Do Acetylcholinesterase Inhibitors Prevent or Delay Psychotropic Prescribing in People With Dementia? Analyses of the Swedish Dementia Registry. **The American Journal of Geriatric Psychiatry**, v. 28, n. 1, p. 108-117, 2020.

TANČINOVÁ, Dana et al. Effect of essential oils of Myrtaceae plants on the *Penicillium commune*. **Potravinárstvo Slovak Journal of Food Sciences**, v. 13, n. 1, p. 604-613, 2019.

TEIXEIRA, Dirceu E. et al. The cell biology of Leishmania: how to teach using animations. **PLoS pathogens**, v. 9, n. 10, 2013.

THE PLANT LIST (2013). Version 1.1. Myrtaceae. Published on the Internet. Disponível em: <<http://www.theplantlist.org/>> (accessed 1st January)>. Acesso em: 9 de Fev. 2020.

- TIETBOHL, Luis AC et al. Comparative study and anticholinesterasic evaluation of essential oils from leaves, stems and flowers of *Myrciaria floribunda* (H. West ex Willd.) O. Berg. **Latin American Journal of Pharmacy**, v. 31, n. 4, p. 637-641, 2012.
- TIETBOHL, Luis AC et al. Laboratory evaluation of the effects of essential oil of *Myrciaria floribunda* leaves on the development of *Dysdercus peruvianus* and *Oncopeltus fasciatus*. **Revista Brasileira de Farmacognosia**, v. 24, n. 3, p. 316-321, 2014.
- TIETBOHL, Luis AC et al. Antiproliferative activity in tumor cell lines, antioxidant capacity and total phenolic, flavonoid and tannin contents of *Myrciaria floribunda*. **Anais da Academia Brasileira de Ciências**, v. 89, n. 2, p. 1111-1120, 2017.
- TIETBOHL, Luis AC et al. Green insecticide against Chagas disease: effects of essential oil from *Myrciaria floribunda* (Myrtaceae) on the development of *Rhodnius prolixus* nymphs. **Journal of Essential Oil Research**, p. 1-11, 2019.
- TIAN, yuhong et al. Repellent, insecticidal and antimicrobial activities of leaf essential oils from three *Eucalyptus* species. **Chemistry & Biodiversity**, 2020.
- TNG, D. Y. P. et al. Plant uses in a traditional fisherman community in northeastern Brazil. **bioRxiv**, p. 620542, 2019.
- TOLBA, Hadjer et al. Essential oil of Algerian *Eucalyptus citriodora*: Chemical composition, antioxidant and antimicrobial activities. **Nature & Technology**, n. 18, p. 19-27, 2018.
- TORRES-GUERRERO, Edoardo et al. Leishmaniasis: a review. **F1000Research**, v. 6, 2017.
- TREICHEL, Helen et al. Biotechnology Application of Pretreated Biomass. In: Utilising Biomass in Biotechnology. **Springer**, Cham, 2020. p. 67-81.
- TRIPATHI, Anurag; SRIVASTAVA, U. C. Acetylcholinesterase: a versatile enzyme of nervous system. **Annals of neurosciences**, v. 15, n. 4, p. 106-111, 2010.
- UNITED NATIONS, 2015. Transforming our world: the 2030 Agenda for Sustainable Development.
- VARELA, Marina Themoteo; FERNANDES, João Paulo S. Natural products: Key prototypes to drug discovery against neglected diseases caused by trypanosomatids. **Current medicinal chemistry**, 2019.
- VASCONCELOS, Thais NC et al. Myrteae phylogeny, calibration, biogeography and diversification patterns: increased understanding in the most species rich tribe of Myrtaceae. **Molecular phylogenetics and evolution**, v. 109, p. 113-137, 2017.
- VERNÈS, Léa; VIAN, Maryline; CHEMAT, Farid. Ultrasound and Microwave as Green Tools for Solid-Liquid Extraction. In: Liquid-Phase Extraction. **Elsevier**, 2020. p. 355-374.
- YAHIA, Elhadi M.; GARCÍA-SOLÍS, Pablo; CELIS, María Elena Maldonado. Contribution of fruits and vegetables to human nutrition and health. In: Postharvest physiology and biochemistry of fruits and vegetables. **Woodhead Publishing**, p. 19-45, 2019.
- YANGUI, Islem et al. Essential oils of Myrtaceae Species growing wild in Tunisia: Chemical variability and antifungal activity against *Biscogniauxia mediterranea*, the causative agent of charcoal canker. **Chemistry & biodiversity**, v. 14, n. 7, p. e1700058, 2017.

XU, Jing; LACOSKE, Michelle H.; THEODORAKIS, Emmanuel A. Neurotrophic natural products: chemistry and biology. *Angewandte Chemie International Edition*, v. 53, n. 4, p. 956-987, 2014.

WANG, Ying et al. Green and solvent-free simultaneous ultrasonic-microwave assisted extraction of essential oil from white and black peppers. *Industrial crops and products*, v. 114, p. 164-172, 2018.

WANG, Huan; ZHANG, Haiyan. Reconsideration of anticholinesterase therapeutic strategies against Alzheimer's disease. *ACS chemical neuroscience*, v. 10, n. 2, p. 852-862, 2018.

WESSLER, I.; KIRKPATRICK, C. J. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. *British journal of pharmacology*, v. 154, n. 8, p. 1558-1571, 2008.

WINKELMAN, Warren J. Aromatherapy, botanicals, and essential oils in acne. *Clinics in dermatology*, v. 36, n. 3, p. 299-305, 2018.

WINNER, Beate; WINKLER, Jürgen. Adult neurogenesis in neurodegenerative diseases. *Cold Spring Harbor perspectives in biology*, v. 7, n. 4, p. a021287, 2015.

WU, Shi-Biao; LONG, Chunlin; KENNELLY, Edward J. Phytochemistry and health benefits of jaboticaba, an emerging fruit crop from Brazil. *Food Research International*, v. 54, n. 1, p. 148-159, 2013.

ZARRAD, Khaoula et al. Chemical composition, fumigant and anti-acetylcholinesterase activity of the Tunisian *Citrus aurantium* L. essential oils. *Industrial Crops and Products*, v. 76, p. 121-127, 2015.

ZATELLI, Gabriele Andressa et al. Antimycoplasmic activity and seasonal variation of essential oil of *Eugenia hiemalis* Cambess. (Myrtaceae). *Natural product research*, v. 30, n. 17, p. 1961-1964, 2016.

ZHANG, Xiaofeng et al. In vitro evaluation of antioxidant and antimicrobial activities of *Melaleuca alternifolia* essential oil. *BioMed research international*, v. 2018, 2018.

ZOLI, Michele et al. Neuronal and extraneuronal nicotinic acetylcholine receptors. *Current neuropharmacology*, v. 16, n. 4, p. 338-349, 2018.

VENTURA, Ana LM et al. Sistema colinérgico: revisitando receptores, regulação e a relação com a doença de Alzheimer, esquizofrenia, epilepsia e tabagismo. *Archives of Clinical Psychiatry* (São Paulo), v. 37, n. 2, p. 66-72, 2010.

WONNACOTT, Sue et al. Nicotinic acetylcholine receptors. *British journal of pharmacology*, v. 175, n. 11, p. 1785-1788, 2018.

WORLD HEALTH ORGANIZATION, 2017. "Dementia: number of people affected to triple in next 30 years". Disponível em: < <https://www.who.int/news-room/detail/07-12-2017-dementia-number-of-people-affected-to-triple-in-next-30-years> >. Acesso em: 31 de Jan. de 2020.

WORLD HEALTH ORGANIZATION, 2017. Depression and other common mental disorders: global health estimates. Disponível em:

<https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf?sequence=1>. Acesso em: 31 de Jan. de 2020.

WORLD HEALTH ORGANIZATION, 2018. Visceral leishmaniasis. Disponível em: https://www.who.int/leishmaniasis/visceral_leishmaniasis/en/. Acesso em: 31 de Jan. de 2020.

WORLD HEALTH ORGANIZATION, 2020. "Depression". Disponível em: <<https://www.who.int/news-room/fact-sheets/detail/depression> >. Acesso em: 31 de Jan. de 2020.


WORLD HEALTH ORGANIZATION, 2020. "Neglected tropical diseases". Disponível em: <https://www.who.int/neglected_diseases/diseases/en/>. Acesso em: 01 de Fev. de 2020.

APÊNDICE A – ARTIGO


Chemical composition and acetylcholinesterase inhibitory potential, *in silico*, of *Myrciaria floribunda* (H. West ex Willd.) O. Berg fruit peel essential oil

ARTIGO PUBLICADO NO PERIÓDICO

“Industrial Crops and Products”



Fator de Impacto: 4.244



Chemical composition and acetylcholinesterase inhibitory potential, *in silico*, of *Myrciaria floribunda* (H. West ex Willd.) O. Berg fruit peel essential oil



Deyzi Caroline da Silva Barbosa^a, Vanderlan Nogueira Holanda^{a,b}, Caio Rodrigo Dias de Assis^a, Júlio César Ribeiro de Oliveira Farias de Aguiar^c, Pedro Henrique do Nascimento^b, Welson Vicente da Silva^b, Daniela Maria do Amaral Ferraz Navarro^c, Márcia Vanusa da Silva^a, Vera Lúcia de Menezes Lima^a, Maria Tereza dos Santos Correia^{a,*}

^a Departamento de Bioquímica, Centro de Biociências, Universidade Federal de Pernambuco, Avenida Professor Moraes Rego, 1235, 50670-901, Recife, PE, Brazil

^b Instituto Aggeu Magalhães, Departamento de Microbiologia, Avenida Professor Moraes Rego, 1235, 50670-901, Recife, PE, Brazil

^c Departamento de Química Fundamental, Centro de Ciências Exatas e da Natureza, Universidade Federal de Pernambuco, Avenida Professor Moraes Rego, 1235, 50670-901 Recife, PE, Brazil

ARTICLE INFO

Keywords:
Myrtaceae
Docking
ADMET
AChE

ABSTRACT

Essential oils (EOs) are volatile compounds obtained from aromatic plants that can act as modulators of neurological systems. Several neurodegenerative diseases have been correlated with changes in the cholinergic system. *Myrciaria floribunda* (H. West ex Willd.) O. Berg (Myrtaceae) was chosen to investigate its biological potential for treating neurodegenerative diseases. *M. floribunda* fruit peel essential oil (MfEO) was collected for analysis. In this study, the chemical composition and *in silico* acetylcholinesterase inhibitory activities were determined. The results revealed the presence of 26 (96.86%) compounds obtained for GC/MS, of which the major compounds were the following: δ -Cadinene (26.8%), γ -Cadinene (15.69%), γ -Murolene (6.21%), α -Selinene, α -Murolene (6.11%) and (*E*)-Caryophyllene (5.54%). The ADMET analysis showed that MfEO compounds have a predicted lethal dose 628 times higher than neostigmine. The molecular docking results between the major components of MfEO and the enzyme acetylcholinesterase resulted in an average energy minimization of -6.6 Kcal/mol when the two structures coupled. In the assay of acetylcholinesterase activity, *M. floribunda* fruit peel oil presented an IC_{50} of $0.08 \mu\text{g/ml}$ and $23 \mu\text{g/ml}$ for commercial AChE of *E. electricus* and that extracted from *C. rhizophorae*, respectively. MfEO showed enzymatic inhibition and other relevant information of bioactive compounds. This study provides the first report of the chemical composition of the fruit peel essential oil of *M. floribunda* and highlights the promising results obtained through *in silico* analysis and the inhibitory potential of AChE through an *in vitro* assay.

1. Introduction

Essential oils (EOs) are volatile substances of natural origin, including a variety of compounds and can be obtained from aromatic plants (Bakkali et al., 2008). Recently, the biological potential of EOs has been investigated, revealing broad potential for biomedical applications with emphasis on antimicrobial and antibiofilm (Kuhn et al., 2019), larvicidal (Pandiyar et al., 2019), leishmanicidal (Silva et al., 2018), trypanocidal (Azeredo and Soares, 2013; Costa et al., 2018) and fungicidal activities (Santos et al., 2018), as well as activities against autoimmune diseases (Cock and Cheesman, 2019) and inflammation (Chou et al., 2018) and as a modulator of the neurological system

(Arruda et al., 2012; Zarrad et al., 2015; Bhavya et al., 2018). Among the groups of botanical species that produce EO the Myrtaceae family stands out, which comprises 121 genera, is abundant in tropical regions and frequently produces edible fruit (Stefanello et al., 2011).

The variety of plant species in Brazil makes the country an essential center of genetic diversity for fruit species worldwide and has been the subject of studies over the years (Pereira et al., 2012; Costa et al., 2017). Among the most important families of the Brazilian flora, Myrtaceae occur throughout the country with more than one thousand species reported (Koch, 2014; Silva and Mazzei, 2016). *Myrciaria floribunda* H. West ex Willd.) O. Berg (Myrtaceae) is native to Brazil and popularly known as *camboim* or *jabuticabinha*; it is characteristic of

* Corresponding author at: Laboratório de Glicoproteínas, Departamento de Bioquímica, Centro de Biociências, Universidade Federal de Pernambuco, Avenida Professor Moraes Rego, 1235, 50670-901 Recife, PE, Brazil.

E-mail address: mtscorreia@gmail.com (M.T. dos Santos Correia).

<https://doi.org/10.1016/j.indcrop.2020.112372>

Received 19 November 2019; Received in revised form 12 February 2020; Accepted 17 March 2020

0926-6690/ © 2020 Elsevier B.V. All rights reserved.

coastal sandy areas (*restingas*) but has a wide geographical distribution (Amaral et al., 2013; Oliveira et al., 2018).

The fruits of *M. floribunda* are important sources of β -cryptoxanthin (pro-vitamin A), are acidic and can be consumed fresh or in processed form (Oliveira et al., 2018; Teixeira et al., 2019). Just like other species of the family, *M. floribunda* has investigated for its biological potential through the use of various plant parts (Franceschinelli et al., 2007; Vaz et al., 2012). However, the use of fruit peel remains poorly explored. Studies using the EO of *M. floribunda* leaves, stems and flowers have revealed the potential for treating neurodegenerative diseases (Tietbohl et al., 2014).

Neurodegeneration plays an important role in various brain diseases, leading to the loss of cerebral neurons; further progression can spread and affect specific neurons such as those in the cholinergic system (Pepeu et al., 2015; Renard and Ludovic, 2017). Several neurodegenerative diseases have been correlated with changes in the cholinergic system, among which the most commonly cited are Alzheimer's disease (Ovsepian, et al., 2016; Hampel et al., 2018), Parkinson's disease (Bohnen and Albin, 2011; Bohnen et al., 2019), Huntington's disease (D'Souza and Waldvogel, 2016), amyotrophic lateral sclerosis (Campanari et al., 2016), myasthenia gravis (Brenner et al., 2008; Han et al., 2017) and glaucoma (Faiq et al., 2019). Thus, it is extremely important to develop new treatments for neurological and psychiatric syndromes. In these syndromes, cholinergic system dysfunction may occur and as consequences cognitive deficits, including memory loss, emotional state modulations, mood changes and dementia (Mu and Huang, 2019; Sharma, 2019; Morris et al., 2019). The development of drugs for treatment is based, among other factors, on decreasing the acetylcholine (ACh) deficit, which is directly linked to the progression and development of neurodegenerative diseases (García-Font et al., 2016).

ACh is a neurotransmitter responsible for propagating an electrical impulse from a pre-synaptic neuron to a post-synaptic neuron (Sirin et al., 2012). ACh is synthesized in vesicles and during the neurotransmission process, the vesicle fuses with the neuron's plasma membrane and releases ACh into the synaptic cleft, which binds to receptors in the postsynaptic neuron, thereby conducting the electrical impulse (Tougu, 2001; Colovic et al., 2013). Acetylcholinesterase (AChE) is a serine hydrolase responsible for terminating nerve impulse transmission by rapidly catalyzing ACh into acetate and choline in cholinergic pathways of the central and peripheral nervous systems (Quinn, 1987; Mercey et al., 2012).

Acetylcholinesterase (AChE) inhibitors prevent the enzyme from breaking down the neurotransmitter, increasing the level and duration of ACh in the synaptic cleft, and have been targeted for the development of drugs against neurodegenerative diseases. Restoration of neurotransmitter levels may provide a beneficial alternative treatment, reducing cognitive and functional symptoms with increased synaptic availability of ACh (Sumit and Kumar, 2019). One of the first AChE inhibitor drugs was Tacrina, a compound belonging to the acridine class with substitution by an amino group at position 9. This compound was withdrawn from clinical use due to hepatotoxicity caused during treatment, as evidenced by increased transaminases in users (Sameem et al., 2017). Like tacrine, neostigmine is another AChE inhibitor, which can also cause severe side effects such as cardiac bradyarrhythmias, bronchoconstriction, nausea, increased peristalsis and potential adverse effects in pregnant women (Neely and Kohli, 2018).

In view of the above, it is important to search for AChE inhibitor compounds that present a lower capacity of systemic toxicity as a tool to fight neurological diseases. In this context, we investigated for the first time the potential of *M. floribunda* fruit peel essential oil (MfEO) in the *in vitro* inhibition of AChE and evaluated the pharmacokinetic and toxicological properties *in silico* of its major compounds.

2. Material and methods

2.1. Chemicals and reagents

Acetylcholinesterases extracted from *Crassostrea rhizophorae* and commercial AChE *Electrophorus electricus*, acetylcholine substrate (ASCh) obtained from Sigma-Aldrich (St. Louis, MO, USA), 5,5'-dithio-bis-2-nitrobenzoic acid (DNTB); neostigmine; dimethyl sulfoxide; 96-well microplate.

2.2. Plant material and extraction of essential oil and chemical composition

The fruits of *M. floribunda* were collected in the city of Exu (Latitude: 7.355809029182327°S; Longitude: 39.887568331218304°W), state of Pernambuco, Brazil, in 2018. The species was collected and a specimen was herborized and deposited at the Herbarium of the Agronomic Institute of Pernambuco (IPA), voucher number 92,722. The extraction of essential oil from *M. floribunda* fruit peels was performed by the hydrodistillation method (clevenger apparatus). To obtain the oil, 200 g of the fruit rind were mixed with 2.5 l distilled water and subjected to hydrodistillation for 3 h. After extraction, the oil was stored at 5 °C and protected from light.

2.2.1. Gas chromatography-mass spectrometry analysis (GC/MS)

The analysis of the essential oil was performed using a Thermo Trace GC Ultra gas chromatograph (Thermo Scientific, Milan, Italy), coupled with a flame ionization detector (FID). A fused silica capillary column VB-5 5 (ValcoBond 30 m $\times$ 0.25 mm $\times$ 0.25 mm) was used for the separation of constituents (Valco Instruments Company Inc., Houston, TX, USA) and nitrogen was used as a carrier gas at a flow rate of 1 l/min and inlet pressure of 30 psi. The initial temperature gradient was 40 °C for 2 min and increased at 4 °C/min to 230 °C, where it was maintained for 5 min. Injector and detector temperatures were set to 250 °C and 280 °C, respectively. The sample (1 μ l) was injected without separation and the relative amount of each component estimated by the corresponding peak and expressed as a percentage of the total chromatogram area. Mass spectra were performed at 70 eV (in EI mode) with a speed of 1.0 scans of m/z 35–350. Identification of the individual components was performed compared to the retention index values of n-alkane series according to the literature (Van den Dool and Kratz, 1963), data available in GC–MS system mass spectral library (MassFinder 4, Hamburg, Germany); Spectral Mass Library NIST08 (ChemSW Inc. Fairfield, CA, USA) and published mass spectral data (Adams, 2007).

2.3. *In silico* ADMET

For predicting the pharmacokinetic and druglike properties of the major compounds of MfEO the following online platforms were used: Swiss ADME, Swiss Target Prediction (SIB, Lausanne, Switzerland) PROTOX-II Server (Charité University, Berlin, Germany), Molinspiration (Molinspiration Cheminformatics, Nova Ulica, Slovakia), Osiris Property Explorer, Osiris Data Warrior (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland) and pKCSM (Pires et al., 2015). Reference drug information (Neostigmine PubChem CID: 4456) for analysis was obtained from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>).

2.4. Molecular docking

The docking approach used in this study aimed to identify binding to the active site capable of modulating the enzymatic activity of acetylcholinesterase (PDB code: 4PQE). The analysis of interactions between oil compounds and target proteins was performed through molecular anchoring using Autodock 4.2 and iGemDock 2.1 software. The corresponding protein structures were obtained from the Protein

Data Bank (Berman et al., 2003). The water molecules were removed and the binding site was established previously. The analysis was performed on a $60 \times 60 \times 60$ grid with a spacing of 0.375 Å, centered on the active site of acetylcholinesterase, with enzymatic residues within 8 Å in all cases. Results were analyzed using the Lamarckian genetic algorithm (López-Camacho et al., 2015) with a population size of 300, 80 generations and 10 different solutions. The functional empirical score of docking tests consists of the sum of Van der Waals-type bonds, hydrogen bridges and electrostatic energy.

2.5. Evaluation of acetylcholinesterase inhibitory activity (IACHe)

Evaluation of the enzymatic inhibition of acetylcholinesterase was determined in a microplate by the spectrophotometric method (Assis et al., 2012; Souza et al., 2018). The enzymes used for the assays were acetylcholinesterase extracted from *C. rhizophorae* gills and commercial AChE from the electric organ of *E. electricus* (Sigma). The commercial enzyme is an excellent *in vitro* model for anti-acetylcholinesterase evaluation of compounds due to its great similarity with the human enzyme. Incubation was performed by adding 10 µl of AChE to 10 µl of oil at different concentrations (0.0001 a 1 mg/ml), considering the absence of oil (0.0 mg/mL) as a negative control (100% activity). DMSO + enzyme buffer (0.5 M Tris–HCl pH 8.0) was used as a blank and neostigmine as a positive control (standard inhibitor). The plate was incubated for 1 h at 25 °C. After the incubation period, 200 µl of the chromogenic reagent DNTB (0.25 mM) and 20 µl of 62 mM acetylthiocholine (ASCh) substrate were added and read at 405 nm at 0 and 180 s. The percentage of enzyme inhibition was determined based on the controls. The test was performed in quadruplicate and the calculations were made using Microsoft Excel and Microcal Origin.

3. Results and discussion

The wide spectrum of biological activities present in EOs has driven the development of increasingly promising research in the field of pharmacology and in the production of therapeutic alternatives. The Myrtaceae family is known for its essential oils which offer good yields and important biological activities, especially the species *M. floribunda* (Apel et al., 2006a; Tietbohl et al., 2014). In this study, we obtained MfEO through the hydrodistillation method. The potential of the fruit peel of this species has been little explored, but the fruit is of great economic and food importance (Santos et al., 2017). Ripe fruits can be consumed *in natura* and are traditionally collected and used whole or macerated for the production of liqueurs (alcoholic solution produced with the fruit and cachaça) by several Brazilian communities (Souza and Morim, 2008; Lima and Barbosa, 2012). These properties, added to the *M. floribunda* biotechnological potential, constitute a field for research in the area of biosciences (Oliveira et al., 2018).

Aromatic plants of the Myrtaceae family show variations in the yields of essential oils, in this study MfEO presented a yield of 0.6% (200 g). In a study on the extraction of essential oils from species of this family from the Cerrado biome, Silva et al. (2018) presented values of 0.05% (*Plinia cauliflora*) and 0.51% (*Eugenia uniflora*), demonstrating the occurrence of variability. Extraction of essential oil from *M. floribunda* has been described in the literature for leaf, stem and flower portions, yielding 0.37% (1100 g), 0.02% (600 g) and 0.64% (186 g), respectively. Considering these data, the fruit peel of *M. floribunda* presents a good EO yield, being similar to the yield already described for flower oil. The chemical characterization of the components of MfEO is essential for understanding the mechanisms of action correlated with the biological potential and possibility of isolation, purification or synthesis of analogs that present the biological activity desired.

Table 1
Identified chemical constituents of MfEO^a obtained by GC/MS^b.

Compounds	I.R. ^c calculated	I.R. read	A ^d (%)	S. D. ^e
(E)-β-Ocimene	1050	1044	0.19	0.01
α-Cubebene	1352	1348	0.01	0.00
α-Ylangene	1374	1373	0.34	0.01
α-Copaene	1378	1374	5.02	0.28
Sativene	1392	1390	0.22	0.01
Sibirene	1398	1400	0.23	0.01
α-Gurjunene	1412	1409	1.25	0.04
(E)-Caryophyllene	1422	1417	5.54	0.22
β-Copaene	1432	1430	1.89	0.08
Aromadendrene	1442	1439	3.95	0.18
α-Humulene	1457	1452	1.81	0.03
allo-Aromadendrene	1464	1458	1.47	0.03
trans-Cadina-1(6),4-diene	1477	1475	0.01	0.00
γ-Murolene	1480	1478	6.21	0.24
β-Selinene	1489	1489	4.21	0.07
δ-Selinene	1494	1492	0.18	0.10
α-Selinene	1498	1498	6.11	0.29
α-Murolene	1503	1500	6.11	0.29
γ-Cadinene	1518	1513	15.69	0.38
δ-Cadinene	1527	1522	26.84	0.50
trans-Cadina-1,4-diene	1536	1533	0.12	0.00
α-Cadinene	1541	1537	1.96	0.05
α-Calacorene	1547	1544	2.31	0.10
Germacrene B	1561	1559	0.31	0.08
β-Calacorene	1567	1564	0.31	0.06
α-Cadinol	1646	1652	4.57	0.91
		Identified	96.86	

^a MfEO: Essential oil of *Myrciaria floribunda* peel fruit.

^b GC/MS: Gasose Chromatography/Mass Spectre.

^c I.R.: Retexion Index.

^d A: Area.

^e S.D.: Standart Deviation.

3.1. Essential oil composition

The chemical characterization of MfEO (Table 1) revealed the presence of 26 compounds that together correspond to 96.86% of the total essential oil, as identified by GC/MS. Most compounds are sesquiterpenes, including six of the major compounds: δ-Cadinene (26.8%), γ-Cadinene (15.69%), γ-Murolene (6.21%), α-Selinene, α-Murolene (6.11%) and (E)-Caryophyllene (5.54%) (Fig. 1). In another study, *M. floribunda* leaf and flower essential oil presented distinct characterization, most of them being monoterpenes, while trunk oil presented 72.2% sesquiterpenes, a result similar to this study. Medicinal plants have molecules with therapeutic potential and represent an important source for compound identification and production of new drugs (Boudjedjou et al., 2019).

MfEO presented two principal components, the Cadinene isomers γ-cadinene and δ-cadinene (Fig. 2) which together account for 42.43% of the total composition. Cadinene is a sesquiterpene present in essential oils, with reported insecticidal (Govindarajan et al., 2016), acaricidal (Guo et al., 2017) and antiprotozoal (Ghazouani et al., 2017) activities and described in the composition of the fruit essential oil of *Myrciaria jaboticaba* (Vell.) O. Berg (Plagemann et al., 2012). Cadinene has not been frequently reported in the literature as a major component of essential oils, where in the family Myrtaceae, α-pinene, α-caryophyllene, (Plagemann et al., 2012), d-limonene, β-caryophyllene (Franco and Shibamoto, 2000) and β-Myrcene (Fortes et al., 2011) are the most common. The compounds α-Selinene and α-Murolene were identified as major components of the essential oil of the fruits of *Myrciaria jaboticaba* (Vell.) O. Berg, while γ-Murolene was described in the composition of *P. trunciflora* (Apel et al., 2006b). Variation in the composition of essential oils of species of the same genus or family occurs due




Fig. 1. Chemical structure of the major components of the essential oil of *M. floribunda*.

to factors such as environmental conditions and seasonal variation. Importantly, the composition of the fruit peel oil of *M. floribunda* described in this study has not yet been reported in the literature (Silva et al., 2019).

3.2. In silico ADMET

The association of folk medicine with medicinal chemistry has become central to developing new medicines. Pharmacokinetic and toxicological analyses of natural compounds are important steps in the classification of molecules based on absorption, distribution,

metabolism, excretion and toxicity (ADMET), enabling better targeting in the formulation of medicines for the treatment of human diseases (Abdulfatai et al., 2017; Daina et al., 2017). For the development of safer and more effective chemotherapy in the treatment of neurodegenerative diseases, new compounds must have characteristics compatible with orally administered pharmaceutical formulations in order to facilitate treatment, patient compliance and avoid discomfort to users (Gleeson and McCartney, 2019). The lipid nature of EO gives these substances an additional advantage for oral capsule formulation due to increased physical absorption and minimization of oxidation susceptibility (Hauss, 2007).




Fig. 2. Mass spectrometry of δ -Cadinene in the essential oil (A), reference standard of δ -Cadinene (B), γ -Cadinene in the essential oil (C), reference standard γ -Cadinene (D).

Table 2
In silico ADMET^a analysis of major constituents of MfEO^b and neostigmine.

Property	δ -Cad ^c	γ -Cad ^d	α -Mu ^e	α -Sel ^f	γ -Mu ^g	Car ^h	Neo ⁱ
PHYSICOCHEMICAL PROPERTIES							
HBA ^j	0	0	0	0	0	0	3
HBD ^k	0	0	0	0	0	0	0
ClogP	4.14	4.18	4.08	4.40	4.18	4.24	0.40
MW ^l (g/mol)	204.35	204.35	204.35	204.35	204.35	204.35	223.29
n-ROTB ^m	1	1	1	1	1	0	4
ABSORPTION							
BBB ⁿ	No	No	No	No	No	No	Yes
HIA ^o	Low	Low	Low	Low	Low	Low	High
P-GPs ^p	No	No	No	No	No	No	Yes
Log Kp (cm/s) ^q	-4.85	-4.49	-4.65	-3.85	-4.49	-4.44	-6.51
METABOLISM							
CYP450 ^r 2C9 inhibitor	Yes	Yes	Yes	Yes	Yes	Yes	No
CYP450 ^r 2D6 inhibitor	No	No	No	No	No	No	No
CYP450 ^r 2C19 inhibitor	Yes	Yes	Yes	Yes	Yes	Yes	No
CYP450 ^r 3A4 inhibitor	No	No	No	No	No	No	No
CYP450 ^r 1A2 inhibitor	No	No	No	No	No	No	No
TOXICITY							
MUT ^s	No	No	No	No	No	No	Little
TUM ^t	No	No	No	No	No	No	-
IRR ^u	No	No	No	No	No	No	-
HEP ^v	No	No	No	No	No	No	Little
LD ₅₀ ^w mg/kg	4400	4400	4400	5000	4400	5000	7

^a ADMET: absorption, distribution, metabolism, excretion and toxicity.

^b MfEO: Essential oil of *Myrciaria floribunda* peel fruit.

^c δ -Cad: delta- Cadinene.

^d γ -Cad: gama-Cadinene.

^e α -Mu:alfa-Murolene.

^f α -Sel: alfa-Selinene.

^g γ -Mu:gama- Murolene.

^h Car: (*E*)-Caryophyllene.

ⁱ Neo: neostigmine.

^j HBA: Number of hydrogen force acceptors.

^k HBD: Number of hydrogen donors.

^l MW: Molecular Weight.

^m n-ROTB: Number of rotary connections.

ⁿ BBB: blood-brain barrier.

^o HIA: gastrointestinal absorption.

^p P-GPs: permeability glycoprotein.

^q Log Kp (cm/s): Skin permeation.

^r CYP450: Cytochrome P450 Enzyme.

^s MUT: mutagenic.

^t TUM: tumorigenic.

^u IRR: irritant.

^v HEP: hepatotoxic.

^w LD₅₀: lethal dose at 50%.

The potential of a compound for oral treatment is related to important factors to ensure adequate absorption including solubility, permeability to biological membranes, dissolution under gastrointestinal conditions, transit time in the digestive tract, among other aspects. In recent years, the development of *in silico* analysis platforms has enabled more accurate information on the absorption of new drug candidate compounds even before being subjected to *in vivo* testing (Daina and Zoete, 2016). Suitable physicochemical properties for a molecule to be absorbed by the gastro-intestinal tract include a molecular weight of 150 to 500 g/mol, a number of hydrogen bond acceptors less than 10, TPSA 20 to 130, (cLogP) partition coefficient logarithm between octanol (lipophilicity) and water from 0 to 5 and finally a number of hydrogen donors below 5 (Daina and Zoete, 2016; Khalid et al., 2018). Thus, we performed an ADMET analysis of the major compounds of MfEO (Table 2).

The major MfEO compounds had similar pharmacokinetic and toxicological potential. Thus, none of the six major compounds had mutagenic, irritant, tumorigenic or hepatotoxic potential, whereas the

reference drug used, neostigmine, had little mutagenic and hepatotoxic potential. The analysis showed that MfEO compounds have a predicted lethal dose 628 times higher than neostigmine, thus highlighting the high toxic potential of the reference drug when compared to the major compounds that make up *M. floribunda* essential oil. The high toxicity of neostigmine has been reported in the literature, thus confirming the data highlighted in the ADMET analysis of this study (Ream, 1963; Adiamah et al., 2017). Besides toxicity, neostigmine has a cLogP of 0.40, characterizing it as very hydrophilic. Compounds that have high affinity for water tend to have a shorter half-life due easy excretion. This feature is unattractive in oral chemotherapeutic agents because in these cases there is need for multiple-dose administration over a short time span (Van de Waterbeemd and Gifford, 2003; Newby, et al., 2015). The six major EOMf compounds have cLogP values above 4, they are compounds with a higher degree of lipophilicity and may have a longer half-life than the reference drug (Newby et al., 2015). These characteristics lead us to believe that, in the *in vivo* treatment model, the EOMf could be administered with longer periods between doses,

Table 3
Interaction profile between major oil compounds with acetylcholinesterase enzyme.

Comp.	BE ^a (Kcal/mol)	KIC ^b (uM)	FE ^c (Kcal/mol)	EE ^d (Kcal/mol)	TIE ^e	IS ^f
δ-Cad ^g	-6.77	10.99	-75.1	-0.01	-7.06	653.724
γ-Cad ^h	-7.35	4.10	71.7	0.00	-7.65	661.2
α-Mu ⁱ	-5.89	17.11	-71.4	-0.01	-6.32	591.832
α-Sel ^j	-6.37	6.33	-73.3	-0.00	-6.98	761.412
γ-Mu ^k	-6.23	8.91	-71.4	-0.02	-7.06	661.21
Car ^l	-6.99	12.33	-72.4	-0.00	-7.32	721.654
Neo ^m	-5.09	184.65	-74.13	-0.03	-5.77	657.542

^a BE: Binding energy.

^b KIC: Ki Constant.

^c FE: Free Energy.

^d EE: Electrostatic Energy.

^e TIE: Total intermolecular energy.

^f IS: Interaction Surface.

^g δ-Cad: delta-Cadinene.

^h γ-Cad: gama-Cadinene.

ⁱ α-Mu: alfa-Murolene.

^j α-Sel: alfa-Selinene.

^k γ-Mu: gama- Murolene.

^l Car: (E)-Caryophyllene.

^m Neo: neostigmine.

reinforcing its pharmacological potential with low chances of toxicity.

3.3. Molecular docking: *in silico* screening of acetylcholinesterase inhibitors in MfEO

Based on the interaction data of the docking test (Table 3), it can be observed that the major constituents interact with acetylcholinesterase with a total free energy of approximately -75 kcal/mol, most of which are Van der Waals interactions.

Molecular docking results between the major components of MfEO and the enzyme acetylcholinesterase resulted in an average energy minimization of -6.6 Kcal/mol when the two structures coupled, as shown in Fig. 3. This result implies that the coupling between molecules is energetically favorable (exergonic bond: dissipates energy) and is located between the Van der Waals bond energy level (< -1 Kcal/mol) and the covalent chemical bond level (< -100 Kcal/mol) (Ferreira et al., 2015). Thus, such binding may be considered exergonically favorable, reversible (because it is non-covalent), may be competitive (the relationship between concentrations or bioavailability of the molecules involved). A link between molecules with these characteristics—exergonic, reversible and competitive—as well as the result of energy minimization obtained, allows the action of other substances (drugs, substances naturally found in the body) either in favor of molecular docking or in its impediment.

In relation to the most expressive major compounds, δ and γ cadinene, they establish connections with low binding energy, but with moderate entropy (total energy). These bonds may occur randomly and establish a continuous interaction between the major compound and the enzyme, which corroborates the inhibitory activity (Silva et al., 2019). As bicyclic sesquiterpenes, they establish hydrophobic and Van der Waals interactions with the amino acids TRP86, TYR124, PHE295, TYR337, TRP286 and VAL294, respectively. Thus, they integrate a type of intermolecular interaction in which nonpolar compounds of these amino acids suffer consequences of the dynamic actions of the polar compounds of the oil, besides establishing communications between the electronic clouds at the dipole-dipole and dipole-permanent levels (Bhuvanendran et al., 2019). The interactions dominated in the region of His447 and Trp286 amino acid residues due to the existence of the pi-alkyl interaction at the catalytic anionic site and the hydrogen bonds with Tyr124 and Phe295 at the edge of the peripheral site region

(Fig. 3).

The compounds δ-cadinene and γ-cadinene against the Alzheimer's Disease target protein AChE showed a higher binding affinity docking score as indicated by a docking score of -7.35 and -6.77, respectively, and forms π-alkyl bonds of length 2.1 Å to the polar aliphatic residues, that is, His447 and Trp286. The other site A2 and A3 form bonds of length 1.7 and 2.1 Å to the hydrophobic residues Phe295 and Tyr124. Docking results also exposed π-π stacking, the site interacted with the receptor and formed Van der Waals stacking with two amino acid residues, Tyr341 and Tyr337. Thus, the functionalities such as positively charged groups at P6 and aromatic rings R8 and R7 were identified to be important for AChE opening activity (Ali et al., 2018). Even though site H5 did not interact with the receptor but due to its presence in the dataset, it can serve as a target for the inhibition process. As with the currently obtained data, computational methods have become essential to biological investigations. Here we have used the computational approach to further understand the mechanism of interactions and binding affinity between AChE and these molecules. Moreover, our findings corroborate the data observed in recent studies of major components of essential oils, including structural similarities (Silva et al., 2019; Byler and Setzer, 2018).

3.4. MfEO is effective in *in vitro* inhibition of acetylcholinesterase in a dose-dependent manner

In silico tests are important tools for directing and estimating drug release and predicting aspects of *in vivo* toxicity (Karkossa and Klein, 2019). The promising results obtained in this study through ADMET and molecular docking analyses led us to investigate the *in vitro* effect of *M. floribunda* essential oil on AChE enzymatic activity. *In vitro* enzyme tests can be designed to explain the ability of enzymes to catalyze a specific type of chemical reaction and provide information mechanism studies (Küchler et al., 2016).

In the assay of acetylcholinesterase activity, *M. floribunda* fruit peel oil presented a median inhibitory concentration (IC₅₀) of 0.08 µg/ml and 23 µg/ml for commercial AChE of *E. electricus* and that extracted from *C. rhizophorae*, respectively. While neostigmine (the standard used) had an IC₅₀ of 23.3 µg/ml and 6.2 µg/ml, respectively, for the same enzymes (Fig. 4). The AChE action may be correlated to the presence of δ and γ cadinene compounds present in the oil, which are part of the sesquiterpene group.

The differences between the IC₅₀ values for the commercial enzyme (*E. electricus*) and *C. rhizophorae* extracts may be related to the degree of purity, sensitivity or small structural distinctions between the AChEs of the species under study. The difference in the binding affinity of inhibitors to the enzyme catalytic site has been reported as variable in relation to the effect exerted by the same compound on terrestrial vertebrates and fish AChEs and between fish AChEs (Assis et al., 2012; Freitas et al., 2016).

The results obtained with MfEO acetylcholinesterase inhibition were higher than those found for the essential oil of flowers (IC₅₀ 1583 µg / ml) and leaves (IC₅₀ 681 µg / ml) of the same species (Tietbohl et al., 2012). In that study, the essential oil of *M. floribunda* stems showed no enzymatic inhibition, having (2E, 6E)-farnesyl acetate and (2E, 6Z)-farnesol as major components, which belong to the same chemical class as cadinenes (δ and γ). However, there are significant differences in a chemical structure that may influence interaction and enzyme inhibition. Furthermore, *in silico* studies have contributed to understanding how the chemical structure and enzyme binding affinity behave by extracting relevant information from bioactive compounds (Rodrigues et al., 2016; Scotti and Scotti, 2018).

Cyclic compounds such as 1,8-cineole (Petrachianan et al., 2019; Kakheshani et al., 2018; Abdelgaleil et al., 2019), α-pinene (Karakaya et al., 2019; Shahriari et al., 2018) and caryophyllene (Owokotomo et al., 2015; Xiang et al., 2017), found in essential oils, have been reported to have AChE inhibitory activity. According to Miyazawa et al.




Fig. 3. Interaction of δ (A) and γ (B) cadinene with human AChE^a. Binding and related amino acid residue in molecular docking (C, D). AChE: Acetylcholinesterase.

(2016), essential oils made mostly of sesquiterpenes have a greater inhibitory effect than those made of monoterpenes. The synergistic association of these sesquiterpenes may be responsible for their inhibitory action. Thus, the essential oil of *M. floribunda* described in this study may serve as an active principle for the development of new drugs against neurodegenerative diseases.

4. Conclusion

Taken together, our results showed that the essential oil of the fruit peel of *M. floribunda* inhibited the acetylcholinesterase of *Crassostrea rhizophorae* and *Electrophorus electricus* (commercial) and in the latter showed a superior effect to neostigmine, a commercial drug with an anticholinesterase effect. Our *in silico* analysis demonstrated good pharmacokinetic activity for the major compounds δ -Cadinene, γ -Cadinene, γ -Murolene, α -Selinene, α -Murolene, (*E*)-Caryophyllene and low potential for toxicity. Molecular docking analyses, associated with *in vitro* enzyme inhibition assays for acetylcholinesterase, indicate that *M. floribunda* essential oil is promising for the development of new formulations for the treatment of neurodegenerative diseases. The exploitation of the pharmacological potential of MfEO is worthy of mention due to the wide variety of organic compounds that compose this plant material. The study of the chemical characteristics of the major compounds of the essential oil of the fruit peel of *M. floribunda* and their interactions with biomacromolecules, such as

acetylcholinesterase, provides support for the development of alternative therapeutic measures and the design of new bioactive compounds based on constituents of the oil.

CRediT authorship contribution statement

Deyzi Caroline da Silva Barbosa: Conceptualization, Methodology, Validation, Investigation, Resources, Writing - original draft, Writing - review & editing. **Vanderlan Nogueira Holanda:** Methodology, Validation, Investigation, Resources, Writing - original draft, Writing - review & editing. **Caio Rodrigo Dias de Assis:** Methodology, Validation, Resources, Investigation, Writing - original draft. **Júlio César Ribeiro de Oliveira Farias de Aguiar:** Methodology, Validation, Resources, Investigation. **Pedro Henrique do Nascimento:** Methodology, Validation, Resources, Investigation, Software, Writing - original draft. **Welson Vicente da Silva:** Methodology, Validation, Resources, Investigation, Software, Writing - original draft. **Daniela Maria do Amaral Ferraz Navarro:** Methodology, Validation, Investigation, Supervision, Project administration. **Márcia Vanusa da Silva:** Investigation, Supervision, Project administration. **Vera Lúcia de Menezes Lima:** Investigation, Supervision, Project administration. **Maria Tereza dos Santos Correia:** Investigation, Supervision, Writing - review & editing, Project administration.




Fig. 4. Determination of inhibition activity (IC_{50}) of MfEO^a (A, B) and neostigmine (C, D) on *Crasostrea rhizophorae* and *Electrophorus electricus* AChE^c respectively. IC_{50} : median inhibitory concentration.

MfEO: Essential oil of *Myrciaria floribunda* peel fruit.
AChE: Acetylcholinesterase.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors would like to thank the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and the Fundação de Amparo a Ciência e Tecnologia de Pernambuco (FACEPE) for supporting this research.

References

- Abdelgaleil, S.A.M., Mohamed, E.I.B., Mahmoud, N.F., Abd El-Salam, M.M., 2019. Acaricidal activity, biochemical effects and molecular docking of some monoterpenes against two-spotted spider mite (*Tetranychus urticae* Koch). *Pestic. Biochem. Physiol.* 156, 105–115. <https://doi.org/10.1016/j.pestbp.2019.02.006>.
- Abdulfatai, U., Uzairu, A., Uba, S., 2017. Quantitative structure-activity relationship and molecular docking studies of a series of quinazolinonyl analogues as inhibitors of gamma amino butyric acid aminotransferase. *J. Adv. Res.* 8, 33–43. <https://doi.org/10.1016/j.jare.2016.10.004>.
- Adams, R.P., 2007. Identification of Essential Oil Components by Gas chromatography/mass Spectrometry (Allured Publishing Corporation Carol Stream, IL). ISBN 978-1-932633-21-4.
- Adiamah, A., Johnson, S., Ho, A., Orbell, J., 2017. Neostigmine and glycopyrronium: a potential safe alternative for patients with pseudo-obstruction without access to conventional methods of decompression. *BMJ Case Rep.* 2017 <https://doi.org/10.1136/bcr-2017-221249>.
- Ali, R., Sadoqi, M., Moller, S., Boutajangout, A., Mezei, M., 2018. Molecular dynamics and docking studies on acetylcholinesterase (AChE) inhibitors. *Biophys. J.* 114 (3) 340a.
- Amaral, R.R., Fernandes, C.P., Caramel, O., Tietbohl, O.P., Santos, L.A.C., Carvalho, M.G., Rocha, J.C.T., 2013. Essential oils from fruits with different colors and leaves of *Neomitranshes obscura* (DC.) N. Silveira: an endemic species from Brazilian Atlantic Forest. *Biomed. Res. Int.* 2013, 7. <https://doi.org/10.1155/2013/723181>.
- Apel, M.A., Lima, M.E.L., Souza, A., Cordeiro, I., Young, M.C.M., Sobral, M.E.G., Suffredini, I.B., Moreno, P.R.H., 2006a. Screening of the biological activity from essential oils of native species from the Atlantic rain forest (São Paulo-Brazil). *Pharmacology online* 3, 376–383.
- Apel, M.A., Sobral, M., Zuanazzi, J., Henriques, A.T., 2006b. Essential oil composition of four *Plinia* species (Myrtaceae). *Flavour Fragrance J.* 21, 565–567. <https://doi.org/10.1002/ffj.1638>.
- Arruda, M., Viana, H., Rainha, N., Neng, N.R., Rosa, J.S., Nogueira, J.M.F., Barreto, M.C., 2012. Anti-acetylcholinesterase and antioxidant activity of essential oils from *Hedychium gardnerianum* sheppard ex ker-gawl. *Molecules* 17. <https://doi.org/10.3390/molecules17033082>.
- Assis, C.R.D., Linhares, A.G., Oliveira, V.M., França, R.C.P., Carvalho, E.V.M.M., Bezerra, R.S., Carvalho Jr., L.B., 2012. Comparative effect of pesticides on brain acetylcholinesterase in tropical fish. *Sci. Total Environ.* 441, 141–150. <https://doi.org/10.1016/j.scitotenv.2012.09.058>.
- Azeredo, C.M.O., Soares, M.J., 2013. Combination of the essential oil constituents citral, eugenol and thymol enhance their inhibitory effect on *Cnithidia fasciculata* and *Trypanosoma cruzi* growth. *Rev. Bras. Farmacogn.* 23, 762–768. <https://doi.org/10.1590/S0102-695X2013000500007>.
- Bakkali, F., Averbeck, S., Averbeck, D., Idaomar, M., 2008. Biological effects of essential oils – a review. *Food Chem. Toxicol.* 46, 446–475. <https://doi.org/10.1016/j.fct.2007.09.106>.
- Berman, H., Henrick, K., Nakamura, H., 2003. Announcing the worldwide protein data bank. *Nat. Struct. Biol.* 10, 980. <https://doi.org/10.1038/nsb1203-980>.
- Bhavya, M.L., Chandu, A.G.S., Devi, S., 2018. *Ocimum tenuiflorum* oil, a potential insecticide against rice weevil with anti-acetylcholinesterase activity. *Ind. Crops Prod.* 126, 434–439. <https://doi.org/10.1016/j.indcrop.2018.10.043>.

- Bhuvanendran, S., Hanapi, N.A., Ahemad, N., Othman, I., Yusof, S.R., Shaikh, M.F., 2019. Embelin, a potent molecule for alzheimer's disease: a proof of concept from blood-brain barrier permeability, acetylcholinesterase inhibition and molecular docking studies. *Front. Neurosci.* 13. <https://doi.org/10.3389/fnins.2019.00495>.
- Bohnen, N.I., Albin, R.L., 2011. The cholinergic system and Parkinson disease. *Behav. Brain Res.* 221, 564–573. <https://doi.org/10.1016/j.bbr.2009.12.048>.
- Bohnen, N.I., Kanel, P., Zhou, Z., Koeppe, R.A., Frey, K.A., Dauer, W.T., Albin, R.L., Müller, M.L.T.M., 2019. Cholinergic system changes of falls and freezing of gait in Parkinson's disease. *Ann. Neurol.* 85, 538–549. <https://doi.org/10.1002/ana.25430>.
- Boudjedjou, L., Ramdani, M., Zeraib, A., Benmeddour, T., Fercha, A., 2019. Chemical composition and biological activities of *Algerian Santolina africana* essential oil. *Sci. Mil. South Afr. J. Mil. Stud.* 4, e00090. <http://creativecommons.org/licenses/by/4.0/>.
- Brenner, T., Nizri, E., Irony-Tur-Sinai, M., Hamra-Amitay, Y., Wirguin, I., 2008. Acetylcholinesterase inhibitors and cholinergic modulation in Myasthenia Gravis and neuroinflammation. *J. Neuroimmunol.* 201, 121–127. <https://doi.org/10.1016/j.jneuroim.2008.05.022>.
- Byler, K.G., Setzer, W.N., 2018. Protein targets of frankincense: a reverse docking analysis of terpenoids from *Boswellia oleo-gum* resins. *Medicines* 5 (3), 96. <https://doi.org/10.3390/medicines5030096>.
- Campanari, M.L., García-Ayllón, M.S., Ciura, S., Sáez-Valero, J., Kabashi, E., 2016. Neuromuscular junction impairment in amyotrophic lateral sclerosis: reassessing the role of acetylcholinesterase. *Front. Mol. Neurosci.* 9, 160. <https://doi.org/10.3389/fnmol.2016.00160>.
- Chou, S.T., Lai, C.C., Lai, C.P., Chao, W.W., 2018. Chemical composition, antioxidant, anti-melanogenic and anti-inflammatory activities of *Glechoma hederacea* (Lamiaceae) essential oil. *Ind. Crops Prod.* 122, 675–685. <https://doi.org/10.1016/j.indcrop.2018.06.032>.
- Cock, I.E., Cheesman, M., 2019. The potential of plants of the genus *syzygium* (myrtaceae) for the prevention and treatment of arthritic and autoimmune diseases. Chapter 23 In: Watson, Ronald Ross, Preedy, Victor R. (Eds.), *Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases* (Second Edition). Academic Press.
- Colovic, M.B., Krstić, D.Z., Lazarević-Pasti, T.D., Bondžić, A.M., Vasić, V.M., 2013. Acetylcholinesterase inhibitors: pharmacology and toxicology. *Curr. Neuropharmacol.* 11, 315–335. <https://doi.org/10.2174/1570159X11311030006>.
- Costa, M., Silva, A.G., Silva, A., Lima, V., Bezerra-Silva, P., Rocha, S., Navarro, D., Correia, M., Napoleão, T., Silva, M., 2017. Essential oils from leaves of medicinal plants of Brazilian flora: chemical composition and activity against *Candida* species. *Medicines* 4, 27. <https://doi.org/10.3390/medicines4020027>.
- Costa, S., Cavadas, C., Cavaleiro, C., Salgueiro, L., Sousa, M.C., 2018. In vitro susceptibility of *Trypanosoma brucei* to selected essential oils and their major components. *Exp. Parasitol.* 190, 34–40. <https://doi.org/10.1016/j.exppara.2018.05.002>.
- Daina, A., Zoete, V., 2016. A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. *ChemMedChem* 11, 1117–1121. <https://doi.org/10.1002/cmdc.201600182>.
- Daina, A., Michielin, O., Zoete, V., 2017. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* 7, 42717. <https://doi.org/10.1038/srep42717>.
- D'Souza, G.X., Waldvogel, H.J., 2016. Targeting the cholinergic system to develop a novel therapy for Huntington's disease. *J. Huntingtons Dis.* 5, 333–342. <https://doi.org/10.3233/JHD-160200>.
- Faiq, M.A., Wolstein, G., Schuman, J.S., Chan, K.C., 2019. Cholinergic nervous system and glaucoma: from basic science to clinical applications. *Prog. Retinal Eye Res.* <https://doi.org/10.1016/j.preteyeres.2019.06.003>.
- Ferreira, L.G., Dos Santos, R.N., Oliva, G., Andricopulo, A.D., 2015. Molecular docking and structure-based drug design strategies. *Molecules* 20 (7), 13384–13421. <https://doi.org/10.3390/molecules200713384>.
- Fortes, G.A.C., Naves, S.S., Godoi, F.F.F., Duarte, A.R., Ferri, P.H., Santos, S.C., 2011. Assessment of a maturity index in jabuticaba fruit by the evaluation of phenolic compounds, essential oil components, sugar content and total acidity. *Am. J. Food Technol.* 6, 974–984. <https://doi.org/10.3923/ajft.2011.974.984>.
- Franceschinelli, E.V., Vasconcelos, G.M.P., Landau, E.C., Ono, K.Y., Santos, F.A.M., 2007. The genetic diversity of *Myrciaria floribunda* (Myrtaceae) in Atlantic Forest fragments of different sizes. *J. Trop. Ecol.* 23, 361–367. <https://doi.org/10.1017/S0266464707004099>.
- Franco, M.R.B., Shibamoto, T., 2000. Volatile composition of some Brazilian fruits: umbu-caja (*Spondias cihnera*), camu-camu (*Myrciaria dubia*), araçá-boi (*Eugenia stipitata*), and cupuaçu (*Theobroma grandiflorum*). *J. Agric. Food Chem.* 48, 1263–1265. <https://doi.org/10.1021/jf9900074>.
- Freitas, A.P., Santos, C.R., Sarcinelli, P.N., Silva Filho, M.V., Hauser-Davis, R.A., Lopes, R.M., 2016. Evaluation of a brain acetylcholinesterase extraction method and kinetic constants after methyl-paraoxon inhibition in three Brazilian fish species. *PLoS One* 11, e0163317. <https://doi.org/10.1371/journal.pone.0163317>.
- García-Font, N., Hayour, H., Belfaitah, A., Pedraz, J., Moraleda, I., Iriepa, I., Bouraiou, A., Chioua, M., Marco-Contelles, J., Oset-Gasque, M.J., 2016. Potent anticholinesterasic and neuroprotective pyranotacrylins as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease. *Eur. J. Med. Chem.* 118, 178–192. <https://doi.org/10.1016/j.ejmech.2016.04.023>.
- Ghazouani, N., Sifoui, I., Bachrouh, O., Abderrabba, M., Pinero, J.E., Lorenzo-Morales, J., 2017. Essential oil composition and anti *Acanthamoeba* studies of *Teucrium ramosissimu*. *Exp. Parasitol.* 183, 207–211. <https://doi.org/10.1016/j.exppara.2017.09.010>.
- Gleeson, J.P., McCartney, F., 2019. Striving towards the perfect in vitro oral drug absorption model, trends pharmacol. Sci. <https://doi.org/10.1016/j.tips.2019.07.010>.
- Govindarajan, M., Rajeswary, M., Benelli, G., 2016. 8-Cadinene, Calarene and 8-4-Carene from *Kadsura heteroclita* essential oil as novel larvicides against malaria, dengue and filariasis mosquitoes. *Comb. Chem. High Throughput Screening* 19, 565–571. <https://doi.org/10.2174/1381612822666160531163144>.
- Guo, X., Shang, X., Li, B., Zhou, X.Z., Wen, H., Zhang, J., 2017. Acaricidal activities of the essential oil from *Rhododendron nivale* Hook. f. and its main compound, 8-cadinene against *Psoroptes cuniculi*. *Vet. Parasitol.* 236, 51–54. <https://doi.org/10.1016/j.vetpar.2017.01.028>.
- Hampel, H., Mesulam, M.M., Cuello, A.C., Farlow, M.R., Giacobini, E., Grossberg, G.T., Khachaturian, A.S., Vergallo, A., Cavado, E., Snyder, P.J., 2018. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain* 141, 1917–1933. <https://doi.org/10.1093/brain/awy132>.
- Han, B., Zhang, C., Liu, S., Xia, Y., Sun, H., Gong, Z., Simard, A.R., Liu, Q., Hao, J., 2017. Non-neuronal cholinergic activity is potentiated in myasthenia gravis. *BMC Neurol.* 17. <https://doi.org/10.1186/s12883-016-0772-3>.
- Hauss, D.J., 2007. Oral lipid-based formulations. *Adv. Drug Delivery Rev.* 59, 667–676. <https://doi.org/10.1016/j.addr.2007.05.006>.
- Kahkeshani, N., Hadjiakhoondi, A., Navidpour, L., Akbarzadeh, T., Safavi, M., Karimpour-Razkenari, E., Khanavi, M., 2018. Chemodiversity of *Nepeta menziesii* Boiss. & Böhse. Essential oil from Iran and antimicrobial, acetylcholinesterase inhibitory and cytotoxic properties of 1, 8-cineole chemotype. *Nat. Prod. Res.* 32. <https://doi.org/10.1080/14786419.2017.1378202>.
- Karakaya, S., Yilmaz, S.V., Koca, M., Demirci, B., Sytar, O., 2019. Screening of non-alkaloid acetylcholinesterase inhibitors from extracts and essential oils of *Anthriscus nemorosa* (M.Bieb.) Spreng. (Apiaceae). *S. Afr. J. Bot.* 125, 261–269. <https://doi.org/10.1016/j.sajb.2019.07.031>.
- Karkossa, F., Klein, S., 2019. Individualized *in vitro* and *in silico* methods for predicting in vivo performance of enteric-coated tablets containing a narrow therapeutic index drug. *Eur. J. Pharm. Biopharm.* 135, 13–24. <https://doi.org/10.1016/j.ejpb.2018.12.004>.
- Khalid, S., Zahid, M.A., Ali, H., Kim, Y.S., Khan, S., 2018. Biaryl scaffold-focused virtual screening for anti-aggregatory and neuroprotective effects in Alzheimer's disease. *BMC Neurosci.* 19, 74. <https://doi.org/10.1186/s12868-018-0472-6>.
- Koch, Ingrid, 2014. Plants with flowers and fruits in vegetation remnants in Sorocaba city, Brazil. *Biodiversidade do Município de Sorocaba* 85–151 (no prelo).
- Küchler, A., Yoshimoto, M., Luginbühl, S., Mavelli, F., Walde, P., 2016. Enzymatic reactions in confined environments. *Nat. Nanotechnol.* 11, 409. <https://doi.org/10.1038/NNANO.2016.54>.
- Kuhn, D., Ziem, R., Scheibel, T., Buhl, B., Vettorello, G., Pacheco, L.A., Heidrich, D., Kauffmann, C., Freitas, E.M., Ethur, E.M., Hoehne, L., 2019. Antibiofilm activity of the essential oil of *Campomanesia aurea* O. Berg against microorganisms causing food borne diseases. *LWT* 108, 247–252. <https://doi.org/10.1016/j.lwt.2019.03.079>.
- Lima, A.R.L., Barbosa, M.R.V., 2012. Myrtaceae em restingas no limite norte de distribuição da Mata Atlântica, Brasil. *Rodriguésia-Instituto de Pesquisas Jardim Botânico do Rio de Janeiro* 63. <https://doi.org/10.1590/S2175-78602012000200011>.
- López-Camacho, E., Godoy, M.J.G., García-Nieto, J., Nebro, A.J., Aldana-Montes, J.F., 2015. Solving molecular flexible docking problems with metaheuristics: a comparative study. *Appl. Soft Comput.* 28, 379–393. <https://doi.org/10.1016/j.asoc.2014.10.049>.
- Oliveira, L.M., Porte, A., Godoy, R.L.O., Souza, M.C., Pacheco, S., Santiago, M.C.P.A., Gouvêa, A.C.M.S., Nascimento, L.S.M., Borguini, R.G., 2018. Chemical characterization of *Myrciaria floribunda* (H. West ex Willd) fruit. *Food Chem.* 248, 247–252. <https://doi.org/10.1016/j.foodchem.2017.12.053>.
- Mercey, G., Verdet, T., Renou, J., Kliachyna, M., Baati, R., Nachon, F., Jean, L., Renard, P.Y., 2012. Reactivators of acetylcholinesterase inhibited by organophosphorus nerve agents. *Acc. Chem. Res.* 45, 756–766. <https://doi.org/10.1021/ar2002864>.
- Miyazawa, M., Nakahashi, H., Usami, A., Matsuda, N., 2016. Chemical composition, aroma evaluation, and inhibitory activity towards acetylcholinesterase of essential oils from *Gynura bicolor* DC. *J. Nat. Med.* 70, 282–289. <https://doi.org/10.1007/s11418-015-0961-1>.
- Morris, R., Martini, D.N., Madhyastha, T., Kelly, V.E., Grabowski, T.J., Nutt, J., Horak, F., 2019. Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease. *Parkinsonism Relat. Disord.* <https://doi.org/10.1016/j.parkreidis.2019.02.017>.
- Mu, P., Huang, Y.H., 2019. Cholinergic system in sleep regulation of emotion and motivation. *Pharmacol. Res.* <https://doi.org/10.1016/j.phrs.2019.03.013>.
- Neely, G.A., Kohli, A., 2018. Neostigmine. *StatPearls [Internet]* (StatPearls Publishing).
- Newby, D., Freitas, A.A., Ghafourian, T., 2015. Decision trees to characterise the roles of permeability and solubility on the prediction of oral absorption. *Eur. J. Med. Chem.* 90, 751–765. <https://doi.org/10.1016/j.ejmech.2014.12.006>.
- Oversepián, S.V., O'Leary, V.B., Zaborszky, L., 2016. Cholinergic mechanisms in the cerebral cortex: beyond synaptic transmission. *Neuroscientist* 22, 238–251. <https://doi.org/10.1177/1073858415588264>.
- Owokotomo, I.A., Ekundayo, O., Abayomi, T.G., Chukwuka, A.V., 2015. In-vitro anti-cholinesterase activity of essential oil from four tropical medicinal plants. *Toxicol. Rep.* 2, 850–857. <https://doi.org/10.1016/j.toxrep.2015.05.003>.
- Pandiyar, G.N., Mathew, N., Munusamy, S., 2019. Larvicidal activity of selected essential oil in synergized combinations against *Aedes aegypti*. *Ecotoxicol. Environ. Saf.* 174, 549–556. <https://doi.org/10.1016/j.ecoenv.2019.03.019>.
- Pepeu, G., Grossi, C., Casamenti, F., 2015. The brain cholinergic system in neurodegenerative diseases. *Annu. Rev. Biol.* 6, 1. <https://doi.org/10.9734/ARRB/2015/14623>.
- Pereira, M.C., Steffens, R.S., Jablonski, A., Hertz, P.F., Rios, A.O., Vizzotto, M., Flôres, S.H., 2012. Characterization and Antioxidant Potential of Brazilian Fruits from the Myrtaceae Family. *J. Agric. Food Chem.* 60, 3061–3067. <https://doi.org/10.1021/jf205263f>.

- Petrachianan, T., Chaiyasirisuwan, S., Athikomkulchai, S., Sareedenchai, V., 2019. Screening of acetylcholinesterase inhibitory activity in essential oil from Myrtaceae. *TJPS* 43, 63–68.
- Pires, D.E.V., Blundell, T.L., Ascher, D.B., 2015. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. *J. Med. Chem.* 58, 4066–4072. <https://doi.org/10.1021/acs.jmedchem.5b00104>.
- Plagemann, L., Krings, U., Berger, R.G., Marostica Jr., M.R., 2012. Volatile constituents of jaboticaba (*Myrciaria jaboticaba* (Vell.) O. Berg) fruits. *J. Essent. Oil Res.* 24, 45–51. <https://doi.org/10.1080/10412905.2012.645651>.
- Quinn, D.M., 1987. Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states. *Chem. Rev.* 87, 955–979. <https://doi.org/10.1021/cr00081a005>.
- Ream, C.R., 1963. Respiratory and cardiac arrest after intravenous administration of kanamycin with reversal of toxic effects by neostigmine. *Ann. Intern. Med.* 59, 384–387. <https://doi.org/10.7326/0003-4819-59-3-384>.
- Renard, P.V., Ludovic, J., 2017. Probing the cholinergic system to understand neurodegenerative diseases. *Future Sci.* <https://doi.org/10.4155/fmc-2016-0213>.
- Rodrigues, T., Reker, D., Schneider, P., Schneider, G., 2016. Counting on natural products for drug design. *Nat. Chem.* 8, 531. <https://doi.org/10.1038/NCHEM.2479>.
- Sameem, B., Mina, S., Mahdavi, M., Shafiee, A., 2017. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease. *Eur. J. Med. Chem.* 128, 332–345. <https://doi.org/10.1016/j.ejmech.2016.10.060>.
- Santos, E.F., Lemos, E.E.P., Sanvador, T.L., Araújo, R.R., 2017. Caracterização físico-química, compostos bioativos e atividade antioxidante total de frutos de cambuizeiro (*Myrciaria floribunda* O. Berg). *Revista Ouricuri* 7, 064–079 ISSN 2317-0131.
- Santos, J.F.S., Rocha, J.E., Bezerra, C.F., Silva, M.K.N., Matos, Y.M.L.S., Freitas, T.S., Santos, A.T.L., Cruz, R.P., Machado, A.J.T., Rodrigues, T.H.S., Brito, E.S., Sales, D.L., Almeida, W.O., Costa, J.G.M., Coutinho, H.D.M., Morais-Braga, M.F.B., 2018. Chemical composition, antifungal activity and potential anti-virulence evaluation of the *Eugenia uniflora* essential oil against *Candida* sp. *Food Chem.* 261, 233–239. <https://doi.org/10.1016/j.foodchem.2018.04.015>.
- Scotti, L., Scotti, M.T., 2018. In silico studies applied to natural products with potential activity against alzheimer's disease. *Computational Modeling of Drugs Against Alzheimer's Disease* (Springer). https://doi.org/10.1007/978-1-4939-7404-7_18.
- Shahriari, M., Zibae, A., Sahebzadeh, N., Shamakhi, L., 2018. Effects of α -pinene, trans-anethole, and thymol as the essential oil constituents on antioxidant system and acetylcholine esterase of *Ephesia kuehniella* Zeller (Lepidoptera: pyralidae). *Pestic. Biochem. Physiol.* 150, 40–47. <https://doi.org/10.1016/j.pestbp.2018.06.015>.
- Sharma, K., 2019. Cholinesterase inhibitors as Alzheimer's therapeutics. *Mol. Med. Rep.* <https://doi.org/10.3892/mmr.2019.10374>.
- Silva, A.T., Mazine, F.F., 2016. A família Myrtaceae na Floresta Nacional de Ipanema. *Iperó, São Paulo, Brasil, Rodriguésia* 67, 203–224. <https://doi.org/10.1590/2175-7860201667110>.
- Silva, V.P., Alves, C.C.F., Miranda, M.L.D., Bretanha, L.C., Balleste, M.P., Gustavo, A.M., Silveira, E.V., Martins, C.H.G., Ambrosio, M.A.L.V., Silva, T.S., Tavares, D.C., Magalhães, L.G., Silva, F.G., Egea, M.B., 2018. Chemical composition and in vitro leishmanicidal, antibacterial and cytotoxic activities of essential oils of the Myrtaceae family occurring in the Cerrado biome. *Ind. Crops Prod.* 123, 638–645. <https://doi.org/10.1016/j.indcrop.2018.07.033>.
- Silva, P.T., Santos, H.S., Teixeira, A.M.R., Bandeira, P.N., Holanda, C.L., Vale, J.P.C., Pereira, E.J.P., Menezes, J.E.S.A., Rodrigues, T.H.S., Souza, E.B., Silva, H.C., Santiago, G.M.P., 2019. Seasonal variation in the chemical composition and larvicidal activity against *Aedes aegypti* of essential oils from *Vitex gardneriana* Schauer. *S. Afr. J. Bot.* 124, 329–332. <https://doi.org/10.1016/j.sajb.2019.04.036>.
- Souza, P.R., Souza, K.S., Assis, C.R.D., Araújo, M.C., Silva, K.C.C., Silva, J.F.X., Ferreira, A.C.M., Silva, V.L.A., Carvalho Jr., L.B., 2018. Acetylcholinesterase of mangrove oyster *Crassostrea rhizophorae*: a highly thermostable enzyme with promising features for estuarine biomonitoring. *Aquat. Toxicol.* 197, 109–121. <https://doi.org/10.1016/j.aquatox.2018.02.008>.
- Sirin, G.S., Zhou, Y., Llor-Hoffmann, L., Wang, S., Zhang, Y., 2012. Aging mechanism of soman inhibited acetylcholinesterase. *J. Phys. Chem. B* 116, 12199–12207. <https://doi.org/10.1021/jp307790v>.
- Souza, M.C., Morim, M.P., 2008. Subtribos Eugeninae O. Berg e myrtinae 3. O. Berg (Myrtaceae) na Restinga Da Marambaia, RJ, brasil. *Acta Bot. Bras.* 22, 652–683. <https://doi.org/10.1590/S0102-33062008000300006>.
- Stefanello, M.E.A., Pascoal, A.C.R.F., Salvador, M.J., 2011. Essential oils from neotropical Myrtaceae: chemical diversity and biological properties. *Chem. Biodiversity* 8, 73–94. <https://doi.org/10.1002/cbdv.201000098>.
- Sumit, J., Kumar, P., 2019. Insight into the emerging role of striatal neurotransmitters in the pathophysiology of parkinson's disease and Huntington's disease: a review. *Curr. Neuropharmacol.* 17, 165–175. <https://doi.org/10.2174/1570159X16666180302115032>.
- Teixeira, N., Melo, J.C.S., Batista, L.F., Paula-Souza, J., Fronza, P., Brandão, M.G.L., 2019. Edible fruits from Brazilian biodiversity: a review on their sensorial characteristics versus bioactivity as tool to select research. *Food Res. Int.* 119, 325–348. <https://doi.org/10.1016/j.foodres.2019.01.058>.
- Tietbohl, L.A., Lima, B.G., Fernandes, C.P., Santos, M.G., Silva, F.E., Denardin, E.L., Bachinsk, R., Alves, G.G., Silva-Filho, M.V., Rocha, L., 2012. Comparative study and anticholinesterase evaluation of essential oils from leaves, stems and flowers of *Myrciaria floribunda* (H. West ex Willd.) O. Berg. *Latin American Journal of Pharmacy* 31 (4), 637–641.
- Tietbohl, L.A.C., Barbosa, T., Fernandes, C.P., Santos, M.G., Machado, F.P., Santos, K.T., Mello, C.B., Araújo, H.P., Gonzalez, M.S., Feder, D., Rocha, L., 2014. Laboratory evaluation of the effects of essential oil of *Myrciaria floribunda* leaves on the development of *Dysdercus peruvianus* and *Oncopeltus fasciatus*. *Rev. Bras. Farmacogn.* 24, 316–321.
- Tougu, V., 2001. Acetylcholinesterase: mechanism of catalysis and inhibition. *Current Medicinal Chemistry-Central Nervous System Agents* 1, 155–170. <https://doi.org/10.2174/1568015013358536>.
- Waterbeemd, V.H., Gifford, E., 2003. ADMET in silico modelling: towards prediction paradise? *Nat. Rev. Drug Discovery* 2, 192–204. <https://doi.org/10.1038/nrd1032>.
- Van den Dool, H., Kratz, P.D., 1963. A Generalization of the Retention Index System Including Linear Temperature Programmed Gas-liquid Partition Chromatography. *Microbiol. Res.* 6, 3173–3185. <https://doi.org/10.5897/AJMR11.1359>.
- Xiang, C.P., Han, J.X., Li, X.C., Li, Y.H., Zhang, Y., Chen, L., Qu, Y., Hao, C.Y., Li, H.Z., Yang, C.R., Zhao, S.J., Xu, M., 2017. Chemical composition and acetylcholinesterase inhibitory activity of essential oils from Piper species. *J. Agric. Food Chem.* 65, 3702–3710. <https://doi.org/10.1021/acs.jafc.7b01350>.
- Zarrad, K., Hamouda, A.B., Chaieb, I., Laarif, A., Jemâa, J.M.B., 2015. Chemical composition, fumigant and anti-acetylcholinesterase activity of the Tunisian *Citrus aurantium* L. Essential oils. *Ind. Crops Prod.* 76, 121–127. <https://doi.org/10.1016/j.indcrop.2015.06.039>.